

SC-19192: 110-WEEK TOXICITY STUDY IN THE MOUSE

P-T NO. 985H73

FINAL REPORT

Submitted to

Searle Laboratories, Division of  
G. D. Searle and Company  
Chicago, Illinois



**HAZLETON LABORATORIES, INC.**

9200 LEESBURG TURNPIKE • VIENNA, VIRGINIA • 22180

September 6, 1974



# TABLE OF CONTENTS

	<u>PAGE NO.</u>
SUMMARY	1
INTRODUCTION	5
MATERIAL	5
Identification	5
Description	5
Received	5
Used on Study	5
Purity	5
METHODS	5
Experimental Animals	5
Groups and Dosage Levels	6
Actual Compound Consumption	6
Administration of Test Material	7
Observations and Records	7
Clinical Laboratory Studies	7
Ophthalmoscopic Examinations	9
Terminal Studies	9
Statistical Evaluation	13
RESULTS	15
Appearance and Behavior	15
Body Weight, Food Consumption, and Survival Data	16
Clinical Laboratory Studies	23
Results of Eye Examinations	30
Observations at Necropsy	32
Organ Weights	32
Tumor Incidence	35
Microscopic Examination of Tissues	54
APPENDIX	
Tables	1
Table No. 1 - Mean Body Weights, Standard Deviations, Food Consumption, and Survival Data	1
Table No. 1A - Mean Daily Compound Consumption	5
Table No. 2 - Hematological Values	6
Table No. 3 - Blood Chemistry Values	46
Table No. 4 - Urine Analysis Values	52
REFERENCES FOR BIOCHEMICAL PROCEDURES	54
Table No. 5 - Ophthalmoscopic Examinations	57
Table No. 6 - Gross Necropsy Incidence Table - Sacrificed	62
Table No. 6A - Gross Necropsy Incidence Table - Deaths	65
Table No. 7 - Mean Terminal Body Weights, Organ Weights, Organ/Body Weight Ratios, and Standard Deviations	72
Key for Table No. 8	77
Table No. 8 - Detailed Histopathology Incidence Table	78





SPONSOR: Searle Laboratories, Division of  
G. D. Searle and Company

MATERIAL: SC-19192

SUBJECT: FINAL REPORT  
110-Week Toxicity Study in the Mouse  
Project No. 700-260

DATE: September 6, 1974

#### SUMMARY

The test material, SC-19192, was administered in the diet to groups of 36 male and 36 female ICR Swiss albino mice at levels of 0.25, 0.50, and 1.00 g/kg/day for 110 weeks. A fourth group of 72 male and 72 female mice served as controls and received only the basal laboratory diet.

Criteria evaluated for a compound effect were physical appearance, behavior, body weight gain, food consumption, survival, clinical laboratory data, eye examinations, terminal body weight and organ weight data, tumor incidence, and gross and microscopic pathology.

There was no evidence that the administration of SC-19192 at any level produced an adverse effect upon the physical appearance and behavior of the animals. The incidence of common signs, including spontaneous disease, signs of aging, etc., were comparable between control and treated animals. Likewise, the results of periodic ophthalmoscopic examinations revealed no indication of a compound-related effect.



Statistical analysis of the rate of body weight gain through the first year did not reveal any significant differences between control and treated groups for either sex. Mean terminal body weights were significantly increased for only the low dose males. Analyses of total food consumption during the first year revealed significantly lower values for the males at the low, mid, and high treatment levels; this finding is considered of minor biological significance since overall body weight gains were not adversely affected.

Statistical analysis of survival at Week 108 according to the life-table technique revealed no significant differences between control and treated groups except for the mid dose females; survival for this latter group was significantly decreased as compared to the female controls. No biological significance is ascribed to this particular finding since there was no indication of a treatment-related effect with respect to mean survival time.

Evaluation of hematological data obtained periodically during the study revealed no indication of any compound-related alterations at any dosage level. Likewise blood chemistry and urinalysis data obtained at termination failed to reveal any consistent evidence of a compound-related effect. Random fluctuations reaching statistical significance were occasionally observed but are considered of little biological significance; affected values were generally within normal limits and differences in individual values between control and test mice were minor in degree.



Likewise, gross observations at necropsy failed to reveal compound-related changes in any organs or tissues. Statistical analysis of organ/body weight ratios revealed no significant differences between data for control and treated males; in females only the thyroid/body weight ratio was affected and was increased at the mid and high doses.

Histopathologic examination was performed on all unusual or usual gross lesions from all animals at each treatment level, plus microscopic examination of 20-27 grossly unremarkable organs from all control and high level animals, and from roughly two-thirds and one-third of the animals at the mid and low treatment levels, respectively. Thus, one or more tissue sections were examined from approximately 3,400 organs from the control group, 1,700 organs at the high treatment level, and proportionately fewer at the lower treatment levels. Detailed microscopic evaluations were performed on brain and urinary bladder from all mice in the control and all three treated groups, including survivors and nonsurvivors, for which suitable tissues were available for histologic preparation. The brain tissue was examined such that five coronal sections representing the major neuroanatomic areas of the brain were evaluated; two sections per block were examined thus providing a total of 10 sections per brain per animal. Urinary bladder likewise received very special attention; after gross examination of the fixed hemisected bladder, four intermittent transverse bladder sections were examined microscopically.



Tumor data were statistically analyzed by sex employing an actuarial (Life-table) technique which adjusts for differing survival rates between groups. Using this method, tumor incidence (adjusted) was based on the number of animals with histologically-proven tumors actually observed and the number of animals actually at risk in each group and sex. In no instance in either sex at any of the treated levels was the adjusted tumor incidence of any of the types of tumors analyzed (any tumor, only benign tumor, any malignant tumor, primary lung tumor, lymphoreticular cell tumor, and vascular tumor) significantly higher than that of the respective controls.

Histopathological examination revealed no evidence of any treatment-related non-neoplastic changes in any organ or tissue.

Thus, SC-19192 administered to the mouse for 110 weeks in the diet at dosage levels of 0.25, 0.50, and 1.0 g/kg/day exhibited no adverse effects regarding survival rate nor did it produce any convincing evidence of an effect with respect to the incidence of neoplasms or with regard to non-neoplastic changes in any organ or tissue.





## INTRODUCTION

The purpose of this study was to evaluate and characterize the effects of long-term dietary feeding of SC-19192 in ICR Swiss albino mice. Administration of the test material was started on December 10, 1971, and was terminated on January 17, 1974. This report covers the entire 110-week experimental period.

## MATERIAL

Identification SC-19192.

Description A flakey, white powder.

Received From Searle Laboratories in two lots: Lot No. 1R: Received November 23, 1971, and Lot No. 3R: Received June 6, 1972.

Used on Study Lot No. 1R - From Weeks 0 through 51 and Lot No. 3R - From Weeks 52 through 110.

Purity Each lot was considered 100% pure for purposes of dosage calculation.

## METHODS

### Experimental Animals

One hundred eighty male and 180 female albino mice of the ICR Swiss strain (Charles River Laboratories; Wilmington, Mass.) approximately 28 days of age at initiation of compound administration were employed.



Genetic Identification: CD-1 (HAM-ICR Swiss).

Weight Range At Initiation: From 12 to 21 grams for males and from 12 to 19 grams for females.

Housing: Individually in elevated wire mesh cages.

Basal Diet: Wayne Laboratory Chow and drinking water available ad libitum.

Selection for Groups: Stratified randomization by body weight for each sex; animals were placed into four groups taking into account the differences in body weights so that a homogeneous distribution of weights was obtained between groups.

#### Groups and Dosage Levels

<u>Group No.</u>	<u>No. of Animals</u>		<u>Dietary Level</u> g/kg/day
	male	female	
1 (Control)	72	72	0
2	36	36	0.25
3	36	36	0.50
4	35*	37*	1.00

\* The design of the study called for 36 mice of each sex in each of the three treated groups. However, at necropsy of mice that had died during the study it was discovered that, apparently at initiation of the study, two males and one female in Group No. 4 had been mis-sexed, thus causing a net shift in sex distribution for this group.

#### Actual Compound Consumption

Mean actual compound consumption for each four-week period of the study through 108 weeks are presented in appended Table No. 1A (Page No. 5 ). Actual consumption mean values of 0.25, 0.50, and 1.00 g/kg/day for Groups No. 2, No. 3, and No. 4 were achieved; these values were based on data through 108 weeks and are considered to be an appropriate representation of compound consumption for the entire 110-week treatment period.



#### Administration of Test Material

The test material was incorporated into the basal diet on a weight-per-weight basis and thoroughly mixed in a twin-shell Patterson-Kelley blender to provide the appropriate dietary levels. Control mice were fed the basal diet only. Individual body weights were obtained and individual food consumption was calculated once weekly for Weeks 0 through 4, every other week from Weeks 5 through 12, and every fourth week from Week 13 through Week 108. After each weighing, the dosages were adjusted according to body weight change.

#### Observations and Records

The animals were observed daily for mortality.

Individual body weight, food consumption, appearance, and behavior of each mouse were recorded in accordance with the indicated regimen for administration of the test material. All test mice were observed for signs of toxicity and/or pharmacologic effect and for the development of palpable tissue masses.

#### Clinical Laboratory Studies

Intervals: At five, 10, 20, 40 and 60 weeks on six mice per sex per group and at 110 weeks on five to 10 mice per sex per group.

Methods: Blood samples for all hematological determinations were obtained from the tail by segmental amputation and collected by the Unopette System. Blood serum samples for the blood chemistry determinations at termination were obtained from the abdominal aorta by arterial puncture.



Specimen volumes were 0.25 ml. of whole mixed arteriovenous blood from the tail and 1.25 ml. of whole arterial blood from the arterial puncture. Individual urine samples, approximately 0.15 ml. in volume, were collected by evacuation of the urinary bladder at necropsy.

Hematology: At Each Interval -- hematocrit and hemoglobin determinations, erythrocyte counts, and total and differential leukocyte counts.

At Five, 10, 40, and 60 Weeks -- prothrombin time.

Blood Chemistry: At Termination Only -- blood urea nitrogen, serum glutamic-pyruvic transaminase, and serum alkaline phosphatase.

In addition at termination, 0.3 ml. frozen serum samples from a representative number of male and female mice per group were sent to Searle Laboratories for L-phenylalanine determinations; these data are included in this report.

Urine Analysis: At Termination Only -- pH, sugar, protein, occult blood, microscopic examination of sediment, and phenylketones (Phenistix Method; Ames Labs).

A bibliography of clinical methods employed is included in the Appendix on Page No. 54.



#### Ophthalmoscopic Examinations

Performed on all mice initially (after four weeks on study\*) and at 20, 40, 60, and 110 weeks, using an indirect ophthalmoscope and tropicamide ophthalmic solution (Mydriacyl<sup>®</sup>; Alcon Laboratories, Inc., Fort Worth, Texas) as a mydriatic.

#### Terminal Studies

Animals Found Dead: Terminal body weights were recorded, necropsies performed under the supervision of the staff pathologist, and representative tissues preserved. All tissues in each major body cavity (head, thorax, abdomen, and pelvis) were examined, as well as the skin and internal and external aspects of the gastrointestinal tract.

Animals Killed in Extremis or by Design: Terminal body weights were recorded, animals were exsanguinated following sodium pentobarbital anesthesia (Diabutal; Diamond Laboratories, Inc., Des Moines, Iowa), necropsies performed under the supervision of a pathologist, organ weights recorded, and representative tissues preserved. The tissues of the major body cavities were examined, as well as skin and the internal and external aspects of the gastrointestinal tract.

\* The eyes of weanling mice at the age of four weeks, such as used for this study, have, as a rule, not attained full transparency and appear cloudy. For this reason, initial eye examinations were delayed until four weeks after the start of the study, when the eyes had attained sufficient transparency to conduct meaningful ophthalmoscopic examinations.



Postmortem Procedures:

Organ Weights - Indicated in the weight column of the following table (Figure B) from each animal killed by design or in extremis; obtained prior to fixation unless indicated otherwise.

Preservation of Tissues - As indicated under "Fixed" in text Figure B, from each animal killed at termination; in 10% neutral buffered formalin. Tissues were also preserved from animals dying on study; some of the carcasses showing advanced autolysis were placed into the fixative in toto, after abdominal and thoracic cavities had been open and inspected.

Microscopic Examination - A full spectrum of tissue specimens (roughly 27 organs) was examined microscopically from all control and high dose mice of each sex, and lesser numbers of medium and low dose mice. Additionally, and most importantly, all gross lesions of usual or unusual nature from all animals in all groups were examined microscopically. A tabulated summary of the animals available for histopathological examination is found in Figure A. Text Figure B indicates the total number of animals per group from which a given tissue (gross lesion or grossly normal) was examined.

All wet tissues, embedded tissues, and mounted tissue sections are on file at Hazleton Laboratories, Inc.

Figure A - Summary of disposition of animals

	MALES				FEMALES			
	C	L	M	H	C	L	M	H
Total No. of Mice Started on Study: (See Page No. 6)	72	36	36	35	72	36	36	37
Total No. of Survivors: (See Figure No. 6 and Tables No. 6 and No. 8)	22	11	14	6	19	7	6	9
Total No. of Non-survivors Available for Histopathological Examination: (See Tables No. 6A and No. 8)	44	21	20	26	49	27	29	26
Total No. of Mice Lost to Histopathological Examination: (See Table No. 6A)	6	4	2	3	4	2	1	2
Total No. of Mice Available for Histopathological Examination:*	66	32	34	32	68	34	35	35
(See Figure No. 10)								

\* Total number mice available for postmortem evaluation includes survivors and non-survivors for which one or more tissues were available for histologic preparation and excludes those animals missing or for which tissues were unsuitable for histopathology due to severe autolysis.

C = Control; L = Low; M = Medium; H = High



Figure No. B - Tabulation of postmortem procedures

Tissues	I Weight	II Fixed	Microscopic Examination (Males/Females)			
			Group No.			
			1	2	3	4
Brain $\phi$		B	65/67	32/34	34/34	32/35
Pituitary		B	47/54	10/12	15/20	20/19
Spinal Cord		B	61/63	0/0	0/0	30/32
Eye, Right		B	63/67	0/0	0/0	32/35
Mandibular Salivary Gland		B	66/65	1/4	0/0	31/33
Thyroid	B*	B	61/54	12/11	23/22	32/29
Lung		B	66/67	13/16	25/24	32/35
Heart	B	B	66/66	13/12	25/24	32/35
Liver	B	B	66/68	15/18	25/25	32/34
Gallbladder		B	53/58	11/10	22/20	24/30
Spleen		B	63/62	17/19	26/30	30/35
Kidney	B	B	66/67	13/16	30/27	32/35
Adrenal	B*	B	59/65	12/12	24/24	29/34
Stomach		B	66/67	14/20	26/29	32/35
Pancreas		B	66/64	14/13	24/25	30/33
Small Intestine		B	63/66	15/14	25/25	31/34
Large Intestine		B	66/65	13/12	25/26	31/34
Mesenteric Lymph Node		B	48/51	5/5	4/5	28/27
Urinary Bladder $\phi\phi$		B	65/64	32/33	33/34	31/34
Testis	M	M	65/	13/	24/	32/
Prostate	M	M	59/	14/	21/	30/
Seminal Vesicle	M	M	66/	13/	23/	31/
Ovary	F*	F	/56	/21	/28	/32
Uterus	F	F	/62	/22	/30	/35
Vagina		F	/56	/11	/20	/30
Mammary Gland, R 4 & 5		B	66/65	1/0	0/0	31/34
Bone (Rib Junction)		B	66/68	0/0	0/0	32/35
Bone Marrow (Femoral)		B	65/68	0/1	0/0	32/35
Skeletal Muscle		B	65/65	0/1	1/0	31/34
Nerve (Brachial Plexus)		B	65/65	0/0	0/0	31/34
Usual and Unusual Lesions		B	**	**	**	**

B = Both Sexes; M = Male Only; F = Female Only

\* = Weight recorded after fixation

\*\* = Usual and unusual gross lesions in all animals were examined microscopically.

$\phi$  = Five coronal blocks representing the major neuroanatomic areas of the brain were evaluated; two sections per block were examined thus providing a total of 10 sections per brain.

$\phi\phi$  = Four sections examined; urinary bladder was cut in half longitudinally, both hemispheres embedded, and two sections cut from each hemisphere with approximately 50 microns between each section.





### Statistical Evaluation

Methods Employed: Treated groups of a given sex and dose were compared with control groups of the same sex by the following methods.

Bartlett's test for a preliminary test of homogeneity of variances relating to rates of body weight change (compared by the method of C. R. Rao<sup>(3)</sup>), food consumption, terminal body weights, organ weights, and organ weight to body weight ratios; the analysis of variance and Scheffe's method of paired comparisons when variances are homogeneous; and the two sample t test when variances are not homogeneous.

Survival rates at the end of 108 weeks were compared by the method of Sachs<sup>(4)</sup>: A life-table technique was used to calculate the proportion of mice surviving the period in treated and control groups, and the two survival rates were compared by the t test.

Clinical laboratory data were compared by the t test.

Tumor incidence (adjusted) was calculated by the method of Sachs<sup>(4)</sup> which involves a life table approach and survival rates. An additional explanation can be found in McKinney<sup>(5)</sup>. Control and treated adjusted tumor incidences were then compared by the t test.

All testing is at the 5% level of significance.



References:

- (1) Dixon, W. J. and F. J. Massey, Jr., Introduction to Statistical Analysis, pp. 123-124, McGraw Hill, 1957.
- (2) Ostle, B., Statistics in Research, Iowa State College Press, Ames, Iowa, 1956.
- (3) Rao, C. R., Biometrics, 14, 1, 1958.
- (4) Sachs, R., Toxicol. Appl. Pharmacol. 1, 203, 1959.
- (5) McKinney, G. R., Toxicol. Appl. Pharmacol. 12, 68, 1968.
- (6) Snedecor, G. W., Statistical Methods, Iowa State College Press, Ames, Iowa, 1956.



## RESULTS

Appearance and Behavior

Throughout the study, there was no evidence of a compound effect with regard to physical appearance and behavior among the mice at any treatment level.

During the first 18 months of treatment signs commonly observed in laboratory mice were seen occasionally among both control and treated animals. During the last six months of the study the incidence of common signs including a hunched and/or bloated appearance, localized alopecia, reddened eyes, and stains on fur increased at a comparable rate in treated as well as control mice. Other signs observed sporadically among all groups including controls were roughening of the hair coat, sores on body or extremities, subcutaneous abscesses, and red vaginal discharge. There were also a small number of isolated observations, varying in nature, in one or a few animals among all groups.

Palpable nodules, tissue masses, and/or swollen areas on the body or legs were evident in a small number of control and treated animals as follows:

<u>Group No.</u>	<u>Males</u>	<u>Females</u>
1	9/72	0/72
2	4/36	1/36
3	6/36	2/36
4	3/35	3/37



Body Weight, Food Consumption, and Survival Data

Group mean body weights, standard deviations, group mean food consumption, and survival data are presented in Table No. 1 (Page No. 1 ). Mean body weight and food consumption data at selected intervals are presented in Figure No. 1. Group mean body weights and standard deviations are presented graphically in Figure No. 1A; a separate graph of body weight and food consumption data is given in Figure No. 1B.

Statistical evaluation of overall body weight gain data through the first year revealed no significant differences between the control and three treated groups for either sex. Body weights for the treated males and females were generally comparable to that for their respective controls throughout the study. Terminal body weights for those animals which survived to 110 weeks were unremarkable except for the low dose males; the mean terminal body weight for this latter group was significantly increased (see appended Table No. 7, Page No. 72 ).

There were no statistically significant differences in total food consumption during the first year between control and treated females. Food consumption for the low, mid, and high dose males was significantly decreased; the decreases observed were similar between these three groups. This finding, however, is considered of minor biological significance since overall body weight gains were not adversely affected. There were no meaningful differences in food consumption data for the control and test groups during the second year. Body weight gain and food consumption were not evaluated statistically after the first year.

Figure No. 1 - Summary of Table No. 1 which appears in the Appendix

Week No.	Mean Body Weight and Food Consumption (Grams)*							
	Group No. 1		Group No. 2		Group No. 3		Group No. 4	
	Weight	Food	Weight	Food	Weight	Food	Weight	Food
MALES**								
0	16	--	16	--	16	--	16	--
2	27	41	25	39	25	41	25	40
4	30	45	28	44	28	47	29	47
12	31	45	32	38	31	41	32	41
20	35	43	35	37	35	35	36	37
28	37	37	35	41	36	40	37	37
36	38	40	37	41	36	43	37	43
44	38	47	38	46	37	42	37	46
52	38	42	38	32	37	32	38	36
60	38	39	38	41	37	41	38	39
68	38	30	39	34	38	34	38	39
76	39	33	40	33	39	32	39	32
84	38	42	39	41	39	38	42	39
92	38	37	40	37	39	34	39	35
100	37	36	37	39	35	36	36	37
108	36	34	38	36	35	35	37	35
FEMALES								
0	15	--	15	--	15	--	15	--
2	22	40	21	40	21	40	20	41
4	24	46	24	46	24	49	25	50
12	26	49	25	43	25	43	27	46
20	28	42	31	38	29	38	29	44
28	28	42	28	41	28	40	33	37
36	31	43	32	44	30	43	32	47
44	31	48	33	46	32	44	35	46
52	33	36	33	36	32	35	34	39
60	33	39	33	44	32	40	34	41
68	34	35	34	33	34	35	36	37
76	35	30	36	30	36	32	35	33
84	35	41	36	41	37	39	40	40
92	34	36	36	34	36	34	36	42
100	34	38	34	36	34	37	35	38
108	34	35	33	32	35	40	33	36

\* Food consumption is expressed as grams per week per mouse.

\*\* Total food consumption over the entire first year for the low, mid, and high dose males was significantly decreased as compared to the control males; food consumption at each interval was not evaluated statistically.




Figure 1A - GROUP MEAN BODY WEIGHTS AND STANDARD DEVIATIONS OF MALE AND FEMALE SWISS MICE WHICH SERVED AS CONTROLS OR RECEIVED THE INDICATED DIETARY LEVELS OF SC - 19192 FOR 110 WEEKS.




Figure 1B -MEAN BODY WEIGHT AND FOOD CONSUMPTION FOR MALE AND FEMALE SWISS MICE WHICH SERVED AS CONTROLS OR RECEIVED THE INDICATED DIETARY LEVELS OF SC - 19192 FOR 110 WEEKS.



Mean daily compound consumption is summarized in Figure No. 1C.

At each treatment level for each sex, mean daily compound consumption for the entire 110-week test period was within 1% of the planned dosage levels. Mean compound consumption data for each four-week period\* of the study are presented in appended Table No. 1A (Page No. 5 ).

Survival data are presented in Figures No. 2 and No. 2A. Through the first 14 months of the study mortality was low and occurred at a generally comparable rate in the male and female treated and control groups. Survival in each sex in all groups was greater than 50% after 18 months. During the latter part of the study mortality in all groups, including the controls, increased markedly. Survival was analyzed statistically at Week 108 corresponding with the last interval at which weekly body weights were recorded. Seven mice (three males and two females in Group No. 1 and one male each in Groups No. 2 and No. 4) escaped during the study and were not recovered; one male in Group No. 4 was accidentally killed; for statistical purposes, these animals were considered as excluded from the study. There were no significant differences between survival data for the respective control and treated groups except for the mid dose females; survival for this latter group was significantly decreased at Week 108 as compared to the female controls. No biological significance is ascribed to this particular finding since there was no indication of a treatment-related effect with respect to mean survival time.

\* Refer to Page No. 7 in the Methods Section for the regimen established for adjustment of dosages. During the latter part of the study when adjustment of dosages was made less frequently, mean daily compound consumption calculated once monthly was assumed to be representative of each respective four-week period.



Figure No. 1C - Summary of Table No. 1A which appears  
in the Appendix

Mean Daily Compound Consumption (g/kg/day) for Mice  
Receiving SC-19192 in the Diet

<u>Group No.</u>	<u>Males</u>	<u>Females</u>
2	Weeks: 0-110	Weeks: 0-110
(0.25 g/kg/day)	0.250	0.250
	$\pm 0.0375^*$	$\pm 0.0465$
3	Weeks: 0-110	Weeks: 0-110
(0.50 g/kg/day)	0.502	0.501
	$\pm 0.0919$	$\pm 0.0859$
4	Weeks: 0-110	Weeks: 0-110
(1.00 g/kg/day)	1.002	1.001
	$\pm 0.1518$	$\pm 0.1680$

\* Values below the mean are standard deviations ( $\pm$  S.D.)

Figure No. 2 - Survival data at Week 108

<u>Test Level</u> g/kg/Day	<u>Percent Survival <math>\pm</math> S.E.</u>		<u>Mean Survival Time-Days</u>	
	Males	Females	Males	Females
0 (Control)	34.8 $\pm$ 5.7	33.9 $\pm$ 5.7	597	581
0.25	30.6 $\pm$ 7.7	25.0 $\pm$ 7.3	616	620
0.50	38.9 $\pm$ 8.2	16.7 $\pm$ 6.3 <sup>S-</sup>	628	621
1.00	20.0 $\pm$ 6.8	25.0 $\pm$ 7.3	600	600

S.E. = Standard Error

S- = Significantly lower than control at  $p < 0.05$

Figure No. 2A - Percent survival at selected intervals

<u>Week</u>	<u>Group No. 1</u>		<u>Group No. 2</u>		<u>Group No. 3</u>		<u>Group No. 4</u>	
	M	F	M	F	M	F	M	F
13	100	97	100	97	97	100	97	100
26	96	94	100	94	94	100	97	94
52	85	82	86	92	89	94	83	89
78	68	68	75	81	81	78	67	67
91	56	56	58	58	75	50	44	56
110*	31	26	31	19	39	17	17	24

\* Week 110 survival corrected for mis-sexed animals in Group No. 4 (refer to Methods Section, Page No. 6); all other survival data based on assumed even distribution of sexes in each group.



There were additional deaths during the last two weeks of the study among the controls, particularly the females, and among the Group No. 2 females and the Group No. 4 males; there was no additional mortality in the remaining groups. The pattern of survival at Week 110 (as compared to Week 108) was not meaningfully different for control or treated groups.

A tabulated summary of all statistically significant alterations in survival and food consumption parameters, as well as hematologic and blood chemistry parameters is presented in Figure No. 3, Page No. 24.

#### Clinical Laboratory Studies

Detailed results of the clinical laboratory determinations are presented in appended Tables No. 2 (hematology, Page No. 6 ), No. 3 (blood chemistry, Page No. 46 ), and No. 4 (urine analyses, Page No. 52 ). Mean clinical values and standard deviations by group are presented in the following pages (Figures No. 4 and No. 4A).

Evaluation of the hematological data revealed no indication of any compound-related alterations at any dosage level in the parameters examined. Some instances of slightly to moderately elevated leukocyte counts were observed at each interval but lacked consistency. Occasional findings of statistically significant differences are considered of minor biological significance since the affected values were within normal limits. At 10 weeks, one Group No. 3 male had a slightly elevated prothrombin time value. At termination, rather low hemograms and/or slightly to moderately elevated leukocyte counts were encountered among a number of male and female animals randomly scattered among all groups including the controls. These findings are considered to be caused by spontaneous disease.

Figure No. 3 - Summary of presence and direction of all statistically significant changes

Group		5 Weeks				10 Weeks				20 Weeks				40 Weeks			
Treatment Level (g/kg)		No. 2	No. 3	No. 4	No. 2	No. 3	No. 4	No. 2	No. 3	No. 4	No. 2	No. 3	No. 4	No. 2	No. 3	No. 4	
		0.25	0.5	1.0	0.25	0.5	1.0	0.25	0.5	1.0	0.25	0.5	1.0	0.25	0.5	1.0	
		M	F	M	M	F	M	M	F	M	M	F	M	M	F	M	
Duration		5 Weeks				10 Weeks				20 Weeks				40 Weeks			
Parameters:																	
Food Consumption*		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Survival**		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemoglobin		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RBC; total		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
WBC; total		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Prothrombin Time		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SG-PT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
L-Phenylalanine		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Duration		52 Weeks				60 Weeks				108 Weeks				110 Weeks			
Parameters:																	
Food Consumption*		+	-	+	-	+	-	-	-	-	-	-	-	-	-	-	
Survival**		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemoglobin		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RBC; total		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
WBC; total		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Prothrombin Time		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SG-PT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
L-Phenylalanine		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

↑ or ↓ = Indicates the presence and direction of a statistically significant change.

- = Indicates the absence of a statistically significant change.

\* = Total food consumption was analyzed statistically from Week 0 through Week 52.

\*\* = Survival was analyzed statistically at Week 108.

Figure No. 4 - Group mean hematological values and standard deviations

MALES

<u>Interval In Weeks</u>	<u>Group No.</u>	<u>HCT %</u>	<u>HGB g.%</u>	<u>RBC mills</u>	<u>WBC ths</u>	<u>Prothrombin seconds</u>
5	1	53.5	16.7	8.37	19.0	8.6
	±	3.9	0.6	1.02	4.7	0.6
	2	55.1	17.4	8.47	19.6	9.0
	±	3.0	0.7	0.27	4.3	0.4
	3	52.2	16.9	8.76	20.2	9.3 S+
	±	2.5	0.8	0.55	2.9	0.3
	4	53.3	16.4	8.62	21.6	8.6
	±	1.7	1.0	0.43	2.9	0.5
10	1	49.6	15.2	8.65	15.8	8.6
	±	1.4	1.4	0.66	3.2	0.5
	2	50.0	16.0	9.33	17.5	8.6
	±	1.1	1.2	0.40	1.7	0.6
	3	49.8	15.2	9.46	16.4	9.4 S+
	±	2.2	0.8	0.82	2.3	0.6
	4	49.7	14.8	9.57 S+	20.1 S+	9.3 S+
	±	0.5	0.8	0.43	2.8	0.4
20	1	48.0	16.5	7.48	17.2	-
	±	1.5	0.6	1.10	4.6	-
	2	48.9	16.5	7.99	17.9	-
	±	3.2	0.8	0.73	4.8	-
	3	49.0	16.2	8.66	18.2	-
	±	1.0	0.3	0.81	4.1	-
	4	49.0	16.5	7.95	19.0	-
	±	2.3	0.8	0.43	3.1	-

S+ = Significantly higher than control at  $p < 0.05$ .

Figure No. 4 - Continued

MALES

<u>Interval In Weeks</u>	<u>Group No.</u>	<u>HCT %</u>	<u>HGB g.%</u>	<u>RBC mills</u>	<u>WBC ths</u>	<u>Prothrombin seconds</u>
40	1	46.5	15.3	8.27	14.0	8.5
	±	2.3	0.7	0.65	3.9	0.5
	2	46.8	15.5	8.89	18.4	8.4
	±	2.6	1.0	0.77	8.5	0.5
	3	46.8	15.6	9.24 S+	17.2	8.5
	±	2.9	0.6	0.50	2.8	0.4
	4	47.0	15.4	8.97 S+	21.2 S+	8.4
	±	1.7	0.8	0.36	4.7	0.5
60	1	46.0	15.5	8.55	14.5	8.3
	±	2.5	0.6	0.83	5.5	0.5
	2	46.8	15.2	8.95	15.5	8.1
	±	2.6	0.8	0.62	4.7	0.3
	3	47.7	15.1	8.87	13.5	8.1
	±	3.1	1.6	0.64	3.8	0.5
	4	46.6	15.6	8.58	15.5	8.3
	±	2.1	0.7	0.27	4.3	0.4
110	1	44.0	14.5	8.21	16.6	-
	±	6.0	2.3	1.18	9.4	-
	2	42.4	13.9	7.87	14.0	-
	±	2.4	0.9	0.63	5.3	-
	3	44.8	15.0	8.82	11.3	-
	±	4.5	1.5	0.71	3.9	-
	4	42.9	14.4	7.89	14.0	-
	±	6.8	2.3	0.97	6.2	-

S+ = Significantly higher than control at  $p < 0.05$ .

Figure No. 4 - Continued

FEMALES

<u>Interval In Weeks</u>	<u>Group No.</u>	<u>HCT %</u>	<u>HGB g.%</u>	<u>RBC mills</u>	<u>WBC ths</u>	<u>Prothrombin seconds</u>
5	1	54.8	17.7	8.02	14.8	8.9
	±	2.1	0.8	0.75	3.0	0.4
	2	53.0	17.1	8.51	19.2 S+	8.6
	±	1.9	0.8	0.49	3.2	0.7
	3	52.5	17.2	7.34	18.0	8.9
	±	2.2	0.8	0.61	3.3	0.4
	4	53.7	17.5	7.25 S-	18.4	8.4
	±	1.0	0.7	0.29	4.2	0.4
10	1	51.3	16.3	9.68	19.7	8.7
	±	3.6	0.3	0.50	3.5	0.7
	2	50.3	16.0	9.72	19.4	8.9
	±	2.0	0.2	1.03	4.2	0.4
	3	49.1	15.7 S-	9.43	19.6	8.8
	±	1.6	0.6	0.38	3.7	0.5
	4	50.4	16.0	9.98	17.6	9.0
	±	1.0	0.7	0.34	4.5	0.4
20	1	50.2	16.4	8.50	14.3	-
	±	3.1	0.5	0.34	3.9	-
	2	50.7	16.8	8.66	19.8 S+	-
	±	1.5	0.4	0.59	2.8	-
	3	51.7	17.1 S+	8.51	12.6	-
	±	0.6	0.2	0.29	2.4	-
	4	50.3	16.6	8.51	15.4	-
	±	1.8	0.7	0.48	4.0	-

S+ = Significantly higher than control at  $p < 0.05$ .

S- = Significantly lower than control at  $p < 0.05$ .

Figure No. 4 -- Continued

FEMALES						
<u>Interval In Weeks</u>	<u>Group No.</u>	<u>HCT %</u>	<u>HGB g.%</u>	<u>RBC mills</u>	<u>WBC ths</u>	<u>Prothrombin seconds</u>
40	1	47.7	15.5	8.47	13.3	8.9
	±	2.8	0.9	0.25	3.3	0.3
	2	47.8	15.7	8.11	17.1	8.7
	±	2.3	0.9	0.83	2.7	0.6
	3	47.3	15.4	8.42	13.6	8.5 <sup>S-</sup>
	±	2.4	1.3	0.38	2.4	0.4
	4	48.6	15.9	8.69	17.4	8.5
	±	1.8	0.7	0.89	4.0	0.6
60	1	47.7	15.1	8.72	13.1	7.8
	±	2.3	1.0	0.60	4.6	0.4
	2	49.4	16.0	9.64	13.7	8.2
	±	3.1	0.9	1.51	4.2	0.3
	3	46.4	15.4	9.29	12.3	7.8
	±	3.0	1.2	0.48	3.8	0.3
	4	47.5	15.7	8.88	14.3	8.1
	±	1.7	0.7	0.63	5.1	0.6
110	1	41.8	14.0	7.22	9.8	-
	±	3.6	1.1	0.99	2.7	-
	2	41.6	14.1	7.31	10.7	-
	±	3.9	1.4	0.75	4.4	-
	3	41.6	14.0	7.59	9.7	-
	±	2.2	0.7	0.59	3.3	-
	4	40.9	13.8	7.48	17.8 <sup>S+</sup>	-
	±	1.4	0.5	0.54	6.6	-

S+ = Significantly higher than control at  $p < 0.05$ .

S- = Significantly lower than control at  $p < 0.05$ .



Figure No. 4A - Group mean blood chemistry values and standard deviations

Interval In Weeks	Group No.	BUN mg. %	SG-PT R-F.	Alk. Phos. K-A Units	L-Phenylalanine mg/dl
MALES					
110	1	37.0	40.0	14.6	1.78
	±	16.8	19.7	6.8	0.27
	2	35.4	43.8	31.8	1.86
	±	7.3	27.1	42.3	0.32
	3	55.0	37.8	16.0	1.62
	±	1.4	12.6	12.0	0.14
	4	66.5	39.5	15.9	1.74
	±	34.7	15.8	5.2	0.34
FEMALES					
110	1	60.2	44.8	16.2	2.32
	±	23.5	12.6	8.1	0.28
	2	45.5	30.7 S-	16.3	1.88 S-
	±	11.0	7.8	10.6	0.31
	3	87.3	27.7 S-	18.9	1.65 S-
	±	33.7	4.9	9.9	0.33
	4	44.0	37.0	16.2	1.71 S-
	±	11.3	13.2	3.5	0.36

S- = Significantly lower than control at  $p < 0.05$ .



Results of blood chemistry determinations obtained at termination likewise failed to reveal consistent evidence of a compound effect. Blood urea nitrogen values for each animal including controls were slightly to markedly elevated. A few control and treated mice exhibited high serum glutamic-pyruvic transaminase or alkaline phosphatase values. There were no biologically meaningful differences between control and test data. Serum L-phenylalanine determinations were unremarkable for male groups but mean values for the three female treated groups were significantly decreased; this finding is considered of little biological significance since differences in individual values for control and test animals were minor in degree.

Results of terminal urine analysis were not remarkable.

#### Results of Eye Examinations

Ophthalmoscopic examinations performed initially at four weeks and at 20, 40, 60, and 110 weeks on all surviving mice (using Mydriacyl<sup>®</sup> as a mydriatic and a binocular indirect ophthalmoscope) revealed no evidence of any compound-related alterations in any of the test groups. At termination the percent of animals with cataracts was increased for Groups No. 2 and No. 4 as compared to the controls but was similar between Group No. 3 and the control group. This finding is considered incidental; the absolute number of affected animals in the treated groups was relatively small and was similar to or less than in the controls; no dose-response relationship was evident. Corneal opacity was observed in only a small number of control and test mice throughout the study. Ophthalmoscopic findings are summarized in Figure No. 5 and are detailed in appended Table No. 5 (Page No. 57).

Figure No. 5 - Summary of eye lesions detected by ophthalmoscopy

Diagnosis	Control		0.25 g/kg		0.50 g/kg		1.00 g/kg	
	Incidence*	%	Incidence	%	Incidence	%	Incidence	%
20-Week Examination								
Corneal opacity; Unilateral	1/140**	0.7	0/71	0.0	0/71	0.0	0/70	0.0
Opaque coating on cornea; Unilateral	1/140	0.7	0/71	0.0	0/71	0.0	0/70	0.0
40-Week Examination								
Corneal opacity; Unilateral	2/129	1.6	2/67	3.0	1/67	1.5	2/68	2.9
Bilateral	2/129	1.6	1/67	1.5	0/67	0.0	0.68	0.0
Cataract; Unilateral	1/129	0.8	1/67	1.5	0/67	0.0	0/68	0.0
60-Week Examination								
Corneal opacity; Unilateral	2/113	1.8	3/62	4.8	2/64	3.1	4/60	6.7
Bilateral	4/113	3.5	2/62	3.2	3/64	4.7	0/60	0.0
Cataract; Unilateral	0/113	0.0	3/62	4.8	0/64	0.0	0/60	0.0
110-Week Examination								
Corneal opacity; Unilateral	1/48	2.1	3/19	15.8	2/20	10.0	0/16	0.0
Bilateral	8/48	16.7	2/19	10.5	2/20	10.0	1/16	6.3
Cataract; Unilateral	3/48	6.3	2/19	10.5	2/20	10.0	2/16	12.5
Bilateral	16/48	33.3	8/19	42.1	5/20	25.0	7/16	43.8

\* Combined sexes; based on Appendix Table No. 5.

\*\* No. of animals affected/No. of animals examined.



#### Observations at Necropsy

A summary of observations recorded at gross necropsy is presented in appended Table No. 6 (Page No. 62) for animals sacrificed at termination, and in appended Table No. 6A (Page No. 65) for deaths (data for mice which died or were killed in extremis are combined).

Evaluation of gross necropsy data did not show any consistent alterations in any organs or tissues that could be attributed to administration of any dosage level of SC-19192. In general, necropsy findings consisted of incidental alterations commonly found in laboratory mice of this age; frequency of findings was not meaningfully different between control and treated groups.

A tabulated summary restricted to gross alterations occurring at ostensibly differing incidences in control or treated surviving mice is presented in Figure No. 6.

#### Organ Weights

Mean terminal body weights, organ weights, organ/body weight ratios, and their standard deviations for those animals that survived the 110-week study are presented in appended Table No. 7 (Page No. 72); a summary of statistically significant differences in relative organ weight data (organ/body weight ratios) is presented in Figure No. 7.

Figure No. 6 - Summary of gross necropsy findings occurring at notably differing incidences in control and treated survivors

Number of Animals Per Group	MALES				FEMALES			
	C	L	M	H	C	L	M	H
	<u>22</u> %	<u>11</u> %	<u>14</u> %	<u>6</u> %	<u>19</u> %	<u>7</u> %	<u>6</u> %	<u>9</u> %
LUNG								
Nodular	14	36	14	17	0	0	0	0
Yellow or gray foci	5	0	14	0	21	0	17	11
LIVER								
Cystic	0	9	21	0	11	0	0	11
SPLEEN								
Small	14	9	64	50	5	14	17	0
Margins translucent	5	0	0	0	0	0	17	22
KIDNEY								
Cortex cystic	27	9	36	0	0	0	0	11
Medulla dark red	14	9	0	17	37	0	0	0
STOMACH								
Lining smooth	14	9	0	0	21	14	0	0
PANCREAS								
Granular	0	0	0	0	0	29	0	0
Yellow or white foci	5	36	50	33	11	43	17	0
SEMINAL VESICLE								
Small	5	0	36	33				
OVARY								
Cystic					95	71	83	78
UTERUS								
Distended					79	57	67	33
Walls thickened					74	43	67	67
Nodular and/or cystic					68	71	100	22

C = Control; L = Low; M = Medium; H = High

Figure No. 7 - Summary of all statistically significant differences in relative organ weight data for the test groups as compared to the controls\*

	<u>Group No. 2</u>		<u>Group No. 3</u>		<u>Group No. 4</u>	
	<u>0.25 g/kg</u>		<u>0.50 g/kg</u>		<u>1.00 g/kg</u>	
	M	F	M	F	M	F
Thyroid/Body						
Weight Ratio			S+			S+

S+ = Significantly higher than control at  $p < 0.05$ .

\* = Statistically significant differences in absolute organ weights are presented in appended Table No. 7.



### Tumor Incidence

The frequencies of types of histologically-proven tumors (Figure No. 8); identification of animals bearing histologically-proven tumors (Figure No. 9); tumor incidence unadjusted, i.e. uncorrected for survival rate (Figure No. 10); and tumor incidence adjusted, i.e. adjusted for differing survival rates (Figure No. 11) are presented on the following pages.

A detailed evaluation of brain tissue to determine the presence or absence of intracranial neoplasms was performed on control and treated mice including all survivors and nonsurvivors for which suitable tissues were available for histologic preparation. The brain tissue was examined such that five coronal sections representing the major neuroanatomic areas of the brain were evaluated from each animal; two sections per block were examined thus providing a total of 10 sections per brain. A single primary neoplasm considered to be a meningioma was noted in one control female. Primary intracranial neoplasms were not noted in any other controls or in any treated animals. Metastatic neoplasms involving brain tissue were evident in a small number of mice as follows: four control males, two low dose males, and one female at each treatment level - lymphosarcoma or reticulum cell sarcoma involved in other organs and tissues also present in the brain.

Four sections of urinary bladder were examined from animals in the control and three treated groups including all survivors and nonsurvivors for which suitable tissues were available for evaluation. The urinary bladder was cut in half longitudinally, both hemispheres embedded, and



two sections cut from each hemisphere with approximately 50 microns between each section. No primary neoplasms were evident in the urinary bladder of any of the control or treated mice. Metastatic lymphosarcoma involved in several organs and tissues including the urinary bladder was noted in one control and one mid dose male and in one low dose, two mid dose, and four high dose females.

The tissues listed in Figure No. 8 and the number of them which were examined microscopically (No. Examined) were obtained as indicated on Page No. 9. These same tissues are listed in the table on Page No.12 along with tissues which were examined microscopically but found to have no tumors present. Only tumors for which the primary site was identified are listed under specific organs; those tumors for which the primary site could not be determined are listed separately and without reference to the tissue(s) in which they were found.

Figure No. 9 identifies those animals bearing histologically-proven tumors. Some mice bore multiple tumors. The time of contraction for each specific type of tumor is taken as the week in which only the tumor in question was first suspected from external signs, provided the suspicion was later confirmed by histological examination. For each animal, all organs in which tumors were found are listed. In cases of metastases, footnotes indicate whether or not the primary site could be determined.



Figure No. 8 - Frequencies of types of histologically-proven tumors in male and female mice receiving SC-19192 or serving as controls.

Tumor Type	MALES				FEMALES			
	GROUP NUMBER				GROUP NUMBER			
	1	2	3	4	1	2	3	4
	Control 0.25 g/kg 0.50 g/kg 1.0 g/kg				Control 0.25 g/kg 0.50 g/kg 1.0 g/kg			
Primary Site Identified:								
Brain (No. Examined)	(65)	(32)	(34)	(32)	(67)	(34)	(34)	(35)
Meningioma - M	0	0	0	0	1	0	0	0
Heart (No. Examined)	(66)	(13)	(25)	(32)	(66)	(12)	(24)	(35)
Angioma - B	0	0	0	0	1	0	0	0
Lung (No. Examined)	(66)	(13)	(25)	(32)	(67)	(16)	(24)	(35)
Adenoma - B	19	4	4	2	3	3	2	1
Adenocarcinoma - M	0	0	0	2	0	0	0	0
Spleen (No. Examined)	(63)	(17)	(26)	(30)	(62)	(19)	(30)	(35)
Angioma - B	2	0	1	0	1	1	1	0
Angiosarcoma - M	0	0	0	0	0	0	1	0
Liver (No. Examined)	(66)	(15)	(25)	(32)	(68)	(18)	(25)	(34)
Hepatoma - M	4	1	3	0	1	0	0	0
Angioma - B	0	1	0	1	0	0	0	0
Angiosarcoma - M	0	1	0	1	0	0	0	0
Kidney (No. Examined)	(66)	(13)	(30)	(32)	(67)	(16)	(27)	(35)
Adenocarcinoma - M	2	0	0	0	0	0	0	0
Adrenal (No. Examined)	(59)	(12)	(24)	(29)	(65)	(12)	(24)	(34)
Cortical Adenoma - B	1	0	0	0	0	0	0	0
Pancreas (No. Examined)	(66)	(14)	(24)	(30)	(64)	(13)	(25)	(33)
Islet Cell Tumor - B	0	0	0	0	0	0	1	0

B=Benign

M=Malignant

Figure No. 8 - Continued

Tumor Type	MALES				FEMALES			
	GROUP NUMBER				GROUP NUMBER			
	1	2	3	4	1	2	3	4
Control	0.25 g/kg	0.50 g/kg	1.0 g/kg	1.0 g/kg	Control	0.25 g/kg	0.50 g/kg	1.0 g/kg
Primary Site Identified (Cont'd)								
Stomach (No. Examined)								
Adenoma - B	(66)	(14)	(26)	(32)	(67)	(20)	(29)	(35)
Squamous Carcinoma - M	0	1	0	0	0	0	0	0
	0	0	0	0	0	1	0	0
Lymph Node (No. Examined)								
Angioma - B	(48)	(5)	(4)	(28)	(51)	(5)	(5)	(27)
Angiosarcoma - M	0	0	0	0	1	0	0	0
Lymphosarcoma - M	1	0	0	0	0	0	0	0
Reticulum Cell Sarcoma - M	4	2	2	0	4	2	3	6
	3	0	0	0	2	0	1	0
Testis (No. Examined)								
Interstitial Cell Tumor - B	(65)	(13)	(24)	(32)				
	2	0	0	0				
Ovary (No. Examined)								
Granulosa Cell Tumor - M	(56)	(21)	(28)	(32)	(56)	(21)	(28)	(32)
	0	1	1	0	0	1	1	0
Uterus (No. Examined)								
Leiomyoma - B	(62)	(22)	(30)	(35)	(62)	(22)	(30)	(35)
Leiomyosarcoma - M	2	1	1	0	2	1	1	0
Scirrhus Carcinoma - M	2	0	2	1	2	0	2	1
Angioma - B	1	0	0	0	1	0	0	0
Angiosarcoma - M	2	1	0	2	2	1	0	2
	0	1	0	0	0	1	0	0
Vagina (No. Examined)								
Carcinoma - M	(56)	(11)	(20)	(30)	(56)	(11)	(20)	(30)
	2	0	0	0	2	0	0	0

B=Benign  
M=Malignant

Figure No. 8 - Continued

Tumor Type	MALES				FEMALES			
	GROUP NUMBER				GROUP NUMBER			
	1	2	3	4	1	2	3	4
Control	0.25 g/kg	0.50 g/kg	1.0 g/kg	1.0 g/kg	Control	0.25 g/kg	0.50 g/kg	1.0 g/kg
Primary Site Identified: (Cont'd)								
Muscle (No. Examined)	(65)	(0)	(1)	(31)	(65)	(1)	(0)	(34)
Undifferentiated Sarcoma - M	0	0	0	0	1	0	0	0
Tissue Mass								
Undifferentiated Sarcoma - M	1	0	0	0	0	0	0	1
Primary Site Not Identified:								
Lymphosarcoma - M	0	0	0	0	3	2	2	0
Reticulum Cell Sarcoma - M	1	0	0	1	0	1	0	1
Angiosarcoma - M	1	0	0	0	0	0	0	0
Mesothelioma - M	1	0	0	0	0	0	0	0
Metastatic Tumor - M	0	0	0	0	0	1	0	0
Sarcoma - M	0	0	0	0	1	0	0	0
Total Number Tumors	42 <sup>a</sup>	10 <sup>a</sup>	10	7	28 <sup>a</sup>	15 <sup>a</sup>	15 <sup>a</sup>	12

B=Benign

M=Malignant

a=For the Group No. 1 males and females, Group No. 2 males and females, and Group No. 3 females, the total number of tumors exceeds the total number of tumor-bearing mice (given in Figure No. 10 under the heading "Any Tumor"), since some mice bore multiple tumors.

Figure No. 9 - Identification of animals bearing histologically-proven tumors

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
1	M	01085	Testis - Interstitial Cell Tumor (B)	110
1	M	01087	Lung - Adenoma (B) Liver - Hepatoma (M)	110 110
1	M	01088	Lung - Adenoma (B)	110
1	M	01090	Lung - Adenoma (B)	109
1	M	01091	Lung - Adenoma (B)	110
1	M	01092	Lymph Node, Spleen, Liver, Kidney, Pancreas and Seminal Vesicle - Lymphosarcoma (M) <sup>a</sup>	110
1	M	01093	Lymph Node, Brain, Spleen, Liver, Pancreas Muscle, and Bone Marrow - Lymphosarcoma (M) <sup>a</sup>	104
1	M	01095	Lung - Adenoma (B)	109
1	M	01099	Lung - Adenoma (B)	105
1	M	01100	Lung - Adenoma (B)	76
1	M	01101	Spleen - Angioma (B)	97
1	M	01102	Lymph Node, Brain, Heart, Lung, Spleen, Liver, Gallbladder, Kidney, Adrenal, Stomach, Pancreas, Salivary Gland, Testis, Prostate, Seminal Vesicle, Urinary Bladder, Muscle, Eye, Spinal Cord, and Bone Marrow - Lymphosarcoma (M) <sup>a</sup>	62

\* The time of contraction is taken as the week in which a tumor was first suspected from external signs provided the suspicion was later confirmed by histological examinations. If a tumor was found at necropsy in an animal in which it had not previously been suspected, the week the animal was found dead or killed is taken as the week of contraction.

(B) = Benign; (M) = Malignant

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
1	M	01103	Lung - Adenoma (B)	110
1	M	01105	Lung - Adenoma (B) Lymph Node - Angiosarcoma (M)	100 100
1	M	01109	Lung - Adenoma (B)	76
1	M	01111	Spleen - Angioma (B)	110
1	M	01112	Lung - Adenoma (B)	110
1	M	01119	Liver - Hepatoma (M) Testis - Interstitial Cell Tumor (B) Lymph Node, Lung, Spleen, Liver, Kidney, Pancreas, Prostate, and Seminal Vesicle - Reticulum Cell Sarcoma (M) <sup>b</sup>	110 110  110
1	M	01121	Kidney - Adenocarcinoma (M)	104
1	M	01123	Lung - Adenoma (B)	110
1	M	01124	Lymph Node - Reticulum Cell Sarcoma (M)	95
1	M	01130	Lung - Adenoma (B) Lymph Node, Brain, Lung, Spleen, Liver, Pancreas, Salivary Gland, Testis, Prostate, Seminal Vesicle, and Mesentery - Lymphosarcoma (M) <sup>a</sup>	80  80
1	M	01131	Lung - Adenoma (B)	109
1	M	01133	Heart, Lung and Testis - Mesothelioma (M) <sup>c</sup>	81

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

b = Reticulum Cell Sarcoma: Lymph node considered primary site; other site(s) considered secondary.

c = Mesothelioma: Primary site not identified.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
1	M	01135	Spleen and Liver - Angiosarcoma (M) <sup>d</sup>	106
1	M	01136	Liver - Hepatoma (M)	100
1	M	01137	Lung - Adenoma (B)	91
1	M	01145	Lung - Adenoma (B)	110
1	M	01146	Lung - Adenoma (B)	110
			Liver - Hepatoma (M)	110
			Kidney - Adenocarcinoma (M)	110
			Tissue Mass - Undifferentiated Sarcoma; liver - Metastatic Sarcoma (M) <sup>e</sup>	88
1	M	01153	Lung - Adenoma (B)	67
1	M	01154	Lung - Adenoma (B)	110
			Lymph Node, Brain, Heart, Lung, Spleen, Kidney, Muscle, and Nerve - Reticulum Cell Sarcoma (M) <sup>b</sup>	110
1	M	01155	Adrenal - Cortical Adenoma (B)	107
			Spleen and Liver - Reticulum Cell Sarcoma (M) <sup>f</sup>	107

b = Reticulum Cell Sarcoma: Lymph node considered primary site; other site(s) considered secondary.

d = Angiosarcoma: Primary site not identified.

e = Undifferentiated Sarcoma: Tissue mass considered primary site; metastatic sarcoma in liver considered secondary site.

f = Reticulum Cell Sarcoma: Primary site not identified.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
2	M	01237	Lymph Node, Brain, and Spleen - Lymphosarcoma (M) <sup>a</sup>	31
2	M	01244	Liver - Angioma (B)	99
2	M	01248	Lymph Node, Brain, and Spleen - Lymphosarcoma (M) <sup>a</sup>	75
2	M	01249	Lung - Adenoma (B)	110
			Stomach - Adenoma (B)	110
2	M	01255	Lung - Adenoma (B)	110
			Liver - Hepatoma (M)	110
2	M	01257	Lung - Adenoma (B)	110
			Liver - Angiosarcoma (M)	110
2	M	01262	Lung - Adenoma (B)	91

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
3	M	01303	Spleen - Angioma (B)	102
3	M	01308	Lung - Adenoma (B)	110
3	M	01311	Lymph Node and Pancreas - Lymphosarcoma (M) <sup>a</sup>	95
3	M	01318	Lung - Adenoma (B)	110
3	M	01319	Liver - Hepatoma (M)	85
3	M	01322	Lymph Node, Heart, Spleen, Kidney, and Urinary Bladder - Lymphosarcoma (M) <sup>a</sup>	57
3	M	01324	Liver - Hepatoma (M)	110
3	M	01330	Lung - Adenoma (B)	101
3	M	01331	Lung - Adenoma (B)	110
3	M	01332	Liver - Hepatoma (M)	110

a = Lymphosarcoma: Lymph node considered the primary site; other site(s) considered secondary.



Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
4	M	01377	Lung - Adenoma (B)	83
4	M	01381	Liver - Angioma (B)	110
4	M	01387	Lung - Adenocarcinoma (M)	110
4	M	01398	Lung - Adenocarcinoma (M)	110
4	M	01401	Lung - Adenoma (B)	110
4	M	01403	Liver - Angiosarcoma (M)	92
4	M	01405	Lung, Spleen, and Liver - Reticulum Cell Sarcoma (M) <sup>f</sup>	52

f = Reticulum Cell Sarcoma: Primary site not identified.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
1	F	01163	Lymph Node, Heart, Lung, Spleen, Liver, Kidney, and Muscle - Lymphosarcoma (M) <sup>a</sup>	93
1	F	01164	Lymph Node - Angioma (B)	110
			Lymph Node, Lung, and Spleen - Reticulum Cell Sarcoma (M) <sup>b</sup>	110
1	F	01165	Uterus - Scirrhus Carcinoma (M)	110
1	F	01170	Lymph Node, Heart, Spleen, Pancreas, Ovary, and Salivary Gland - Lymphosarcoma (M) <sup>a</sup>	110
1	F	01173	Tissue Mass - Sarcoma (M) <sup>g</sup>	110
1	F	01174	Brain - Meningioma; Lung - Metastatic Tumor (M) <sup>h</sup>	65
1	F	01179	Heart, Lung, Liver, and Bone Marrow - Lymphosarcoma (M) <sup>i</sup>	55
1	F	01180	Uterus - Leiomyosarcoma (M)	110
			Vagina - Carcinoma (M)	110
1	F	01181	Spleen and Liver - Lymphosarcoma (M) <sup>i</sup>	99
1	F	01184	Lung - Adenoma (B)	110
			Uterus - Angioma (B)	110
1	F	01187	Spleen - Angioma (B)	110
1	F	01191	Lung - Adenoma (B)	92
1	F	01195	Uterus - Leiomyoma (B)	60

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

b = Reticulum Cell Sarcoma: Lymph node considered primary site; other site(s) considered secondary.

g = Sarcoma: Primary site not identified.

h = Meningioma: Brain primary site; metastatic tumor found in the lung had features comparable to the meningioma and was considered to be a secondary site.

i = Lymphosarcoma: Primary site not identified.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
1	F	01197	Lymph Node, Heart, Lung, Spleen, Liver Pancreas, Ovary, Salivary Gland, and Muscle - Lymphosarcoma (M) <sup>a</sup>	69
1	F	01199	Lymph Node, Lung, Muscle and Bone Marrow - Lymphosarcoma (M) <sup>a</sup>	50
1	F	01200	Uterus - Angioma (B)	91
1	F	01204	Uterus - Leiomyosarcoma (M)	80
1	F	01211	Heart, Spleen, Liver, and Pancreas - Lymphosarcoma (M) <sup>i</sup>	109
1	F	01215	Uterus - Leiomyoma (B)	110
1	F	01216	Heart - Angioma (B) Lymph Node, Spleen, Liver, Kidney, Pancreas, Small Intestine and Ovary - Reticulum Cell Sarcoma (M) <sup>b</sup>	104 104
1	F	01217	Liver - Hepatoma (M)	110
1	F	01218	Lung - Adenoma (B)	110
1	F	01222	Muscle, Lung, and Mesentery - Undifferentiated Sarcoma (M) <sup>j</sup>	101
1	F	01228	Vagina - Carcinoma (M)	110

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

b = Reticulum Cell Sarcoma: Lymph node considered primary site; other site(s) considered secondary.

i = Lymphosarcoma: Primary site not identified.

j = Undifferentiated Sarcoma: Skeletal muscle considered primary site; other sites considered secondary.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
2	F	01265	Lung - Adenoma (B)	107
2	F	01268	Stomach - Squamous Carcinoma (M)	82
2	F	01269	Spleen, Kidney, and Liver - Lymphosarcoma (M) <sup>i</sup>	110
2	F	01272	Ovary - Granulosa Cell Tumor (M)	110
			Uterus - Angioma (B)	110
2	F	01275	Lung - Adenoma (B)	110
2	F	01276	Uterus - Angiosarcoma (M)	91
2	F	01285	Lung - Adenoma (B)	110
2	F	01288	Uterus - Leiomyoma (B)	110
2	F	01289	Lymph Node, Spleen, Liver, Kidney, Pancreas, Ovary, Urinary Bladder, Salivary Gland, Muscle, and Bone Marrow - Lymphosarcoma (M) <sup>a</sup>	52
2	F	01293	Stomach - Metastatic Tumor (M) <sup>k</sup>	72
2	F	01294	Spleen - Angioma (B)	107
2	F	01296	Spleen and Liver - Reticulum Cell Sarcoma (M) <sup>f</sup>	101
2	F	01299	Lymph Node, Brain, Spleen, Ovary, and Salivary Gland - Lymphosarcoma (M) <sup>a</sup>	78
2	F	01300	Liver - Lymphosarcoma (M) <sup>i</sup>	107

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

f = Reticulum Cell Sarcoma: Primary site not identified.

i = Lymphosarcoma: Primary site not identified.

k = Metastatic Tumor: Primary site not identified although neoplasm involving the stomach had morphological features suggestive of a granulosa cell tumor.

Figure No. 9 - Continued

Group No.	Sex	Mouse No.	Tumor Type	Time of* Contraction Week No.
3	F	01338	Spleen - Angiosarcoma (M)	74
3	F	01340	Lymph Node and Liver - Lymphosarcoma (M) <sup>a</sup>	72
3	F	01344	Uterus - Leiomyosarcoma; Liver - Metastatic Sarcoma (M) <sup>1</sup>	107
3	F	01346	Lung - Adenoma (B)	82
3	F	01347	Pancreas - Islet Cell Tumor (B)	110
3	F	01348	Lymph Node, Brain, Spleen, Stomach, Pancreas, Uterus, and Urinary Bladder - Lymphosarcoma (M) <sup>a</sup>	79
3	F	01352	Uterus - Leiomyoma (B)	108
3	F	01353	Spleen - Angioma (B)	101
3	F	01354	Ovary - Granulosa Cell Tumor (M)	110
3	F	01356	Lymph Node, Spleen, and Pancreas - Reticulum Cell Sarcoma (M) <sup>b</sup>	93
3	F	01362	Lung - Adenoma (B)	103
3	F	01365	Heart, Lung, Spleen, Liver, Pancreas, Large Intestine, Uterus and Urinary Bladder - Lymphosarcoma (M) <sup>i</sup>	83
3	F	01366	Lymph Node, Spleen, and Stomach - Lymphosarcoma (M) <sup>a</sup>	61
3	F	01367	Spleen - Lymphosarcoma (M) <sup>i</sup>	95
			Uterus - Leiomyosarcoma (M)	95

a = Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

b = Reticulum Cell Sarcoma: Lymph node considered primary site; other site(s) considered secondary.

i = Lymphosarcoma: Primary site not identified.

1 = Leiomyosarcoma: Uterine tumor considered primary site; liver tumor (sarcoma) considered secondary site.

Figure No. 9 - Continued

<u>Group No.</u>	<u>Sex</u>	<u>Mouse No.</u>	<u>Tumor Type</u>	<u>Time of* Contraction Week No.</u>
4	F	01330	Lymph Node, Heart, Lung, Spleen, Liver, Kidney, Stomach, Pancreas, Ovary, Uterus, Muscle, Urinary Bladder, Salivary Gland, and Tissue Mass - Lymphosarcoma (M) <sup>a</sup>	84
4	F	01410	Uterus - Leiomyosarcoma (M)	110
4	F	01414	Uterus - Angioma (B)	106
4	F	01415	Lung - Adenoma (B)	104
4	F	01420	Lymph Node, Heart, Lung, Spleen, Liver, Kidney, Uterus, Urinary Bladder, Muscle, Spinal Cord, and Bone Marrow - Lymphosarcoma (M) <sup>a</sup>	68
4	F	01422	Lymph Node, Heart, Lung, Spleen, Liver, Kidney, Stomach, Pancreas, Ovary, Urinary Bladder, Salivary Gland, Muscle and Bone Marrow - Lymphosarcoma (M) <sup>a</sup>	57
4	F	01423	Lymph Node, Brain, Lung, Spleen, Liver, Kidney, Stomach, Pancreas, Uterus, Urinary Bladder, and Eye - Lymphosarcoma (M) <sup>a</sup>	80
4	F	01428	Lymph Node, Liver, and Kidney - Lymphosarcoma (M) <sup>a</sup>	89
4	F	01432	Uterus - Angioma (B)	96
4	F	01438	Tissue Mass - Undifferentiated Sarcoma (M)	100
4	F	01440	Heart, Lung, Liver, and Kidney - Reticulum Cell Sarcoma (M) <sup>f</sup>	106
4	F	01442	Lymph Node, Spleen, Liver, Pancreas, Large Intestine, and Muscle - Lymphosarcoma (M) <sup>a</sup>	100

a - Lymphosarcoma: Lymph node considered primary site; other site(s) considered secondary.

f - Reticulum Cell Sarcoma: Primary site not identified.



Figure No. 10 presents tumor incidence unadjusted, i.e. uncorrected for survival rate (no. of mice affected/no. mice available for histopathological examination X 100). It includes all mice, whether dead, killed in extremis, or killed by design, which had histologically-proven tumors. Tumor types presented in this figure are any tumor, only benign tumor, and any malignant tumor as well as primary lung tumor, lymphoreticular cell tumor, and vascular tumor; the latter three were included since they represent the types of tumors most frequently found in this study.

Tumor incidence adjusted, i.e. based on the number of animals actually at risk in each group and sex\*, is presented in Figure No. 11. Statistical analysis was performed on these data. In no instance in either sex at any of the treated levels was the adjusted tumor incidence (P) of any of the tumor types analyzed (any tumor, only benign tumor, any malignant tumor, primary lung tumor, lymphoreticular cell tumor, and vascular tumor) significantly higher than that of the respective controls. The adjusted tumor incidences for any tumors in the Group No. 2 and Group No. 3 males, only benign tumors in the Group No. 2 males, primary lung tumors in the Group No. 3 males, and lymphoreticular cell tumors in the Group No. 2 and Group No. 4 males were significantly lower than that of the control males. There were no statistically significant differences between adjusted tumor incidence data for the control and treated females.

\* This analysis is based on the number of animals started on test.

Figure No. 10 - Tumor incidence (unadjusted) for male and female ICR Swiss mice\* receiving SC-19192 or serving as controls

TUMOR TYPE		MALES				FEMALES			
		GROUP NUMBER				GROUP NUMBER			
		1	2	3	4	1	2	3	4
		CONTROL	.25 G/KG	.50 G/KG	1.0 G/KG	CONTROL	.25 G/KG	.50 G/KG	1.0 G/KG
No. Mice Started on Test:		72	36	36	35	72	36	36	37
No. Mice Available for Histopathological Examination:		66	32	34	32	68	34	35	35
Any Tumor <sup>a</sup> :	No. %	32**	7	10	7	24	14	14	12
		48.5 <sup>φ</sup>	21.9	29.4	21.9	35.3	41.2	40.0	34.3
Only Benign Tumor <sup>b</sup> :	No. %	17	3	5	3	7	5	5	3
		25.8	9.4	14.7	9.4	10.3	14.7	14.3	8.6
Any Malignant Tumor <sup>c</sup> :	No. %	15	4	5	4	17	9	9	9
		22.7	12.5	14.7	12.5	25.0	26.5	25.7	25.7
Primary Lung Tumor <sup>d</sup> :	No. %	19	4	4	4	3	3	2	1
		28.8	12.5	11.8	12.5	4.4	8.8	5.7	2.9
Lymphoreticular Cell Tumor <sup>e</sup> :	No. %	8	2	2	1	9	5	6	7
		12.1	6.3	5.9	3.1	13.2	14.7	17.1	20.0
Vascular Tumor <sup>f</sup> :	No. %	4	2	1	2	5	3	2	2
		6.1	6.3	2.9	6.3	7.4	8.8	5.7	5.7

a = Includes all histologically-proven tumors listed in Figures No. 8 and No. 9; some mice had more than one tumor type.

b = Includes mice that had only benign tumors.

c = Includes mice that had only malignant or both malignant and benign tumors.

d = Includes mice that had lung adenomas or adenocarcinomas.

e = Includes mice that had lymphosarcomas or reticulum cell sarcomas.

f = Includes mice that had angiosarcomas or angiosarcomas.

\* = Includes all mice on study whether found dead, killed in extremis, or killed by design.

\*\* = No. mice affected.

φ = Percent of mice affected; no. with tumor/no. available for histopathological examination X 100.



Figure No. 11 - Tumor incidence (adjusted) for male and female ICR Swiss mice receiving SC-19192 or serving as controls

TUMOR TYPE	MALES					FEMALES				
	GROUP NUMBER					GROUP NUMBER				
	1	2	3	4		1	2	3	4	
	CONTROL	.25 G/KG	.50 G/KG	1.0 G/KG		CONTROL	.25 G/KG	.50 G/KG	1.0 G/KG	
Any Tumor: P [N]	76.6 41.8	38.6 <sup>S-</sup> 18.1	48.5 <sup>S-</sup> 20.6	63.3 11.1		64.8 37.0	78.1 17.9	69.9 20.0	52.8 22.7	
Only Benign Tumor: P [N]	51.5 33.0	18.1 <sup>S-</sup> 16.6	29.8 <sup>S-</sup> 16.8	32.2 9.3		24.3 28.8	50.4 9.9	42.5 11.8	20.4 14.7	
Any Malignant Tumor: P [N]	41.6 36.1	23.3 17.2	23.2 21.6	37.5 10.7		48.0 35.4	47.0 19.1	45.5 19.8	40.6 22.2	
Primary Lung Tumor: P [N]	56.1 33.9	30.5 13.1	25.5 <sup>S-</sup> 15.7	45.7 8.8		11.7 25.6	33.3 9.0	12.5 16.0	7.6 13.2	
Lymphoreticular Cell Tumor: P [N]	24.7 32.4	6.2 <sup>S-</sup> 32.3	7.1 28.2	3.3 <sup>S-</sup> 30.3		25.0 36.0	30.3 16.5	23.4 25.6	29.1 24.1	
Vascular Tumor: P [N]	13.3 30.1	14.2 14.1	5.7 17.5	21.0 9.5		19.3 25.9	24.7 12.1	10.9 18.3	13.8 14.5	

P = Adjusted tumor incidence, i.e. based on the number of animals with histologically-proven tumors actually observed and the number of animals actually at risk in each group and sex (adjusted for differing survival rates): calculated probability, x 100, of developing a tumor during the total test period.

[N] = Estimate of the "effective number" of animals on test over the entire period: number of tumor bearing mice/P.

S- = Significantly lower than control at  $p < 0.05$ .

[Adjusted tumor incidences (probability data) for each specific tumor type were determined by the life-table technique. References: Primary method - Sachs, R., Toxicol. Appl. Pharmacol. 1, 203, 1959. Additional explanation - McKinney, et al., Toxicol. Appl. Pharmacol. 12, 68, 1968. Statistical analysis of adjusted tumor incidences between control and test groups was performed by the student's t-test at the 5.0% probability level.]



### Microscopic Examination of Tissues

A tabulation of all non-neoplastic lesions is presented in Figures No. 12 and No. 12A, Pages No. 55 and No. 62 .

Small mineral deposits which elicited no tissue reaction were noted within the cerebral parenchyma in a small number of control and treated animals. However, the actual number of affected animals was low; the finding was clearly not dose related; and the high level females (survivors and non-survivors combined) exhibited the lowest incidence. Therefore this finding is considered of minor biological significance. Focal hemorrhage which was probably due to incidental trauma was noted within the brain of one control and two high dose females; degeneration apparently due to trauma was evident in one mid dose female. Mild perivascular cuffing with mononuclear cells was noted within the brain of one high dose female. These cerebral changes, with the exception of the mineral deposition, were observed in animals which died during the study. No significant alterations were evident with regard to the pituitary.

Deposition of amyloid in the thyroid was generally accompanied by similar deposition in other organs and tissues. Incidence of this finding was not meaningfully different between control and treated groups. Minimal to mild nonsuppurative interstitial thyroiditis was noted in small numbers of control and treated mice. Moderate adenomatous hyperplasia involved the thyroid of one high dose male.

Hyperplasia of the outer adrenal cortex or capsule, characterized by a proliferation of cells in that area, was noted in large numbers of both control and treated animals; this change was slightly more common in females than in males. Deposition of amyloid within the adrenal was likewise noted in

Figure No. 12 - Summary of histopathological findings (all non-neoplastic changes)  
for surviving mice treated with SC-19192 or serving as controls

	MALES								FEMALES								
	INCIDENCE				%				INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H	
BRAIN																	
Mineral Deposition	3/22*	1/11	4/14	2/6	14	9	29	33	5/19	1/7	3/6	0/9	26	14	50	0	0
PITUITARY																	
Unremarkable	19/19	9/9	10/10	4/4	100	100	100	100	18/18	7/7	5/5	7/7	100	100	100	100	100
THYROID																	
Amyloid	4/22	2/11	3/14	2/6	18	18	21	33	3/17	1/5	3/6	2/9	18	20	50	22	22
Nonsuppurative Thyroiditis	1/22	0/11	2/14	1/6	5	0	14	17	2/17	1/5	0/6	1/9	12	20	0	11	11
ADRENAL																	
Cortical Hyperplasia	10/21	5/11	9/14	3/6	48	45	64	50	18/19	4/7	6/6	9/9	95	57	100	100	100
Amyloid	8/21	3/11	6/14	4/6	38	27	43	67	7/19	1/7	1/6	3/9	37	14	17	33	33
Cortical Hypertrophy	0/21	2/11	0/14	1/6	0	18	0	17	0/19	0/7	0/6	0/9	0	0	0	0	0
Cortical Atrophy	1/21	1/11	0/14	0/6	5	9	0	0	0/19	0/7	0/6	0/9	0	0	0	0	0
HEART																	
Nonsuppurative																	
Myocarditis	3/22	3/11	5/14	2/6	14	27	36	33	1/19	0/7	3/6	2/9	5	0	50	22	22
Arteritis	5/22	4/11	1/14	0/6	23	36	7	0	2/19	0/7	0/6	2/9	11	0	0	22	22
Thrombosis	3/22	1/11	1/14	0/6	14	9	7	0	2/19	0/7	1/6	0/9	11	0	17	0	0
Amyloid	3/22	1/11	3/14	3/6	14	9	21	50	1/19	1/7	1/6	0/9	5	14	17	17	0

C = Control; L = Low; M = Medium; H = High  
\* = No. of animals affected/No. of animals examined

Figure No. 12 - Continued

	MALES							FEMALES								
	INCIDENCE				%			INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H
LUNG																
Peribronchial Lymphoid Hyperplasia	9/22	5/11	8/14	3/6	41	45	57	50	9/19	0/7	2/6	6/9	47	0	33	67
Perivascular Lymphoid Hyperplasia	4/22	0/11	5/14	1/6	18	0	36	17	3/19	0/7	3/6	4/9	16	0	50	44
Alveolar Macrophages	0/22	0/11	2/14	2/6	0	0	14	33	0/19	0/7	0/6	0/9	0	0	0	0
Amyloid	1/22	0/11	0/14	0/6	5	0	0	0	0/19	0/7	0/6	1/9	0	0	0	11
Interstitial Pneumonitis	1/22	1/11	2/14	1/6	5	9	14	17	2/19	1/7	0/6	2/9	11	14	0	22
Epithelial Hyperplasia	0/22	0/11	0/14	0/6	0	0	0	0	0/19	0/7	0/6	1/9	0	0	0	11
SPLEEN																
Extramedullary Hematopoiesis	4/22	0/11	1/14	0/6	18	0	7	0	6/19	0/7	0/6	1/9	32	0	0	11
Amyloid	2/22	0/11	1/14	2/6	9	0	7	33	0/19	0/7	0/6	1/9	0	0	0	11
Reticuloendothelial Cell Hyperplasia	2/22	0/11	2/14	0/6	9	0	14	0	1/19	0/7	0/6	1/9	5	0	0	11
Lymphoid Hyperplasia	0/22	1/11	2/14	0/6	0	9	14	0	0/19	0/7	0/6	0/9	0	0	0	0
LIVER																
Amyloid	6/22	1/11	3/14	2/6	27	9	21	33	5/19	1/7	2/6	3/9	26	14	33	33
Necrosis/Caudate Lobe	1/22	0/11	0/14	1/6	5	0	0	17	0/19	0/7	0/6	0/9	0	0	0	0
Pericholangitis	3/22	0/11	2/14	2/6	14	0	14	33	1/19	0/7	0/6	2/9	5	0	0	22
Vacuolation	0/22	0/11	0/14	0/6	0	0	0	0	0/19	0/7	1/6	0/9	0	0	17	0
Necrosis	1/22	1/11	2/14	0/6	5	9	14	0	0/19	0/7	0/6	1/9	0	0	0	11
Acute Hepatitis	1/22	0/11	0/14	0/6	5	0	0	0	0/19	0/7	0/6	0/9	0	0	0	0
Nodular Hyperplasia	0/22	0/11	1/14	0/6	0	0	7	0	0/19	0/7	1/6	0/9	0	0	17	0
Nonsuppurative Hepatitis	4/22	4/11	5/14	0/6	18	36	36	0	10/19	2/7	3/6	6/9	53	29	50	67
Mononuclear Infiltration	3/22	3/11	1/14	2/6	14	27	7	33	7/19	1/7	0/6	0/9	37	14	0	0
Sinusoidal Infiltrate	2/22	0/11	0/14	0/6	9	0	0	0	0/19	0/7	0/6	0/9	0	0	0	0
Thrombosis	0/22	1/11	0/14	0/6	0	9	0	0	0/19	0/7	0/6	0/9	0	0	0	0
Cyst	1/22	1/11	1/14	0/6	5	9	7	0	2/19	1/7	0/6	0/9	11	14	0	0
Cytomegaly	0/22	1/11	0/14	0/6	0	9	0	0	0/19	0/7	0/6	0/9	0	0	0	0

Figure No. 12 - Continued

	MALES							FEMALES								
	INCIDENCE				%			INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H
GALLBLADDER																
Acute Cholecystitis	1/19	0/10	0/14	1/5	5	0	0	20	1/17	0/6	1/5	2/9	6	0	20	22
Autolysis	0/19	0/10	1/14	0/5	0	0	7	0	0/17	0/6	0/5	0/9	0	0	0	0
KIDNEY																
Interstitial Nephritis	12/22	5/11	5/14	4/6	55	45	36	67	12/19	2/7	3/6	7/9	63	29	50	78
Regenerative																
Epithelium	13/22	7/11	10/14	4/6	59	64	71	67	10/19	2/7	2/6	2/9	53	29	33	22
Dilated Pelvis	3/22	0/11	1/14	1/6	14	0	7	17	0/19	0/7	0/6	0/9	0	0	0	0
Perivascular Mononuclear																
Infiltration	12/22	7/11	12/14	6/6	55	64	86	100	17/19	7/7	6/6	7/9	89	100	100	78
Tubular Dilatation	4/22	0/11	2/14	0/6	18	0	14	0	2/19	0/7	0/6	2/9	11	0	0	22
Glomerular Amyloid	9/22	7/11	7/14	3/6	41	64	50	50	7/19	3/7	3/6	4/9	37	43	50	44
Interstitial Amyloid	2/22	0/11	0/14	1/6	9	0	0	17	0/19	0/7	0/6	0/9	0	0	0	0
Mineral Deposition	5/22	2/11	3/14	0/6	23	18	21	0	0/19	0/7	0/6	0/9	0	0	0	0
Arteritis	2/22	0/11	0/14	0/6	9	0	0	0	0/19	0/7	0/6	0/9	0	0	0	0
Pigment/Tubular	1/22	0/11	0/14	0/6	5	0	0	0	0/19	1/7	0/6	0/9	0	14	0	0
STOMACH																
Gastritis	2/22	0/11	0/14	0/6	9	0	0	0	1/19	0/7	0/6	2/9	5	0	0	22
Amyloid	3/22	0/11	0/14	0/6	14	0	0	0	1/19	0/7	0/6	0/9	5	0	0	0
Mucosal Hyperplasia	0/22	0/11	2/14	0/6	0	0	14	0	0/19	0/7	0/6	0/9	0	0	0	0
PANCREAS																
Mononuclear Infiltration	4/22	1/11	5/14	1/6	18	9	36	17	7/18	0/7	1/6	0/9	39	0	17	0
Amyloid	0/22	0/11	0/14	0/6	0	0	0	0	0/18	0/7	2/6	0/9	0	0	33	0
Arteritis	3/22	0/11	1/14	2/6	14	0	7	33	1/18	0/7	0/6	0/9	6	0	0	0
Nonsuppurative																
Pancreatitis	0/22	0/11	1/14	0/6	0	0	7	0	1/18	2/7	1/6	1/9	6	29	17	11
Atrophy	0/22	1/11	2/14	1/6	0	9	14	17	2/18	1/7	0/6	2/9	11	14	0	22
Cystic Ducts	0/22	0/11	0/14	0/6	0	0	0	0	0/18	1/7	0/6	0/9	0	14	0	0
Islet Cell Hyperplasia	0/22	1/11	0/14	0/6	0	9	0	0	0/18	0/7	0/6	0/9	0	0	0	0

Figure No. 12 - Continued

	MALES						FEMALES								
	INCIDENCE			H	% C L M			INCIDENCE			H	C L M			
	C	L	M		C	L	M	C	L	M					
SMALL INTESTINE															
Amyloid	6/22	4/11	3/14	2/6	27	36	21	33	9/19	2/7	2/6	3/9	47	29	33
Enteritis	0/22	0/11	0/14	0/6	0	0	0	0	1/19	0/7	0/6	0/9	5	0	0
LARGE INTESTINE															
Nematodiasis	2/22	1/10	1/14	0/6	9	10	7	0	3/19	0/6	0/6	2/9	16	0	22
Amyloid	1/22	0/10	0/14	0/6	5	0	0	0	0/19	0/6	0/6	0/9	0	0	0
LYMPH NODE															
Amyloid	3/20	0/0	0/0	2/5	15	0	0	40	1/18	0/0	0/1	0/9	6	0	0
Hemorrhage	0/20	0/0	0/0	0/5	0	0	0	0	1/18	0/0	0/1	0/9	6	0	0
Reticuloendothelial															
Cell Hyperplasia	0/20	0/0	0/0	0/5	0	0	0	0	2/18	0/0	0/1	0/9	11	0	0
Arteritis	0/20	0/0	0/0	0/5	0	0	0	0	1/18	0/0	0/1	0/9	6	0	0
Lymphoid Hyperplasia	0/20	0/0	0/0	0/5	0	0	0	0	1/18	0/0	0/1	0/9	6	0	0
SALIVARY GLAND															
Mononuclear Infiltration	8/22	0/1	0/0	3/6	36	0	0	50	11/19	0/0	0/0	5/9	58	0	56
Amyloid	5/22	1/1	0/0	2/6	23	100	0	33	6/19	0/0	0/0	5/9	32	0	56
Adenitis	1/22	0/1	0/0	0/6	5	0	0	0	0/19	0/0	0/0	0/9	0	0	0
TESTIS															
Amyloid	6/22	0/11	3/14	1/6	27	0	21	17							
Atrophy	2/22	0/11	0/14	0/6	9	0	0	0							
Hyospermatogenesis	10/22	7/11	9/14	3/6	45	64	64	50							
Interstitial Cell															
Hyperplasia	1/22	1/11	0/14	0/6	5	9	0	0							
Arteritis	1/22	0/11	1/14	0/6	5	0	7	0							
Dilatation/Epididymis	1/22	2/11	0/14	0/6	5	18	0	0							
Mineralization	2/22	2/11	1/14	2/6	9	18	7	33							
Epididymitis	0/22	1/11	1/14	0/6	0	9	7	0							

Figure No. 12 - Continued

	MALES								FEMALES								
	INCIDENCE				%				INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H	
PROSTATE																	
Nonsuppurative																	
Prostatitis	1/21	2/11	1/13	0/6	5	18	8	0									
Acute Prostatitis	1/21	0/11	0/13	0/6	5	0	0	0									
Arteritis	1/21	0/11	0/13	0/6	5	0	0	0									
SEMINAL VESICLE																	
Glandular Dilatation	3/22	0/11	2/14	0/6	14	0	14	0									
Perivascular																	
Mononuclear Infiltration	1/22	0/11	0/14	0/6	5	0	0	0									
Acute Vesiculitis	3/22	1/11	1/14	0/6	14	9	7	0									
Arteritis	1/22	0/11	0/14	0/6	5	0	0	0									
OVARY																	
Cystic Follicles									16/19	6/7	5/6	8/8	84	86	83	100	
Hemorrhagic Cyst									0/19	2/7	2/6	0/8	0	29	33	0	
Amyloid									7/19	1/7	2/6	2/8	37	14	33	25	
Mineralization									1/19	0/7	0/6	0/8	5	0	0	0	
UTERUS																	
Glandular Dilatation									17/18	7/7	6/6	9/9	94	100	100	100	
Glandular Hyperplasia									13/18	2/7	3/6	6/9	72	29	50	67	
Hemorrhage									3/18	0/7	3/6	1/9	17	0	50	11	
Angiectasis									1/18	1/7	3/6	0/9	6	14	50	0	
Thrombosis									5/18	0/7	0/6	0/9	28	0	0	0	
Polyp									1/18	0/7	1/6	0/9	6	0	17	0	
VAGINA																	
Vaginitis									1/18	1/7	1/5	1/9	6	14	20	11	

Figure No. 12 - Continued

	MALES						FEMALES								
	INCIDENCE			%			INCIDENCE			%					
	C	L	M	H	C	L	M	H	C	L	M	H			
MUSCLE															
Myositis	2/22	0/0	0/0	0/5	9	0	0	0	0/19	0/0	0/0	0/9	0	0	0
NERVE															
Unremarkable	21/22	0/0	0/0	5/5	95	0	0	100	19/19	0/0	0/0	9/9	100	0	100
MAMMARY GLAND															
Acinar Tissue Present	0/22	0/1	0/0	0/6	0	0	0	0	9/19	0/0	0/0	4/9	47	0	44
Acinar Tissue Not Present	18/22	1/1	0/0	5/6	82	100	0	83	4/19	0/0	0/0	0/9	21	0	0
Ductal Tissue Present	4/22	0/1	0/0	1/6	18	0	0	17	15/19	0/0	0/0	9/9	79	0	100
Ductal Tissue Not Present	18/22	1/1	0/0	5/6	82	100	0	83	4/19	0/0	0/0	0/9	21	0	60
Mastitis	0/22	0/1	0/0	0/6	0	0	0	0	2/19	0/0	0/0	0/9	11	0	0
URINARY BLADDER															
Mononuclear Infiltration	10/22	5/11	9/14	3/6	45	45	64	50	11/19	4/7	4/6	6/9	58	57	67
Mucosal Separation	8/22	8/11	3/14	1/6	36	73	21	17	3/19	3/7	2/6	3/9	16	43	33
EYE															
Dacryoadenitis	0/22	0/0	0/0	0/6	0	0	0	0	1/19	0/0	0/0	0/9	5	0	0
Retinal Degeneration	2/22	0/0	0/0	0/6	9	0	0	0	5/19	0/0	0/0	2/9	26	0	22
Keratitis	2/22	0/0	0/0	1/6	9	0	0	17	1/19	0/0	0/0	0/9	5	0	0
Lens Vacuolation	1/22	0/0	0/0	0/6	5	0	0	0	1/19	0/0	0/0	0/9	5	0	0
Ophthalmitis	0/22	0/0	0/0	1/6	0	0	0	17	0/19	0/0	0/0	0/9	0	0	0
SPINAL CORD															
Unremarkable	22/22	0/0	0/0	6/6	100	0	0	100	18/18	0/0	0/0	9/9	100	0	100
BONE															
Fibroplasia	0/22	0/0	0/0	0/6	0	0	0	0	1/19	0/0	0/0	0/9	5	0	0



Figure No. 12 - Continued

	MALES							FEMALES						
	INCIDENCE			%				INCIDENCE			%			
	C	L	M	H	C	L	M	C	L	M	H	C	L	M
BONE MARROW														
Unremarkable	22/22	0/0	0/0	6/6	100	0	0	18/19	0/0	0/0	9/9	95	0	0
Osteomyelitis	0/22	0/0	0/0	0/6	0	0	0	1/19	0/0	0/0	0/9	5	0	0
SKIN														
Parasite	1/1	0/0	0/0	2/2	100	0	0	1/1	0/0	0/0	0/0	100	0	0
Acute Dermatitis	0/1	0/0	0/0	0/2	0	0	0	1/1	0/0	0/0	0/0	100	0	0
MESENTERY														
Arteritis	1/1	0/0	0/0	0/0	100	0	0	1/1	0/1	0/0	0/0	100	0	0
Peritonitis	0/1	0/0	0/0	0/0	0	0	0	0/1	1/1	0/0	0/0	0	100	0

Figure No. 12A - Summary of histopathological findings (all non-neoplastic changes) for mice treated with SC-19192 or serving as controls which were found dead or killed in extremis

	MALES								FEMALES								
	INCIDENCE				%				INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H	
BRAIN																	
Mineral Deposition	3/43*	6/21	3/20	5/26	7	29	15	19	2/48	5/27	6/28	3/26	4	19	21	12	
Hemorrhage	0/43	0/21	0/20	0/26	0	0	0	0	1/48	0/27	0/28	2/26	2	0	0	8	
Perivascular Cuffing	0/43	0/21	0/20	0/26	0	0	0	0	0/48	0/27	0/28	1/26	0	0	0	4	
Degeneration, Traumatic	0/43	0/21	0/20	0/26	0	0	0	0	0/48	0/27	1/28	0/26	0	0	4	0	
Autolysis	1/43	0/21	0/20	0/26	2	0	0	0	0/48	0/27	0/28	0/26	0	0	0	0	
PITUITARY																	
Unremarkable	27/28	1/1	5/5	15/16	96	100	100	94	34/36	5/5	15/15	12/12	94	100	100	100	
Autolysis	1/28	0/1	0/5	1/16	4	0	0	6	2/36	0/5	0/15	0/12	6	0	0	0	
THYROID																	
Amyloid	12/39	1/1	5/9	8/26	31	100	56	31	7/37	4/6	6/16	4/20	19	67	38	20	
Nonsuppurative																	
Thyroiditis	1/39	0/1	0/9	1/26	3	0	0	4	0/37	0/6	0/16	0/20	0	0	0	0	
Adenomatous Hyperplasia	0/39	0/1	0/9	1/26	0	0	0	4	0/37	0/6	0/16	0/20	0	0	0	0	
Autolysis	15/39	0/1	2/9	15/26	38	0	25	58	11/37	2/6	10/16	5/20	30	33	63	25	
ADRENAL																	
Cortical Hyperplasia	15/38	0/1	7/10	4/23	39	0	70	17	29/46	3/5	15/18	15/25	63	60	83	60	
Amyloid	14/38	1/1	5/10	12/23	37	100	50	52	13/46	5/5	12/18	5/25	28	100	67	20	
Autolysis	3/38	0/1	1/10	2/23	8	0	10	9	6/46	0/5	2/18	2/25	13	0	11	8	

C = Control; L = Low; M = Medium; H = High  
 \* = No. of animals affected/No. of animals examined

Figure No. 12A - Continued

	MALES							FEMALES								
	INCIDENCE				%			INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H
HEART																
Nonsuppurative																
Myocarditis	5/44	0/2	2/11	8/26	11	0	18	31	4/47	1/5	2/18	3/26	9	20	11	12
Arteritis	4/44	0/2	1/11	5/26	9	0	9	19	1/47	0/5	1/18	0/26	2	0	6	0
Thrombosis	6/44	0/2	3/11	7/26	14	0	27	27	1/47	1/5	1/18	3/26	2	20	6	12
Amyloid	10/44	1/2	5/11	9/26	23	50	45	35	9/47	3/5	5/18	6/26	19	60	28	23
Epicarditis	0/44	0/2	0/11	0/26	0	0	0	0	1/47	0/5	0/18	0/26	2	0	0	0
Autolysis	1/44	0/2	0/11	0/26	2	0	0	0	1/47	0/5	0/18	2/26	2	0	0	8
LUNG																
Peribronchial																
Lymphoid Hyperplasia	8/44	0/2	2/11	5/26	18	0	18	19	7/48	1/9	5/18	3/26	15	11	28	12
Perivascular Lymphoid																
Hyperplasia	7/44	0/2	1/11	1/26	16	0	9	4	7/48	0/9	3/18	0/26	15	0	17	0
Alveolar Macrophages	2/44	0/2	0/11	2/26	5	0	0	8	2/48	0/9	0/18	1/26	4	0	0	4
Pigment	1/44	0/2	0/11	0/26	2	0	0	0	0/48	0/9	0/18	0/26	0	0	0	0
Amyloid	1/44	0/2	1/11	1/26	2	0	9	4	0/48	0/9	0/18	0/26	0	0	0	0
Thrombosis	0/44	0/2	0/11	1/26	0	0	0	4	0/48	0/9	0/18	0/26	0	0	0	0
Interstitial																
Pneumonitis	7/44	0/2	0/11	4/26	16	0	0	15	0/48	0/9	0/18	1/26	0	0	0	4
Epithelial Hyperplasia	0/44	0/2	0/11	0/26	0	0	0	0	3/48	1/9	0/18	0/26	6	11	0	0
Pneumonia	0/44	0/2	0/11	0/26	0	0	0	0	1/48	0/9	0/18	0/26	2	0	0	0
Autolysis	1/44	0/2	1/11	1/26	2	0	9	4	6/48	1/9	1/18	3/26	13	11	6	12

Figure No. 12A - Continued

	MALES							FEMALES						
	INCIDENCE				%			INCIDENCE				%		
	C	L	M	H	C	L	M	C	L	M	H	C	L	M
SPLEEN														
Extramedullary	1/41	0/6	0/12	0/24	2	0	0	0/43	0/12	2/24	1/26	0	0	8
Hematopoiesis	4/41	3/6	3/12	8/24	10	50	33	6/43	3/12	5/24	3/26	14	25	21
Amyloid	5/41	1/6	2/12	1/24	12	17	4	5/43	0/12	3/24	2/26	12	0	13
Lymphoid Depletion														8
Reticuloendothelial														
Cell Hyperplasia	1/41	0/6	1/12	0/24	2	0	8	1/43	1/12	2/24	1/26	2	8	4
Thrombosis	1/41	0/6	1/12	0/24	2	0	8	0/43	0/12	0/24	0/26	0	0	0
Lymphoid Hyperplasia	3/41	1/6	0/12	1/24	7	17	4	7/43	1/12	3/24	2/26	16	8	13
Congestion	0/41	0/6	0/12	0/24	0	0	0	0/43	0/12	0/24	1/26	0	0	0
Macrophages	0/41	0/6	0/12	0/24	0	0	0	0/43	0/12	0/24	1/26	0	0	0
Autolysis	4/41	1/6	2/12	2/24	10	17	17	9/43	4/12	2/24	5/26	21	33	8
LIVER														
Amyloid	13/44	3/4	6/11	9/26	30	75	55	7/49	4/11	5/19	6/25	14	36	26
Pericholangitis	1/44	0/4	1/11	0/26	2	0	9	0/49	0/11	3/19	0/25	0	0	16
Vacuolation	0/44	0/4	0/11	1/26	0	0	4	0/49	0/11	0/19	0/25	0	0	0
Necrosis	5/44	0/4	1/11	3/26	11	0	12	3/49	1/11	3/19	2/25	6	9	16
Acute Hepatitis	0/44	0/4	0/11	0/26	0	0	0	1/49	0/11	1/19	0/25	2	0	5
Nodular Hyperplasia	1/44	0/4	1/11	1/26	2	0	9	0/49	0/11	0/19	0/25	0	0	0
Nonsuppurative														
Hepatitis	1/44	0/4	0/11	3/26	2	0	12	1/49	2/11	3/19	1/25	2	18	16
Mononuclear Infiltration														
Sinusoidal Infiltrate	2/44	0/4	2/11	1/26	5	0	18	2/49	1/11	0/19	0/25	4	9	0
Thrombosis	2/44	0/4	1/11	0/26	5	0	9	1/49	0/11	3/19	0/25	2	0	16
Cyst	0/44	1/4	0/11	1/26	0	25	0	0/49	0/11	0/19	0/25	0	0	0
Cytomegaly	1/44	1/4	0/11	0/26	2	25	0	0/49	0/11	0/19	0/25	0	0	0
Angiectasis	0/44	0/4	2/11	0/26	0	0	18	0/49	0/11	0/19	0/25	0	0	0
Autolysis	8/44	2/4	1/11	6/26	18	50	9	16/49	1/11	5/19	4/25	33	9	26

Figure No. 12A - Continued

	MALES							FEMALES								
	INCIDENCE				%			INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H
GALLBLADDER																
Acute Cholecystitis	0/34	0/1	0/8	0/19	0	0	0	0	0/41	0/4	0/15	0/21	0	0	0	0
Autolysis	24/34	1/1	8/8	17/19	71	100	100	89	39/41	4/4	15/15	18/21	95	100	100	86
KIDNEY																
Interstitial Nephritis	13/44	1/2	3/16	9/26	30	50	19	35	11/48	4/9	7/21	4/26	23	44	33	15
Regenerative Epithelium	6/44	0/2	2/16	7/26	14	0	13	27	3/48	4/9	2/21	2/26	6	44	10	8
Dilated Pelvis	3/44	1/2	1/16	3/26	7	50	6	12	1/48	0/9	0/21	0/26	2	0	0	0
Perivascular Mononuclear Infiltration	27/44	1/2	10/16	13/26	61	50	63	50	19/48	7/9	11/21	7/26	40	78	52	27
Tubular Dilatation	2/44	0/2	1/16	2/26	5	0	6	8	0/48	1/9	0/21	0/26	0	11	0	0
Glomerular Amyloid	17/44	1/2	7/16	12/26	39	50	44	46	13/48	6/9	13/21	9/26	27	67	62	35
Interstitial Amyloid	1/44	0/2	0/16	0/26	2	0	0	0	6/48	1/9	3/21	1/26	13	11	14	4
Mineral Deposition	8/44	1/2	0/16	3/26	18	50	0	12	0/48	0/9	0/21	0/26	0	0	0	0
Arteritis	3/44	0/2	2/16	2/26	7	0	13	8	0/48	0/9	0/21	0/26	0	0	0	0
Pyelonephritis	0/44	0/2	1/16	0/26	0	0	6	0	1/48	0/9	0/21	0/26	2	0	0	0
Autolysis	11/44	1/2	6/16	9/26	25	50	38	35	22/48	2/9	5/21	8/26	46	22	24	31
STOMACH																
Gastritis	2/44	0/3	1/12	0/26	5	0	8	0	0/48	1/13	0/23	0/26	0	8	0	0
Ulceration	3/44	0/3	1/12	3/26	7	0	8	12	2/48	2/13	1/23	1/26	4	15	4	4
Amyloid	4/44	1/3	1/12	2/26	9	33	8	8	3/48	0/13	4/23	0/26	6	0	17	0
Mucosal Hyperplasia	0/44	0/3	1/12	0/26	0	0	8	0	0/48	0/13	1/23	0/26	0	0	4	0
Autolysis	14/44	1/3	2/12	8/26	32	33	17	31	13/48	3/13	3/23	5/26	27	23	13	19

Figure No. 12A - Continued

	MALES							FEMALES								
	INCIDENCE				%			INCIDENCE				%				
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H
PANCREAS																
Mononuclear																
Infiltration	1/44	0/3	0/10	0/24	2	0	0	0	0/46	2/6	0/19	2/24	0	33	0	8
Amyloid	1/44	0/3	1/10	0/24	2	0	10	0	3/46	0/6	0/19	0/24	7	0	0	0
Arteritis	1/44	0/3	0/10	2/24	2	0	0	8	0/46	0/6	0/19	0/24	0	0	0	0
Nonsuppurative																
Pancreatitis	0/44	0/3	0/10	0/24	0	0	0	0	0/46	1/6	0/19	1/24	0	17	0	4
Atrophy	1/44	0/3	1/10	0/24	2	0	10	0	1/46	0/6	0/19	0/24	2	0	0	0
Autolysis	9/44	2/3	1/10	4/24	20	67	10	17	11/46	1/6	3/19	4/24	24	17	16	17
SMALL INTESTINE																
Amyloid	10/41	0/4	1/11	4/25	24	0	9	16	10/47	3/7	5/19	2/25	21	43	26	8
Hemorrhage	1/41	0/4	0/11	0/25	2	0	0	0	1/47	0/7	0/19	0/25	2	0	0	0
Mucosal Erosion	1/41	0/4	0/11	0/25	2	0	0	0	0/47	0/7	0/19	0/25	0	0	0	0
Autolysis	30/41	3/4	9/11	19/25	73	75	82	76	33/47	7/7	15/19	20/25	70	100	79	80
LARGE INTESTINE																
Nematodiasis	8/44	0/3	1/11	7/25	18	0	9	28	9/46	0/6	3/20	6/25	20	0	15	24
Amyloid	0/44	0/3	1/11	0/25	0	0	9	0	0/46	0/6	0/20	0/25	0	0	0	0
Hemorrhage	0/44	0/3	0/11	0/25	0	0	0	0	1/46	0/6	0/20	0/25	2	0	0	0
Autolysis	21/44	2/3	6/11	13/25	48	67	55	52	21/46	3/6	11/20	10/25	46	50	55	40
LYMPH NODE																
Amyloid	4/28	0/5	2/4	1/23	14	0	50	4	3/33	0/5	0/4	0/18	9	0	0	0
Hemorrhage	3/28	0/5	1/4	1/23	11	0	25	4	5/33	0/5	0/4	4/18	15	0	0	22
Reticuloendothelial																
Cell Hyperplasia	1/28	0/5	0/4	0/23	4	0	0	0	2/33	1/5	0/4	0/18	6	20	0	0
Arteritis	1/28	0/5	0/4	0/23	4	0	0	0	0/33	0/5	0/4	0/18	0	0	0	0
Lymphoid Hyperplasia	0/28	1/5	0/4	0/23	0	20	0	0	1/33	0/5	0/4	0/18	3	0	0	0
Adenitis	0/28	0/5	0/4	0/23	0	0	0	0	0/33	0/5	0/4	1/18	0	0	0	6
Autolysis	8/28	2/5	1/4	8/23	29	40	25	35	6/33	2/5	0/4	2/18	18	40	0	11

Figure No. 12A - Continued

	MALES						FEMALES									
	INCIDENCE			%			INCIDENCE			%						
	C	L	M	H	C	L	M	H	C	L	M	H				
SALIVARY GLAND																
Mononuclear	3/44	0/0	0/0	4/25	7	0	0	16	7/46	0/4	0/0	4/24	15	0	0	17
Infiltration	11/44	0/0	0/0	11/25	25	0	0	44	18/46	1/4	0/0	8/24	39	25	0	33
Amyloid	3/44	0/0	0/0	1/25	7	0	0	4	3/46	0/4	0/0	2/24	7	0	0	8
Autolysis																
TESTIS																
Amyloid	10/43	1/2	3/10	10/26	23	50	30	38								
Hyospermatogenesis	17/43	2/2	4/10	14/26	40	100	40	54								
Interstitial Cell																
Hyperplasia	0/43	0/2	0/10	1/26	0	0	0	4								
Arteritis	2/43	0/2	1/10	2/26	5	0	10	8								
Dilatation/																
Epididymis	1/43	0/2	1/10	0/26	2	0	10	0								
Mineralization	6/43	0/2	3/10	3/26	14	0	30	12								
Epididymitis	0/43	0/2	1/10	0/26	0	0	10	0								
Autolysis	4/43	1/2	1/10	4/26	9	50	10	15								
PROSTATE																
Nonsuppurative																
Prostatitis	0/38	0/3	0/8	1/24	0	0	0	4								
Acute Prostatitis	0/38	0/3	1/8	0/24	0	0	13	0								
Hemorrhage	0/38	1/3	0/8	0/24	0	33	0	0								
Autolysis	6/38	2/3	1/8	3/24	16	67	13	13								
SEMINAL VESICLE																
Glandular Dilatation	2/44	1/2	3/9	1/25	5	50	33	4								
Acute Vesiculitis	2/44	0/2	0/9	0/25	5	0	0	0								
Atrophy	0/44	0/2	0/9	1/25	0	0	0	4								
Autolysis	21/44	1/2	5/9	13/25	48	50	56	52								

Figure No. 12A - Continued

	MALES						FEMALES							
	INCIDENCE			%			INCIDENCE			%				
	C	L	M	H	C	L	C	L	M	H	C	L	M	H
OVARY														
Cystic Follicles							16/37	8/14	10/22	9/24	43	57	45	38
Hemorrhagic Cyst							7/37	3/14	3/22	2/24	19	21	14	8
Amyloid							11/37	7/14	8/22	3/24	30	50	36	13
Arteritis							1/37	0/14	0/22	0/24	3	0	0	0
Autolysis							7/37	0/14	3/22	3/24	19	0	14	13
UTERUS														
Glandular Dilatation							26/44	12/15	18/24	14/26	59	80	75	54
Glandular Hyperplasia							15/44	3/15	8/24	2/26	34	20	33	8
Hemorrhage							1/44	3/15	2/24	3/26	2	20	8	12
Angiectasis							2/44	3/15	3/24	3/26	5	20	13	12
Acute Endometritis							0/44	2/15	4/24	2/26	0	13	17	8
Arteritis							1/44	0/15	0/24	0/26	2	0	0	0
Endometriosis							0/44	2/15	0/24	0/26	0	13	0	0
Autolysis							6/44	2/15	4/24	3/26	14	13	17	12
VAGINA														
Vaginitis							0/38	2/4	1/15	1/21	0	50	7	5
Autolysis							5/38	0/4	0/15	4/21	13	0	0	19
MUSCLE														
Myositis	0/43	0/0	0/1	0/26	0	0	3/46	0/1	0/0	0/25	7	0	0	0
Autolysis	0/43	0/0	0/1	0/26	0	0	2/46	0/1	0/0	1/25	4	0	0	4
NERVE														
Unremarkable	43/43	0/0	0/0	26/26	100	0	44/46	0/0	0/0	23/25	96	0	0	92
Autolysis	0/43	0/0	0/0	0/26	0	0	2/46	0/0	0/0	2/25	4	0	0	8



Figure No. 12A - Continued

	MALES						FEMALES									
	INCIDENCE			%			INCIDENCE			%						
	C	L	M	H	C	L	M	H	C	L	M	H				
MAMMARY GLAND																
Acinar Tissue Present	0/44	0/0	0/0	0/25	0	0	0	0	3/46	0/0	0/0	2/25	7	0	0	8
Acinar Tissue Not Present	41/44	0/0	0/0	25/25	93	0	0	100	16/46	0/0	0/0	10/25	35	0	0	40
Ductal Tissue Present	3/44	0/0	0/0	0/25	7	0	0	0	29/46	0/0	0/0	15/25	63	0	0	60
Ductal Tissue Not Present	41/44	0/0	0/0	25/25	93	0	0	100	16/46	0/0	0/0	10/25	35	0	0	40
Mastitis	0/44	0/0	0/0	0/25	0	0	0	0	1/46	0/0	0/0	0/25	2	0	0	0
URINARY BLADDER																
Mononuclear	18/43	8/21	5/19	3/25	42	38	26	12	19/45	7/26	7/28	10/25	42	27	25	40
Infiltration	1/43	0/21	0/19	0/25	2	0	0	0	0/45	0/26	0/28	0/25	0	0	0	0
Epithelial Hyperplasia	0/43	0/21	1/19	1/25	0	0	5	4	0/45	0/26	0/28	0/25	0	0	0	0
Acute Cystitis	2/43	0/21	0/19	1/25	5	0	0	4	0/45	0/26	0/28	0/25	0	0	0	0
Nonsuppurative Cystitis	1/43	0/21	0/19	2/25	2	0	0	8	0/45	0/26	0/28	0/25	0	0	0	0
Arteritis	0/43	1/21	0/19	0/25	0	5	0	0	0/45	0/26	0/28	0/25	0	0	0	0
Hemorrhage	18/43	13/21	10/19	15/25	42	62	53	60	29/45	20/26	15/28	11/25	64	77	54	44
Autolysis																
EYE																
Dacryoadenitis	1/41	0/0	0/0	1/26	2	0	0	4	0/48	0/0	0/0	1/26	0	0	0	4
Retinal Degeneration	1/41	0/0	0/0	3/26	2	0	0	12	1/48	0/0	0/0	2/26	2	0	0	8
Keratitis	0/41	0/0	0/0	1/26	0	0	0	4	0/48	0/0	0/0	0/26	0	0	0	0
Lens Vacuolation	4/41	0/0	0/0	1/26	10	0	0	4	1/48	0/0	0/0	0/26	2	0	0	0
Lacrimal Gland																
Hyperplasia	1/41	0/0	0/0	0/26	2	0	0	0	0/48	0/0	0/0	0/26	0	0	0	0
Ophthalmitis	0/41	0/0	0/0	0/26	0	0	0	0	0/48	0/0	0/0	0/26	0	0	0	0
Autolysis	25/41	0/0	0/0	20/26	61	0	0	77	37/48	0/0	0/0	20/26	77	0	0	77
SPINAL CORD																
Unremarkable	38/39	0/0	0/0	22/24	97	0	0	92	44/45	0/0	0/0	22/23	98	0	0	96
Autolysis	0/39	0/0	0/0	2/24	0	0	0	8	1/45	0/0	0/0	0/23	2	0	0	0

Figure No. 12A - Continued

	MALES								FEMALES							
	INCIDENCE				%				INCIDENCE				%			
	C	L	M	H	C	L	M	H	C	L	M	H	C	L	M	H
BONE																
Fibroplasia	0/44	0/0	0/0	0/26	0	0	0	0	2/49	0/0	0/0	0/26	4	0	0	0
BONE MARROW																
Unremarkable	38/43	0/0	0/0	22/26	88	0	0	85	39/49	0/1	0/0	22/26	80	0	0	85
Angiectasis	0/43	0/0	0/0	0/26	0	0	0	0	0/49	0/1	0/0	1/26	0	0	0	4
Autolysis	3/43	0/0	0/0	4/26	7	0	0	15	8/49	0/1	0/0	1/26	16	0	0	4
SKIN																
Parasite	0/1	0/0	0/0	1/2	0	0	0	50	0/2	0/0	0/0	1/2	0	0	0	50
Acute Dermatitis	1/1	0/0	0/0	0/2	100	0	0	0	2/2	0/0	0/0	0/2	100	0	0	0
Edema	0/1	0/0	0/0	1/2	0	0	0	50	0/2	0/0	0/0	1/2	0	0	0	50
Lymphangiectasis	0/1	0/0	0/0	1/2	0	0	0	50	0/2	0/0	0/0	0/2	0	0	0	0
Autolysis	0/1	0/0	0/0	1/2	0	0	0	50	0/2	0/0	0/0	0/2	0	0	0	0
MESENTERY																
Arteritis	0/1	0/0	0/1	0/0	0	0	0	0	0/1	0/2	0/0	1/2	0	0	0	50
Peritonitis	0/1	0/0	1/1	0/0	0	0	100	0	0/1	2/2	0/0	1/2	0	100	0	50



several control and test animals. Both of these findings were considered to be spontaneous alterations. Incidental cortical hypertrophy and cortical atrophy were infrequently observed among control or treated male survivors.

Thrombosis which generally involved the atria was noted in heart sections of occasional test and control animals. Generally an associated myocarditis accompanied this finding. Focal nonsuppurative myocarditis, epicarditis, or arteritis were observed in relatively small numbers of control or treated mice. Deposits of amyloid were also noted in the myocardium with no meaningful differences in frequency between control and treated groups.

Examination of lung tissue revealed various components of chronic pulmonary disease which were generally mild in degree throughout the study and which were seen among both control and treated groups with essentially comparable incidence. A small number of control and treated mice exhibited focal epithelial hyperplasia.

Deposition of amyloid in the spleen was noted in a small number of control and treated mice. All other alterations including extramedullary hematopoiesis and reticuloendothelial cell or lymphoid hyperplasia were evident in only a small number of animals and likewise were considered incidental in nature.

There were no meaningful differences between control and treated groups in incidence or degree of alterations with regard to liver sections. Perivascular deposits of amyloid were noted in moderate numbers of control and test mice. A low to moderate incidence of inflammatory or degenerative conditions was observed throughout the groups. Non-neoplastic angiectasis was seen in a very small number of control and treated females. Gallbladder sections were unremarkable except for a few instances of acute inflammation.



Various manifestations of chronic kidney disease were present in moderately large numbers of both control and treated animals; the incidence and severity of findings were generally comparable between control and test groups. Significant deposition of amyloid within glomeruli and to a lesser extent within the interstitium was also noted among relatively large numbers of control and treated mice.

Stomach sections were unremarkable except for deposits of amyloid seen infrequently among control and treated mice and incidental gastritis, ulceration, and focal mucosal hyperplasia in a few animals.

Examination of pancreatic sections revealed only incidental findings which generally consisted of inflammatory conditions and deposition of amyloid. Relatively few numbers of control and treated mice were affected. Enlargement of a single islet, classified as moderate hyperplasia, was noted in one low dose male.

Deposition of amyloid was seen in submucosa of the small intestine of moderate numbers of control and treated mice with no meaningful differences in frequency. Nematodiasis was evident in the large intestine of comparable numbers of control and test animals.

Occasional treated and control mice were found to have deposits of amyloid in sections of lymph node. A few other incidental alterations were infrequently observed.



Deposits of amyloid were noted in sections of salivary gland in moderately large numbers of control and high dose animals. Interstitial accumulations of mononuclear cells were likewise relatively common among control and high dose mice. Incidence of findings were not meaningfully different between groups.

A complex which consisted of interstitial deposition of amyloid and hypospermatogenesis was noted rather commonly in both control and treated males. Hypospermatogenesis in the absence of amyloid deposition was also observed frequently in control and test groups. There were no meaningful differences in the incidence and severity of these changes between control and test males. A low incidence of inflammatory alterations in the prostate and seminal vesicles was seen in both control and treated groups. Other findings for these organs were limited to incidental alterations seen in only a few control or treated animals.

Simple follicular cysts and/or hemorrhagic cysts were observed in large numbers of females from the control and all test groups. Deposits of amyloid within the ovary were likewise noted in moderate numbers of control and test mice. These and other incidental ovarian findings were considered spontaneous in nature and unrelated to treatment.

Glandular dilatation and hyperplasia in the uterus were seen very commonly throughout the control and test groups. Occasionally associated hemorrhage and thrombosis were noted. Other incidental uterine findings included acute endometritis, the presence of polyps, endometriosis, angiectasis, and arteritis. Sections of vagina were unremarkable except for acute vaginitis which occurred at a low incidence among control and test females.



Muscle and nerve sections were unremarkable except for spontaneous inflammatory involvement of skeletal muscle involving a small number of control animals only.

Acinar or ductal tissue was generally not present in mammary gland sections from male mice. Acinar or ductal tissue, when available, was generally comparable in content between control and high dose female mice. There was a low incidence of nonsuppurative mastitis in control females.

Examination of urinary bladders revealed focal submucosal accumulations of mononuclear cells in numerous control and test animals which were considered incidental in nature. Focal or diffuse separation of the mucosa from the underlying tissue was noted in occasional control and test survivors and was considered to have resulted from the postmortem administration of fixative. A slight hyperplasia of the mucosal epithelium was noted in one control male; this and the remaining described alterations in the urinary bladder were likewise considered incidental.

Eye sections revealed few notable findings. Retinal degeneration which was characterized by the absence of a nuclear layer was evident in occasional control and high dose animals as a spontaneous finding.

Sections of spinal cord, bone, and bone marrow were essentially unremarkable. There was fibroplasia involving the bone in a very small number of control female mice. Hematogenic activity in bone marrow was generally comparable between the control and high level test animals.



A detailed incidence of histologic alterations for individual animals is presented in Appendix Table No. 8.

In conclusion, no consistent non-neoplastic alterations were detected in the tissues evaluated which could be attributed to administration of SC-19192.

Submitted by

FREDERICK E. RENO, Ph.D.

Director

Toxicology Department

Pathology by

JOHN F. FERRELL, D.V.M.

Consultant Pathologist

Report Preparation: Kundzins, Trutter

Supervision: Minner, McHugh

gbb;msb

NOTE: The research described in this report involved animals maintained in animal care facilities fully accredited by the American Association for Accreditation of Laboratory Animal Care.





APPENDIX

SC-19192: 110-WEEK TOXICITY STUDY IN THE MOUSE

P-T NO. 985H73



TABLE NO. 1 - MEAN BODY WEIGHTS, STD. DEVIATIONS, FOOD CONSUMPTION\*, AND SURVIVAL DATA FOR MALE ANIMALS  
 SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

TIME INTERVAL WEEKS	GROUP 1			GROUP 2			GROUP 3			GROUP 4		
	BODY MEAN G.	STD-DEV G.	EDD SURV. G.	BODY MEAN G.	STD-DEV G.	EDD SURV. G.	BODY MEAN G.	STD-DEV G.	EDD SURV. G.	BODY MEAN G.	STD-DEV G.	EDD SURV. G.
0	16	2.6	0 72/72	16	2.6	0 36/36	16	2.6	0 36/36	16	2.6	0 35/36
1	26	8.2	36 72/72	25	2.1	36 36/36	24	2.1	37 36/36	30	3.8	28 36/36
2	27	2.5	41 72/72	25	2.2	39 36/36	25	2.1	41 36/36	25	2.6	40 36/36
3	29	2.6	45 72/72	26	2.6	42 36/36	27	2.3	38 36/36	27	2.8	39 36/36
4	30	2.9	45 72/72	28	2.4	44 36/36	28	2.9	47 36/36	29	2.9	47 36/36
6	34	2.9	40 72/72	32	3.0	38 36/36	30	1.9	41 35/36	31	2.8	40 36/36
8	30	3.9	46 72/72	31	2.3	43 36/36	30	2.5	44 35/36	30	2.9	44 35/36
10	30	3.6	49 72/72	29	2.9	45 36/36	30	2.3	41 35/36	32	2.7	41 35/36
12	31	3.4	45 72/72	32	2.6	38 36/36	31	2.1	41 35/36	32	2.7	41 35/36
16	35	2.9	38 72/72	34	2.7	38 36/36	33	2.7	38 35/36	34	2.9	40 35/36
20	35	3.1	43 72/72	35	2.1	37 36/36	35	2.5	35 35/36	36	2.6	37 35/36
24	39	3.1	37 70/72	37	2.6	37 36/36	36	2.5	36 34/36	37	2.8	36 35/36
28	37	3.8	37 69/72	35	2.5	41 36/36	36	2.5	40 34/36	37	2.8	37 35/36
32	37	3.2	40 66/72	37	2.8	37 34/36	37	2.6	38 32/36	39	2.6	36 35/36
36	38	2.9	40 66/72	37	3.1	41 33/36	36	2.4	43 32/36	37	3.2	43 35/36
40	38	3.0	37 65/72	37	2.6	37 32/36	36	2.8	35 32/36	37	2.5	34 34/36
44	38	3.5	47 62/72	38	3.2	46 32/36	37	3.0	42 32/36	37	2.7	46 33/36
48	38	3.3	39 61/72	39	2.7	34 31/36	37	2.9	44 32/36	38	3.0	43 31/36
52	38	2.8	42 61/72	38	2.3	32 31/36	37	2.7	32 32/36	38	2.5	36 30/36

\* Food consumption is expressed as grams of food consumed per week per mouse.

TABLE NO. 1 - MEAN BODY WEIGHTS, STD. DEVIATIONS, FOOD CONSUMPTION, AND SURVIVAL DATA FOR MALE ANIMALS

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

TIME INTERVAL WEEKS	GROUP 1			GROUP 2			GROUP 3			GROUP 4		
	MEAN G.	STD. DEV. G.	WEIGHT G.	MEAN G.	STD. DEV. G.	WEIGHT G.	MEAN G.	STD. DEV. G.	WEIGHT G.	MEAN G.	STD. DEV. G.	WEIGHT G.
52	33	2.8	42 61/72	38	2.8	32 31/36	37	2.7	32 32/36	38	2.5	36 30/36
56	38	2.9	29 61/72	37	2.6	27 31/36	38	2.7	25 32/36	38	2.4	29 30/36
60	38	3.1	39 60/72	38	2.8	41 30/36	37	2.6	41 30/36	38	2.6	32 30/36
64	37	3.2	43 55/72	37	2.7	37 29/36	37	2.6	37 30/36	36	2.4	41 30/36
68	35	3.7	30 55/72	39	2.8	34 29/36	38	2.4	34 29/36	38	2.0	39 30/36
72	39	2.9	35 55/72	41	3.2	33 29/36	38	2.9	34 29/36	39	3.2	35 29/36
76	39	3.6	33 51/72	40	2.7	33 27/36	39	2.5	32 29/36	39	2.9	32 25/36
80	39	3.5	36 47/72	40	3.3	35 26/36	38	2.3	35 29/36	40	3.6	34 24/36
84	38	3.5	42 43/72	39	3.5	41 26/36	39	2.4	38 29/36	42	4.0	39 13/36
88	39	3.6	34 43/72	40	4.0	31 24/36	39	2.4	32 27/36	39	3.3	35 16/36
92	38	3.2	37 40/72	40	3.5	37 21/36	39	2.7	34 26/36	39	3.5	35 15/36
96	39	4.4	37 38/72	38	3.4	36 19/36	38	2.2	33 22/36	38	3.1	34 14/36
100	37	2.9	36 30/72	37	5.2	39 16/36	35	2.3	36 19/36	36	3.3	37 13/36
104	37	3.3	33 28/72	39	3.9	33 14/36	37	2.3	34 15/36	37	4.0	32 11/36
108	36	3.3	34 25/72	38	2.3	36 11/36	35	1.9	35 14/36	37	3.9	35 7/36

1  
2  
1

TABLE NO. 1 - MEAN BODY WEIGHTS, STD. DEVIATIONS, FOOD CONSUMPTION, AND SURVIVAL DATA FOR FEMALE ANIMALS

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

TIME INTERVAL WEEKS	GROUP 1			GROUP 2			GROUP 3			GROUP 4		
	BODY WEIGHT			BODY WEIGHT			BODY WEIGHT			BODY WEIGHT		
	MEAN	STD-DEV	EGG SURV.	MEAN	STD-DEV	EGG SURV.	MEAN	STD-DEV	EGG SURV.	MEAN	STD-DEV	EGG SURV.
	G.	G.	G.	G.	G.	G.	G.	G.	G.	G.	G.	G.
0	15	1.7	0	15	1.7	0	15	1.3	0	15	1.8	0
1	22	4.0	33	20	2.7	36	21	3.6	33	20	3.0	37
2	22	2.0	40	21	2.4	40	21	1.9	40	20	2.7	41
3	23	1.8	42	22	2.0	38	21	2.0	39	24	2.3	41
4	24	2.1	46	24	1.6	46	24	2.0	49	25	2.3	50
6	29	2.3	42	25	1.7	43	26	2.1	41	28	1.9	44
8	26	2.0	45	26	2.3	45	24	1.9	45	26	2.0	49
10	24	3.6	46	23	3.2	47	26	2.5	44	27	2.9	48
12	26	2.6	49	25	4.1	43	25	2.6	43	27	2.4	46
16	28	2.3	41	28	2.0	41	27	1.9	40	28	2.0	44
20	28	2.5	42	31	2.1	38	29	1.9	38	29	1.8	44
24	31	2.2	39	31	2.3	45	30	1.9	40	31	2.1	41
28	28	2.5	42	28	2.1	41	28	2.0	40	33	2.7	37
33	31	2.3	39	32	2.2	41	31	1.8	41	32	2.1	37
36	31	2.5	43	32	2.0	44	30	1.8	43	32	1.8	47
40	31	2.8	39	32	2.2	37	31	1.8	38	32	2.0	39
44	31	2.4	48	33	2.2	46	32	1.9	44	35	2.1	46
48	32	2.6	41	32	2.5	43	32	1.8	45	33	2.0	45
52	33	3.3	36	33	2.8	36	32	1.9	35	34	2.4	39

TABLE NO. 1 - MEAN BODY WEIGHTS, STD. DEVIATIONS, FOOD CONSUMPTION, AND SURVIVAL DATA FOR FEMALE ANIMALS

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

TIME INTERVAL WEEKS	GROUP 1			GROUP 2			GROUP 3			GROUP 4		
	BODY WEIGHT			BODY WEIGHT			BODY WEIGHT			BODY WEIGHT		
	MEAN	ST-DEV	EGGD SURV.	MEAN	ST-DEV	EGGD SURV.	MEAN	ST-DEV	EGGD SURV.	MEAN	ST-DEV	EGGD SURV.
	G.	G.	G.	G.	G.	G.	G.	G.	G.	G.	G.	G.
52	33	3.3	36 59/72	33	2.8	36 33/36	32	1.9	35 34/36	34	2.4	39 32/36
56	33	3.1	32 58/72	34	2.8	26 32/36	32	1.8	27 34/36	33	3.3	26 32/36
60	33	2.8	39 56/72	33	3.0	44 32/36	32	2.1	40 34/36	34	2.3	41 30/36
64	32	3.6	35 56/72	33	3.0	34 31/36	32	2.5	38 33/36	33	2.0	40 29/36
68	34	3.2	35 54/72	34	2.4	33 31/36	34	2.7	35 33/36	35	2.8	37 26/36
72	35	3.0	35 51/72	36	3.0	33 30/36	35	2.9	33 31/36	38	6.3	35 26/36
76	35	4.6	30 50/72	36	3.1	30 30/36	36	3.1	32 29/36	35	2.4	33 24/36
80	35	3.2	36 45/72	35	3.5	33 29/36	35	2.9	35 27/36	36	2.5	37 23/36
84	35	3.2	41 45/72	36	3.4	41 23/36	37	3.2	39 22/36	40	3.0	40 23/36
88	35	3.3	34 43/72	36	3.6	32 22/36	36	3.9	36 20/36	38	4.0	35 23/36
92	34	3.4	36 39/72	36	3.6	34 21/36	36	4.5	34 18/36	36	2.8	42 20/36
96	35	3.8	37 34/72	35	3.7	32 17/36	35	3.6	32 13/36	36	3.3	42 19/36
100	34	3.9	38 31/72	34	4.0	36 15/36	34	4.0	37 13/36	35	3.7	38 17/36
104	35	4.9	33 27/72	35	4.7	31 12/36	35	4.1	33 10/36	34	3.7	35 11/36
108	34	4.0	35 24/72	33	3.3	32 9/36	35	1.9	40 6/36	33	3.3	36 9/36

Table No. 1A - Mean Daily Compound Consumption(g/kg/day)  
for Mice Receiving SC-19192 in the Diet

Interval Weeks	Group No. 2 0.25 g/kg/day		Group No. 3 0.50 g/kg/day		Group No. 4 1.00 g/kg/day	
	Males	Females	Males	Females	Males	Females
0-4	0.271	0.268	0.562	0.567	1.132	1.157
4-8	0.245	0.242	0.477	0.488	0.962	0.992
8-12	0.229	0.234	0.470	0.469	0.924	0.959
12-16	0.239	0.233	0.439	0.466	1.006	0.906
16-20	0.242	0.216	0.431	0.440	0.828	0.937
20-24	0.233	0.292	0.501	0.497	0.973	0.907
24-28	0.284	0.236	0.547	0.540	0.993	0.844
28-33	0.224	0.232	0.476	0.474	0.952	1.073
33-36	0.258	0.271	0.559	0.545	1.223	1.196
36-40	0.229	0.206	0.423	0.419	0.813	0.822
40-44	0.301	0.301	0.586	0.578	1.354	1.157
44-48	0.191	0.232	0.515	0.507	0.897	0.987
48-52	0.231	0.220	0.365	0.376	0.847	0.914
52-56	0.221	0.171	0.382	0.378	0.792	0.624
56-60	0.359	0.409	0.839	0.777	1.397	1.558
60-64	0.229	0.206	0.456	0.461	1.091	1.013
64-68	0.223	0.231	0.435	0.432	0.901	0.870
68-72	0.226	0.236	0.491	0.458	0.859	0.960
72-76	0.261	0.232	0.466	0.486	0.922	0.929
76-80	0.265	0.278	0.579	0.571	1.058	1.115
80-84	0.298	0.304	0.528	0.543	1.079	0.970
84-88	0.186	0.200	0.407	0.475	0.971	0.895
88-92	0.290	0.247	0.549	0.452	0.988	1.183
92-96	0.261	0.257	0.495	0.473	0.993	1.075
96-100	0.275	0.285	0.582	0.634	1.168	0.967
100-104	0.204	0.206	0.441	0.415	0.887	0.932
104-108	0.276	0.293	0.560	0.618	1.033	1.089
Mean *	0.250	0.250	0.502	0.501	1.002	1.001
± S.D.	0.0375	0.0465	0.0919	0.0859	0.1518	0.1680

\* Group mean values were based on data through 108 weeks; these data are considered to be an appropriate representation of compound consumption for the entire 110-week treatment period.

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

700-250

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
1	01085	M	0.0N	51.0	17.2	7.42	18.6	0	0	9	91	0	0	0	0.0N
1	01086	M	0.0N	56.0	17.4	7.30	12.6	0	0	8	92	0	0	0	0.0N
1	01087	M	0.0N	53.0	16.3	9.51	19.2	0	0	8	91	0	1	0	0.0N
1	01088	M	0.0N	57.0	15.9	9.69	15.2	0	0	12	87	0	1	0	0.0N
1	01089	M	0.0N	49.0	16.7	8.23	25.3	0	0	17	83	0	0	0	0.0N
1	01090	M	0.0N	50.0	16.7	8.10	23.0	0	0	18	82	0	0	0	0.0N
GROUP MEANS			0.00N	53.50	16.70	8.37	18.98								0.00N
GROUP STD. DEV.			0.00N	3.94	0.56	1.02	4.72								0.00N
2	01229	M	0.0N	50.0	17.2	8.30	23.3	0	0	27	72	0	1	0	0.0N
2	01230	M	0.0N	53.0	17.2	8.59	13.8	0	0	40	57	0	3	0	0.0N
2	01231	M	0.0N	56.0	17.9	8.30	20.1	0	0	13	87	0	0	0	0.0N
2	01232	M	0.0N	56.0	16.7	8.10	25.4	0	0	12	86	0	2	0	0.0N
2	01233	M	0.0N	57.5	18.5	8.78	18.0	0	0	22	78	0	0	0	0.0N
2	01234	M	0.0N	53.0	16.7	8.73	17.0	0	0	20	78	1	1	0	0.0N
GROUP MEANS			0.00N	55.08	17.37	8.47	19.60								0.00N
GROUP STD. DEV.			0.00N	3.04	0.71	0.27	4.26								0.00N
3	01301	M	0.0N	53.5	16.3	8.38	19.7	0	0	18	82	0	0	0	0.0N
3	01302	M	0.0N	51.0	16.5	9.03	18.7	0	0	27	72	1	0	0	0.0N
3	01303	M	0.0N	50.0	17.7	8.86	17.6	0	0	8	92	0	0	0	0.0N
3	01304	M	0.0N	56.5	17.7	9.69	25.7	0	0	25	75	0	0	0	0.0N
3	01305	M	0.0N	52.0	15.9	8.37	19.0	0	0	11	89	0	0	0	0.0N
3	01306	M	0.0N	50.0	17.2	8.23	20.6	0	0	10	89	1	0	0	0.0N
GROUP MEANS			0.00N	52.17	16.88	8.76	20.22								0.00N
GROUP STD. DEV.			0.00N	2.50	0.76	0.55	2.87								0.00N
4	01373	M	0.0N	53.5	17.9	8.69	19.0	0	0	33	66	1	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST



TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

700-158

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RESC /100 RESC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	01374	M	0.0N	52.0	15.0	8.46	21.1	0	0	15	83	0	2	0	0.0N
4	01375	M	0.0N	51.0	15.9	8.99	26.0	0	0	24	76	0	0	0	0.0N
4	01376	M	0.0N	54.0	17.2	8.45	19.9	0	0	11	87	1	1	0	0.0N
4	01377	M	0.0N	55.0	15.9	7.96	19.4	0	0	21	79	0	0	0	0.0N
4	01378	M	0.0N	53.0	16.5	9.17	24.4	0	0	25	73	0	2	0	0.0N
GROUP MEANS			0.00N	53.25	16.40	8.62	21.63								0.00N
GROUP STD. DEV.			0.00N	1.72	1.04	0.43	2.90								0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

700-260

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL-RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
1	01157	F	0.0N	54.0	16.9	6.94	14.6	0	0	12	86	0	2	0	0.0N
1	01158	F	0.0N	55.0	18.7	7.55	11.5	0	0	14	84	0	2	0	0.0N
1	01159	F	0.0N	50.5	17.7	7.64	13.6	0	0	9	90	0	1	0	0.0N
1	01160	F	0.0N	55.0	17.2	8.59	19.0	0	0	14	85	1	0	0	0.0N
1	01161	F	0.0N	57.0	18.7	8.67	12.4	0	0	11	89	0	0	0	0.0N
1	01162	F	0.0N	51.0	17.2	8.75	17.8	0	0	10	90	0	0	0	0.0N
GROUP MEANS			0.00N	54.75	17.73	8.02	14.82								0.00N
GROUP STD. DEV.			0.00N	2.14	0.79	0.75	2.99								0.00N
2	01265	F	0.0N	52.0	15.9	8.50	21.1	0	0	21	78	0	1	0	0.0N
2	01266	F	0.0N	51.0	16.3	8.13	20.4	0	0	19	80	0	1	0	0.0N
2	01267	F	0.0N	51.0	16.9	8.16	22.2	0	0	19	79	0	2	0	0.0N
2	01268	F	0.0N	54.0	17.9	9.40	20.5	0	0	18	82	0	0	0	0.0N
2	01269	F	0.0N	55.0	17.9	8.20	13.4	0	0	13	86	0	1	0	0.0N
2	01270	F	0.0N	55.0	17.4	8.67	17.8	0	0	11	87	0	2	0	0.0N <sup>8</sup>
GROUP MEANS			0.00N	53.00	17.05	8.51	19.23 <sup>8</sup>								0.00N <sup>8</sup>
GROUP STD. DEV.			0.00N	1.90	0.83	0.49	3.20								0.00N
3	01337	F	0.0N	49.0	16.3	8.08	19.0	0	0	15	82	0	3	0	0.0N
3	01338	F	0.0N	53.0	17.2	8.05	19.6	0	0	18	80	0	2	0	0.0N
3	01339	F	0.0N	55.0	18.2	7.04	20.6	0	0	22	78	0	0	0	0.0N
3	01340	F	0.0N	54.0	17.7	6.74	15.3	0	0	12	86	0	2	0	0.0N
3	01341	F	0.0N	53.0	17.7	7.43	21.0	0	0	10	89	0	1	0	0.0N
3	01342	F	0.0N	51.0	16.3	6.73	12.7	0	0	18	81	0	1	0	0.0N
GROUP MEANS			0.00N	52.50	17.23	7.34	18.03								0.00N
GROUP STD. DEV.			0.00N	2.17	0.79	0.61	3.31								0.00N
4	01409	F	0.0N	53.0	16.9	7.36	15.7	0	0	19	80	0	1	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

S+ = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 005

700-26

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE 44/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL-RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	01410	F	0.0N	54.0	16.7	7.10	26.2	0	0	11	87	1	1	0	0.0N
4	01411	F	0.0N	54.0	16.9	7.76	19.8	0	0	8	92	0	0	0	0.0N
4	01412	F	0.0N	55.0	18.2	6.95	17.9	0	0	13	85	0	2	0	0.0N
4	01413	F	0.0N	52.0	17.9	7.23	15.1	0	0	8	91	0	1	0	0.0N
4	01414	F	0.0N	54.0	18.2	7.10	15.6	0	0	12	87	0	1	0	0.0N
GROUP MEANS			0.00N	53.67	17.47	7.25 <sup>S-</sup>	18.38								0.00N
GROUP STD. DEV.			0.00N	1.03	0.71	0.29	4.22								0.00N

N = NO TEST

S- = Significantly lower than control at  $p < 0.05$ .

1 9 1

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
 ICP SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
 WEEK 010

700-100

GROUP	ANIMAL	SEX	SED RATE MM/HR	PCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL					BASO %	NUCL. RES. /100 WBC
								WBC	BAND	SEG	LYMPH	MONO	EOSIN	
1	01085	M	0.0N	50.0	13.4	8.02	18.3		0	0	89	2	0	0.0N
1	01086	M	0.0N	50.0	15.9	3.70	11.2		0	23	73	3	1	0.0N
1	01087	M	0.0N	49.5	16.1	9.69	17.3		0	14	81	4	1	0.0N
1	01088	M	0.0N	51.0	16.3	4.02	15.5		0	18	77	3	2	0.0N
1	01089	M	0.0N	47.0	13.4	7.90	12.8		0	18	79	3	0	0.0N
1	01090	M	0.0N	50.0	16.1	3.56	19.5		0	25	72	1	1	0.0N
GROUP MEANS														
GROUP STD. DEV.														
			0.00N	49.58	15.20	8.65	15.77							0.00N
			0.00N	1.36	1.40	0.66	3.24							0.00N
2	01229	M	0.0N	48.0	14.4	3.63	15.4		0	28	72	0	0	0.0N
2	01230	M	0.0N	45.5	15.4	9.53	17.1		0	33	65	1	1	0.0N
2	01231	M	0.0N	50.0	16.7	5.33	16.6		0	20	77	1	2	0.0N
2	01232	M	0.0N	51.0	15.2	9.17	20.1		0	24	73	1	2	0.0N
2	01233	M	0.0N	50.5	17.4	9.53	16.8		0	25	72	3	0	0.0N
2	01234	M	0.0N	51.0	16.9	9.80	19.0		0	19	81	0	0	0.0N
GROUP MEANS														
GROUP STD. DEV.														
			0.00N	50.00	16.00	9.33	17.50							0.00N
			0.00N	1.14	1.17	0.40	1.73							0.00N
3	01301	M	0.0N	50.5	15.6	9.47	18.5		0	14	84	2	0	0.0N
3	01302	M	0.0N	49.0	13.8	9.07	13.7		0	20	75	3	2	0.0N
3	01303	M	0.0N	51.0	16.1	9.84	16.1		0	25	75	0	0	0.0N
3	01304	M	0.0N	53.0	14.8	10.89	15.5		0	14	86	0	0	0.0N
3	01305	M	0.0N	49.5	15.6	8.71	14.7		0	12	88	0	0	0.0N
3	01306	M	0.0N	47.0	15.4	8.81	19.8		0	9	88	1	2	0.0N
GROUP MEANS														
GROUP STD. DEV.														
			0.00N	49.82	15.22	9.46	16.38							0.00N
			0.00N	2.16	0.81	0.82	2.33							0.00N
4	01373	M	0.0N	50.0	13.4	9.41	22.3		0	10	90	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
FOR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 010

700-260

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE mm/HR	WCT %	HGB GMA	RBC MILLS	WPC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								MET %	BAND %	SFG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	01374	M	0.0N	50.0	14.8	9.48	19.9	0	0	21	73	4	2	0	0.0N
4	01375	M	0.0N	50.0	14.4	9.89	21.7	0	0	20	79	1	1	0	0.0N
4	01376	M	0.0N	40.0	15.4	9.41	22.0	0	0	25	72	3	0	0	0.0N
4	01377	M	0.0N	40.0	15.0	9.99	14.9	0	0	35	64	1	0	0	0.0N
4	01378	M	0.0N	50.0	15.4	10.22	19.5	0	0	24	73	1	2	0	0.0N
GROUP MEANS			0.00N	49.67	14.77	9.57	20.0 <sup>S+</sup>								0.00N
GROUP STD. DEV.			0.00N	1.52	0.79	0.43	2.77								0.00N

N = NO TEST

S+ = Significantly higher than control at p < 0.05.

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 010

700-200

-----DIFFERENTIAL-----															- 12 -
GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/Hr	HCT %	HGB GM%	RBC MILLS	WBC THS	MET %	HAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	NUCL. RBC /100 WBC
1	01157	F	0.0N	56.0	16.2	10.33	19.9	0	0	16	83	1	0	0	0.0N
1	01158	F	0.0N	52.0	16.1	9.70	17.9	0	0	14	84	0	2	0	0.0N
1	01159	F	0.0N	51.0	16.9	9.86	23.7	0	0	12	85	2	1	0	0.0N
1	01160	F	0.0N	50.0	16.1	10.00	24.0	0	0	12	88	0	0	0	0.0N
1	01161	F	0.0N	49.0	16.1	9.26	19.0	0	0	3	89	3	0	0	0.0N
1	01162	F	0.0N	49.0	16.1	8.96	16.1	0	0	13	86	0	1	0	0.0N
GROUP MEANS			0.00N	51.33	16.28	9.68	19.70								0.00N
GROUP STD. DEV.			0.00N	3.56	0.30	0.50	3.46								0.00N
2	01265	F	0.0N	47.0	15.9	8.07	18.6	0	0	23	74	0	3	0	0.0N
2	01266	F	0.0N	52.0	15.9	10.30	13.3	0	0	14	85	1	0	0	0.0N
2	01267	F	0.0N	50.0	15.9	8.86	24.8	0	0	18	74	6	2	0	0.0N
2	01268	F	0.0N	52.5	16.3	10.16	23.3	0	0	18	69	0	3	0	0.0N
2	01269	F	0.0N	49.0	16.1	10.13	17.5	0	0	14	83	2	1	0	0.0N
2	01270	F	0.0N	51.0	15.9	10.80	19.1	0	0	9	89	1	1	0	0.0N
GROUP MEANS			0.00N	50.25	16.00	9.72	19.43								0.00N
GROUP STD. DEV.			0.00N	2.04	0.17	1.03	4.15								0.00N
3	01337	F	0.0N	51.0	16.5	9.93	20.9	0	0	12	88	0	0	0	0.0N
3	01338	F	0.0N	49.0	15.9	9.76	22.8	0	0	10	90	0	0	0	0.0N
3	01339	F	0.0N	50.0	15.9	9.48	23.1	0	0	13	55	2	0	0	0.0N
3	01340	F	0.0N	48.0	15.4	8.88	13.3	0	0	22	76	1	1	0	0.0N
3	01341	F	0.0N	50.0	15.6	9.27	20.0	0	0	11	87	2	0	0	0.0N
3	01342	F	0.0N	46.5	14.8	9.26	17.3	0	0	9	91	0	0	0	0.0N
GROUP MEANS			0.00N	49.08	15.68	9.43	19.57								0.00N
GROUP STD. DEV.			0.00N	1.63	0.57	0.38	3.72								0.00N
4	01400	F	0.0N	50.5	16.7	10.29	22.5	0	0	13	87	0	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

IN = NO TEST

S- = Significantly lower than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICF SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WFFK010

700-260

GROUP NUMBER	ANIMAL NUMBER	SEX	SPD RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								MFTA %	RAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	01410	F	0.00N	50.0	15.4	9.66	23.0	0	0	11	86	2	1	0	0.0N
4	01411	F	0.00N	49.0	15.6	9.92	12.8	0	0	9	91	0	0	0	0.0N
4	01412	F	0.00N	50.0	15.2	9.50	13.4	0	0	12	85	3	0	0	0.0N
4	01413	F	0.00N	51.0	16.3	10.22	15.6	0	0	9	83	0	3	0	0.0N
4	01414	F	0.00N	52.0	16.7	10.29	13.3	0	0	8	91	1	0	0	0.0N
GROUP MEANS															
GROUP STD. DEV.															
			0.00N	50.42	15.98	9.98	17.60								0.00N
			0.00N	1.02	0.67	0.34	4.46								0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 020

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL					BASO %	NUCL. /100 W
								MET %	BAND %	SEG %	LYMPH %	MUNO %	EOSIN %	
1	1085	M	0.0N	49.5	17.2	8.75	23.4	0	0	23	77	0	0	0.0N
1	1086	M	0.0N	50.0	17.0	8.12	19.7	0	0	17	80	1	2	0.0N
1	1087	M	0.0N	47.5	15.4	8.11	15.0	0	0	12	88	0	0	0.0N
1	1088	M	0.0N	48.0	16.7	7.59	20.0	0	0	36	61	0	3	0.0N
1	1089	M	0.0N	46.5	16.3	5.87	14.2	0	0	20	80	0	0	0.0N
1	1090	M	0.0N	46.5	16.3	6.45	11.1	0	0	15	84	0	1	0.0N
GROUP MEANS			0.00N	48.00	16.48	7.48	17.23							0.00N
GROUP STD. DEV.			0.00N	1.48	0.64	1.10	4.55							0.00N
2	1229	M	0.0N	47.5	16.7	7.49	22.6	0	0	27	72	1	0	0.0N
2	1230	M	0.0N	48.0	15.2	7.18	16.7	0	0	38	61	1	0	0.0N
2	1231	M	0.0N	55.0	17.7	8.56	18.4	0	0	29	71	0	0	0.0N
2	1232	M	0.0N	49.0	16.3	8.13	10.8	0	0	19	79	0	2	0.0N
2	1233	M	0.0N	49.0	16.7	9.08	15.1	0	0	18	82	0	0	0.0N
2	1234	M	0.0N	47.0	16.3	7.52	23.7	0	0	16	83	1	0	0.0N
GROUP MEANS			0.00N	48.92	16.48	7.99	17.88							0.00N
GROUP STD. DEV.			0.00N	3.20	0.81	0.73	4.81							0.00N
3	1301	M	0.0N	49.5	16.7	9.08	25.2	0	0	26	70	3	1	0.0N
3	1302	M	0.0N	48.0	16.1	8.62	17.9	0	0	15	85	0	0	0.0N
3	1303	M	0.0N	49.0	16.5	8.89	19.2	0	0	18	81	1	0	0.0N
3	1304	M	0.0N	50.5	16.1	9.53	13.7	0	0	21	76	2	1	0.0N
3	1305	M	0.0N	49.0	16.1	8.73	18.2	0	0	12	88	0	0	0.0N
3	1306	M	0.0N	48.0	15.9	7.14	14.8	0	0	10	88	1	1	0.0N
GROUP MEANS			0.00N	49.00	16.23	8.66	18.17							0.00N
GROUP STD. DEV.			0.00N	0.95	0.30	0.81	4.05							0.00N
4	1373	M	0.0N	47.0	15.4	7.83	21.1	0	0	15	84	0	1	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NC TEST



TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 020

700-20

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	1374	M	C.CCN	48.0	16.7	7.33	20.2	0	0	23	77	0	0	0	C.CCN
4	1375	M	C.CCN	52.0	17.7	8.63	23.0	0	0	20	80	0	0	0	C.CCN
4	1375	M	C.CCN	51.5	16.7	8.11	17.9	0	0	11	88	1	0	0	C.CCN
4	1377	M	C.CCN	49.0	16.5	7.79	17.3	0	0	25	74	0	1	0	C.CCN
4	1378	M	C.CCN	46.5	15.9	8.03	14.3	0	0	13	87	0	0	0	C.CCN
GROUP MEANS			C.CCN	49.00	16.48	7.95	18.97								C.CCN
GROUP STD. DEV.			C.CCN	2.30	0.79	0.43	3.10								C.CCN

N = NU TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 020

700-

S	GROUP NUMBER	ANIMAL NUMBER	F	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL						NUCL. R /100	
									META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %		BASO %
	1	1157	F	0.00	54.0	16.7	8.92	17.2	0	0	13	85	0	2	0	0.0
	1	1158	F	0.00	49.0	16.1	8.58	17.9	0	0	20	80	0	0	0	0.0
	1	1159	F	0.00	54.0	17.2	8.85	12.7	0	0	21	79	0	0	0	0.0
	1	1160	F	0.00	49.5	16.3	8.31	10.2	0	0	11	89	0	0	0	0.0
	1	1162	F	0.00	47.0	15.9	8.05	9.8	0	0	9	90	0	1	0	0.0
	1	1163	F	0.00	47.5	16.3	8.30	17.9	0	0	22	78	0	0	0	0.0
GROUP MEANS				0.00	50.17	16.42	8.50	14.28								0.00
GROUP STD. DEV.				0.00	3.11	0.47	0.34	3.85								0.00
	2	1265	F	0.00	50.0	16.7	8.69	19.5	0	0	23	77	0	0	0	0.0
	2	1266	F	0.00	48.0	16.1	7.96	14.9	0	0	19	80	0	1	0	0.0
	2	1267	F	0.00	51.0	16.7	8.10	21.4	0	0	20	79	0	0	0	0.0
	2	1268	F	0.00	52.0	17.2	9.53	20.1	0	0	18	82	0	0	0	0.0
	2	1269	F	0.00	51.0	16.7	8.63	19.5	0	0	21	79	0	0	0	0.0
	2	1270	F	0.00	52.0	17.2	9.08	23.1	0	0	17	83	0	0	0	0.0
GROUP MEANS				0.00	50.67	16.77	8.66	19.75								0.00
GROUP STD. DEV.				0.00	1.51	0.41	0.59	2.75								0.00
	3	1337	F	0.00	51.0	16.7	8.69	10.5	0	0	10	90	0	0	0	0.0
	3	1338	F	0.00	52.0	17.2	8.81	15.8	0	0	11	89	0	0	0	0.0
	3	1339	F	0.00	52.0	17.2	8.55	9.8	0	0	17	81	0	2	0	0.0
	3	1340	F	0.00	51.5	17.2	8.03	11.5	0	0	21	79	0	0	0	0.0
	3	1341	F	0.00	51.0	16.9	8.67	15.0	0	0	19	80	0	1	0	0.0
	3	1342	F	0.00	52.5	17.2	8.30	13.2	0	0	28	72	0	0	0	0.0
GROUP MEANS				0.00	51.67	17.07 <sup>st</sup>	8.51	12.63								0.00
GROUP STD. DEV.				0.00	0.61	0.22	0.29	2.44								0.00
	4	1409	F	0.00	50.0	16.5	7.99	20.1	0	0	14	85	0	0	0	0.0

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

st = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 20

S	GROUP	ANIMAL	E	X	SED	RATE	HCT	HGB	RBC	WBC	DIFFERENTIAL							NUCL. R. /100 W.
											THS	MILLS	META	BAND	SEG	LYMPH	MONO	
4	1410	F			0.00N	47.5	15.4	7.88	15.6	0	0	12	88	0	0	0	0.00	
4	1411	F			0.00N	50.0	16.7	8.51	9.9	0	0	13	86	1	0	0	0.00	
4	1412	F			0.00N	53.0	17.2	9.02	16.3	0	0	21	79	0	0	0	0.00	
4	1413	F			0.00N	50.0	16.7	8.85	13.3	0	0	14	86	0	0	0	0.00	
4	1414	F			0.00N	51.0	17.2	8.83	12.9	0	0	32	68	0	0	0	0.00	
GROUP MEANS					0.00N	50.25	16.62	8.51	15.35								0.00	
GROUP STD. DEV.					0.00N	1.78	0.66	0.48	4.04								0.00	

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
 100 SWISS MICE RECEIVING SC-19112 FOR 110 WEEKS  
 WEEK 040

700-20

GROUP NUMBER	ANIMAL NUMBER	SEX	S.E. RATE MN/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. /100 WBC
								MET %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
1	1035	M	0.0N	49.0	15.3	8.03	21.3	0	0	16	84	0	0	0	0.0N
1	1036	M	0.0N	44.0	14.4	8.51	13.2	0	0	8	92	0	0	0	0.0N
1	1037	M	0.0N	44.5	16.1	8.21	11.0	0	0	6	84	0	0	0	0.0N
1	1038	M	0.0N	44.5	14.3	7.44	15.1	0	0	17	83	0	0	0	0.0N
1	1039	M	0.0N	46.0	15.0	7.73	12.3	0	0	6	94	0	0	0	0.0N
1	1040	M	0.0N	46.0	15.6	8.63	10.5	0	0	7	93	0	0	0	0.0N
GROUP MEANS			0.00N	46.50	15.30	8.27	14.02								0.00N
GROUP STD. DEV.			0.00N	2.25	0.67	0.65	3.90								0.00N
2	1229	M	0.0N	45.0	15.2	8.08	15.2	0	0	16	84	0	0	0	0.0N
2	1230	M	0.0N	43.0	13.8	8.15	17.1	0	0	16	84	0	0	0	0.0N
2	1231	M	0.0N	46.0	16.1	8.86	19.6	0	0	16	84	0	0	0	0.0N
2	1232	M	0.0N	43.0	16.3	8.63	17.2	0	0	11	89	0	0	0	0.0N <sup>1</sup>
2	1233	M	0.0N	46.0	15.4	8.85	7.6	0	0	6	94	0	0	0	0.0N <sup>18</sup>
2	1234	M	0.0N	49.0	16.3	9.76	33.6	0	0	6	94	0	0	0	0.0N <sup>1</sup>
GROUP MEANS			0.00N	46.33	15.52	8.89	18.38								0.00N
GROUP STD. DEV.			0.00N	2.56	0.96	0.77	3.51								0.00N
3	1301	M	0.0N	44.5	15.2	8.46	19.7	0	0	9	91	0	0	0	0.0N
3	1302	M	0.0N	46.0	15.2	8.58	15.3	0	0	12	88	0	0	0	0.0N
3	1303	M	0.0N	47.0	15.6	8.26	20.7	0	0	4	95	0	1	0	0.0N
3	1304	M	0.0N	47.0	16.1	9.39	14.0	0	0	10	90	0	0	0	0.0N
3	1305	M	0.0N	44.0	15.2	8.86	14.7	0	0	8	92	0	0	0	0.0N
3	1307	M	0.0N	52.0	16.5	9.89	16.5	0	0	5	95	0	0	0	0.0N
GROUP MEANS			0.00N	46.75	15.63	8.24 <sup>S+</sup>	17.23								0.00N
GROUP STD. DEV.			0.00N	2.36	0.55	0.50	2.78								0.00N
4	1373	M	0.0N	48.5	16.3	9.25	24.6	0	0	5	95	0	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

S+ = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 040

700-26

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL					BASO %	NUCL. RBC /100 WBC
								MET	BAND	SEG	LYMPH	MONO	EOSIN	
4	1374	M	0.0N	46.0	15.0	8.49	20.8	0	0	9	91	0	0	0.0N
4	1375	M	0.0N	49.0	15.9	8.88	27.2	0	0	7	91	0	0	0.0N
4	1376	M	0.0N	45.0	15.0	3.66	22.8	0	0	6	94	0	0	0.0N
4	1377	M	0.0N	48.0	15.9	9.10	16.5	0	0	5	95	0	0	0.0N
4	1379	M	0.0N	45.5	14.2	9.42	15.0	0	0	9	91	0	0	0.0N
GROUP MEANS				47.00	15.38	8.57	21.15	St+						0.00N
GROUP STD. DEV.				1.70	0.78	0.36	4.71							0.00N

N = NO TEST

St+ = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK040

700-260

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
1	1158	F	0.0N	49.0	16.3	8.12	19.0	0	0	13	87	0	0	0	0.0N
1	1159	F	0.0N	45.0	14.8	8.56	14.4	0	0	9	91	0	0	0	0.0N
1	1160	F	0.0N	46.0	15.2	8.42	13.2	0	0	6	94	0	0	0	0.0N
1	1162	F	0.0N	49.0	15.6	8.56	9.2	0	0	14	86	0	0	0	0.0N
1	1163	F	0.0N	45.0	14.2	8.29	11.3	0	0	10	90	0	0	0	0.0N
1	1164	F	0.0N	52.0	16.7	8.85	12.4	0	0	5	95	0	0	0	0.0N
GROUP MEANS			0.00N	47.67	15.47	8.47	13.25								0.00N
GROUP STD. DEV.			0.00N	2.80	0.93	0.25	3.33								0.00N
2	1265	F	0.0N	47.0	15.9	7.95	14.6	0	0	14	86	0	0	0	0.0N
2	1266	F	0.0N	46.5	15.0	7.87	19.1	0	0	5	95	0	0	0	0.0N
2	1267	F	0.0N	47.0	16.1	8.73	16.9	0	0	5	95	0	0	0	0.0N
2	1268	F	0.0N	50.5	16.3	9.37	20.6	0	0	8	92	0	0	0	0.0N
2	1269	F	0.0N	45.0	14.2	6.99	17.8	0	0	8	92	0	0	0	0.0N
2	1270	F	0.0N	50.5	16.7	7.76	13.3	0	0	8	92	0	0	0	0.0N
GROUP MEANS			0.00N	47.75	15.70	8.11	17.05								0.00N
GROUP STD. DEV.			0.00N	2.25	0.93	0.83	2.74								0.00N
3	1337	F	0.0N	46.0	15.2	8.24	12.5	0	0	15	85	0	0	0	0.0N
3	1338	F	0.0N	48.0	14.2	8.45	15.4	0	0	3	97	0	0	0	0.0N
3	1339	F	0.0N	50.5	17.7	8.69	11.3	0	0	18	82	0	0	0	0.0N
3	1340	F	0.0N	45.0	14.6	8.04	14.7	0	0	8	92	0	0	0	0.0N
3	1341	F	0.0N	45.0	14.6	8.11	16.7	0	0	3	97	0	0	0	0.0N
3	1342	F	0.0N	49.5	16.3	9.02	10.9	0	0	3	97	0	0	0	0.0N
GROUP MEANS			0.00N	47.33	15.43	8.42	13.58								0.00N
GROUP STD. DEV.			0.00N	2.36	1.33	0.38	2.36								0.00N
4	1409	F	0.0N	48.0	15.2	8.77	24.9	0	0	6	94	0	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK040

700-26

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								MET %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	1410	F	0.0N	47.5	15.6	8.88	15.2	0	0	3	97	0	0	0	0.0N
4	1411	F	0.0N	49.0	16.3	9.26	17.2	0	0	3	97	0	0	0	0.0N
4	1412	F	0.0N	46.0	15.2	6.94	13.2	0	0	4	96	0	0	0	0.0N
4	1413	F	0.0N	51.0	16.5	9.34	17.8	0	0	3	97	0	0	0	0.0N
4	1414	F	0.0N	50.0	16.7	8.97	16.2	0	0	3	97	0	0	0	0.0N
GROUP MEANS			0.00N	48.58	15.92	8.69	17.42								0.00N
GROUP STD. DEV.			0.00N	1.80	0.67	0.89	4.01								0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK060

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HK	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL-----							NUCL.RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
1	1085	M	0.0N	47.0	15.9	9.54	20.4	0	2	29	64	3	2	0	0.0N
1	1086	M	0.0N	46.0	15.0	9.06	22.0	0	1	18	75	2	4	0	0.0N
1	1087	M	0.0N	44.5	15.4	7.53	12.8	0	0	29	68	1	2	0	0.0N
1	1088	M	0.0N	50.5	16.5	9.10	13.3	0	0	20	78	1	1	0	0.0N
1	1089	M	0.0N	43.5	15.0	7.63	9.9	0	0	22	73	2	3	0	0.0N
1	1090	M	0.0N	44.5	15.0	8.46	8.5	0	0	14	79	5	2	0	0.0N
GROUP MEANS			0.00N	45.00	15.47	8.55	14.48								0.00N
GROUP STD. DEV.			0.00N	2.53	0.62	0.83	5.52								0.00N
2	1229	M	0.0N	46.0	15.6	8.42	14.9	0	0	23	69	6	2	0	0.0N
2	1230	M	0.0N	42.5	13.8	8.23	15.4	0	0	25	69	3	3	0	0.0N
2	1231	M	0.0N	49.0	15.9	9.82	14.4	0	0	31	65	2	2	0	0.0N <sup>1</sup>
2	1232	M	0.0N	47.0	15.9	8.67	11.6	0	0	25	66	5	4	0	0.0N <sup>22</sup>
2	1233	M	0.0N	46.0	14.6	9.17	12.3	0	0	26	71	3	0	0	0.0N <sup>1</sup>
2	1234	M	0.0N	50.0	15.4	9.42	24.5	0	0	12	81	2	5	0	0.0N <sup>1</sup>
GROUP MEANS			0.00N	46.75	15.20	8.95	15.52								0.00N
GROUP STD. DEV.			0.00N	2.04	0.84	0.62	4.65								0.00N
3	1301	M	0.0N	45.0	15.0	9.25	16.5	0	0	34	64	1	1	0	0.0N
3	1302	M	0.0N	46.5	15.0	9.18	12.8	0	0	37	54	6	3	0	0.0N
3	1303	M	0.0N	49.5	16.1	8.52	12.6	0	0	21	69	7	3	0	0.0N
3	1304	M	0.0N	51.0	17.2	9.79	15.3	0	0	22	72	5	1	0	0.0N
3	1305	M	0.0N	43.5	12.3	8.16	6.8	0	0	31	60	5	4	0	0.0N
3	1307	M	0.0N	50.5	15.0	8.30	17.2	0	0	24	72	3	1	0	0.0N
GROUP MEANS			0.00N	47.67	15.10	8.87	13.53								0.00N
GROUP STD. DEV.			0.00N	3.11	1.63	0.64	3.80								0.00N
4	1373	M	0.0N	48.0	16.1	8.59	13.0	0	0	23	76	1	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST



TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK060

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL.RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
4	1374	M	0.0N	46.5	15.4	8.51	19.9	0	0	20	79	0	1	0	0.0N
4	1375	M	0.0N	47.5	15.0	8.81	19.3	0	1	21	76	0	2	0	0.0N
4	1376	M	0.0N	42.5	15.0	8.81	18.5	0	0	44	48	7	1	0	0.0N
4	1377	M	0.0N	47.0	16.7	8.08	9.6	0	0	23	71	1	5	0	0.0N
4	1379	M	0.0N	48.0	15.6	8.71	12.4	0	0	20	79	1	0	0	0.0N
GROUP MEANS				46.58	15.63	8.58	15.45								0.00N
GROUP STD. DEV.				2.08	0.67	0.27	4.32								0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK060

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL						BASO %	NUCL.RBC /100 WBC
								MET	BAND	SEG	LYMPH	MONO	EOSIN		
								%	%	%	%	%	%	%	
1	1158	F	0.0N	50.0	14.4	7.81	16.0	0	0	24	72	3	1	0	0.0N
1	1159	F	0.0N	45.0	14.6	9.22	11.0	0	0	27	71	2	0	0	0.0N
1	1160	F	0.0N	47.0	15.0	8.45	17.7	0	0	34	62	4	0	0	0.0N
1	1162	F	0.0N	49.5	17.0	8.45	6.7	0	0	52	43	5	0	0	0.0N
1	1163	F	0.0N	49.5	15.0	8.96	17.3	0	0	24	71	3	2	0	0.0N
1	1164	F	0.0N	45.0	14.6	9.44	9.8	0	0	46	48	4	2	0	0.0N
GROUP MEANS			0.00N	47.67	15.10	8.72	13.08								0.00N
GROUP STD. DEV.			0.00N	2.32	0.96	0.60	4.55								0.00N
2	1265	F	0.0N	48.0	15.9	8.29	8.0	0	0	18	79	3	0	0	0.0N
2	1266	F	0.0N	49.0	15.6	9.07	11.5	0	0	23	74	2	1	0	0.0N
2	1267	F	0.0N	46.0	15.2	8.60	20.7	0	0	24	75	1	0	0	0.0N
2	1268	F	0.0N	50.5	16.7	9.82	14.6	0	0	22	76	2	0	0	0.0N
2	1269	F	0.0N	55.0	17.4	9.57	14.6	0	0	16	80	2	2	0	0.0N
2	1270	F	0.0N	48.0	15.4	12.50	12.5	0	0	38	55	7	0	0	0.0N
GROUP MEANS			0.00N	49.42	16.03	9.64	13.65								0.00N
GROUP STD. DEV.			0.00N	3.11	0.85	1.51	4.23								0.00N
3	1337	F	0.0N	48.0	15.4	9.96	8.5	0	0	27	70	3	0	0	0.0N
3	1338	F	0.0N	44.5	14.8	9.15	11.1	0	0	33	65	2	0	0	0.0N
3	1339	F	0.0N	50.0	17.7	9.12	12.3	0	0	35	61	3	1	0	0.0N
3	1340	F	0.0N	41.5	14.2	9.50	8.8	0	0	37	59	1	3	0	0.0N
3	1341	F	0.0N	48.0	15.4	8.53	14.3	0	0	27	72	1	0	0	0.0N
3	1342	F	0.0N	46.5	14.8	9.48	18.6	0	0	38	60	2	0	0	0.0N
GROUP MEANS			0.00N	46.42	15.38	9.29	12.27								0.00N
GROUP STD. DEV.			0.00N	3.02	1.22	0.48	3.79								0.00N
4	1409	F	0.0N	45.5	15.9	8.44	21.7	0	0	17	82	1	0	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK060 700-260

S	GROUP	ANIMAL	E	X	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL.RBC /100 WBC
										META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
	4	1410	F		0.0N	46.0	14.8	8.20	18.4	0	0	15	80	2	3	0	0.0N
	4	1411	F		0.0N	49.5	16.3	10.04	11.9	0	0	20	80	0	0	0	0.0N
	4	1412	F		0.0N	46.5	15.0	8.85	7.9	0	0	37	62	1	0	0	0.0N
	4	1413	F		0.0N	48.5	16.1	8.93	15.2	0	0	33	67	0	0	0	0.0N
	4	1414	F		0.0N	49.0	16.3	8.85	10.8	0	0	16	80	2	2	0	0.0N
GROUP MEANS					0.00N	47.50	15.73	8.88	14.32								0.00N
GROUP STD. DEV.					0.00N	1.70	0.67	0.63	5.13								0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

700-2500

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL					BASO %	NUCL. SHE /100 WBC
								MET %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	
1	1085	M	0.0N	46.0	15.4	9.15	15.5	0	0	14	86	0	0	0.0N
1	1087	M	0.0N	57.0	18.9	10.27	19.6	0	0	50	45	1	4	0.0N
1	1088	M	0.0N	47.0	16.1	8.65	12.7	0	0	17	81	0	2	0.0N
1	1089	M	0.0N	41.5	13.9	7.26	11.4	0	0	29	71	0	0	0.0N
1	1096	M	0.0N	40.0	13.4	7.92	16.7	0	0	71	28	0	1	0.0N
1	1103	M	0.0N	40.0	13.2	7.16	7.3	0	0	33	67	0	0	0.0N
1	1107	M	0.0N	35.0	10.3	6.39	38.8	0	0	25	67	3	5	0.0N
1	1110	M	0.0N	48.0	16.1	9.37	6.6	0	0	11	88	0	1	0.0N
1	1112	M	0.0N	42.0	13.9	7.52	24.0	0	0	52	46	1	1	0.0N
1	1116	M	0.0N	43.0	14.2	8.42	13.0	0	0	19	80	1	0	0.0N
GROUP MEANS			0.00N	43.95	14.54	8.21	16.56							0.00N
GROUP STD. DEV.			0.00N	5.98	2.28	1.18	9.43							0.00N
2	1229	M	0.0N	38.5	12.8	7.27	14.1	0	0	61	38	0	1	0.0N <sup>26</sup>
2	1234	M	0.0N	42.5	13.6	7.90	25.3	0	0	73	26	0	1	0.0N <sup>1</sup>
2	1240	M	0.0N	42.0	13.4	8.07	7.4	0	0	25	75	0	0	0.0N
2	1241	M	0.0N	43.0	14.4	8.03	12.4	0	0	59	41	0	0	0.0N
2	1249	M	0.0N	42.0	13.2	7.40	11.3	0	0	55	43	1	1	0.0N
2	1255	M	0.0N	46.5	15.4	7.95	12.5	0	0	38	60	2	0	0.0N
2	1257	M	0.0N	40.5	13.4	6.88	17.2	0	0	31	69	0	0	0.0N
2	1258	M	0.0N	46.0	15.4	9.22	11.4	0	0	36	62	0	2	0.0N
2	1260	M	0.0N	41.0	13.9	7.73	19.4	0	0	18	82	0	0	0.0N
2	1263	M	0.0N	42.0	13.9	8.25	8.8	0	0	68	27	1	4	0.0N
GROUP MEANS			0.00N	42.40	13.94	7.87	13.98							0.00N
GROUP STD. DEV.			0.00N	2.39	0.88	0.63	5.34							0.00N
3	1304	M	0.0N	42.5	14.2	8.62	11.9	0	0	45	52	0	3	0.0N
3	1305	M	0.0N	42.0	13.9	8.05	9.7	0	0	20	80	0	0	0.0N
3	1308	M	0.0N	43.0	14.6	8.89	11.4	0	0	50	48	2	0	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS-MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
3	1309	M	0.0N	42.5	14.2	8.06	11.0	0	0	32	68	0	0	0	0.0N
3	1313	M	0.0N	44.5	14.8	8.67	11.7	0	0	39	57	1	3	0	0.0N
3	1314	M	0.0N	45.0	15.0	9.94	12.4	0	0	69	29	1	1	0	0.0N
3	1317	M	0.0N	39.5	13.4	8.05	13.0	0	0	56	44	0	0	0	0.0N
3	1318	M	0.0N	48.0	16.3	9.07	6.4	0	0	53	45	1	1	0	0.0N
3	1324	M	0.0N	56.0	18.7	9.97	19.9	0	0	71	26	0	3	0	0.0N
3	1326	M	0.0N	45.0	15.0	8.88	5.6	0	0	61	38	0	1	0	0.0N
GROUP MEANS			0.00N	44.80	15.01	8.82	11.30								0.00N
GROUP STD. DEV.			0.00N	4.54	1.51	0.71	3.91								0.00N
4	1374	M	0.0N	38.5	12.5	7.60	7.2	0	0	30	70	0	0	0	0.0N
4	1376	M	0.0N	32.0	10.9	6.19	15.0	0	0	52	45	0	3	0	0.0N
4	1381	M	0.0N	39.5	13.6	7.62	5.8	0	0	47	53	0	0	0	0.0N
4	1387	M	0.0N	47.0	15.9	8.39	21.9	0	0	17	83	0	0	0	0.0N
4	1398	M	0.0N	46.0	15.4	8.89	13.2	0	0	47	52	1	0	0	0.0N
4	1401	M	0.0N	44.0	14.8	7.55	21.0	0	0	83	17	0	0	0	0.0N
4	1404	M	0.0N	53.0	17.9	9.02	13.7	0	0	12	86	1	1	0	0.0N
GROUP MEANS			0.00N	42.86	14.43	7.89	13.97								0.00N
GROUP STD. DEV.			0.00N	6.82	2.31	0.97	6.15								0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL					BASO %	NUCL. RM /100 WBC
								MET	BAND	SEG	LYMPH	MONO	EOSIN	
								%	%	%	%	%	%	
1	1158	F	0.0N	40.0	13.8	5.56	7.7	0	0	69	30	0	1	0.0N
1	1160	F	0.0N	41.0	13.9	6.92	14.4	0	0	40	57	0	3	0.0N
1	1165	F	0.0N	41.0	13.9	6.88	8.2	0	0	64	34	1	1	0.0N
1	1168	F	0.0N	43.0	14.2	7.56	9.1	0	0	38	60	0	2	0.0N
1	1172	F	0.0N	44.0	14.4	7.93	6.5	0	0	83	15	1	1	0.0N
1	1173	F	0.0N	33.0	11.0	5.84	8.5	0	0	63	35	1	1	0.0N
1	1176	F	0.0N	45.0	15.0	7.11	11.6	0	0	69	24	3	4	0.0N
1	1180	F	0.0N	46.0	15.2	8.56	13.7	0	0	32	62	1	5	0.0N
1	1183	F	0.0N	43.0	14.2	7.38	7.7	0	0	39	61	0	0	0.0N
1	1184	F	0.0N	42.0	14.0	8.44	10.6	0	0	30	66	4	0	0.0N
GROUP MEANS			0.00N	41.80	13.96	7.22	9.80							0.00N
GROUP STD. DEV.			0.00N	3.61	1.14	0.99	2.68							0.00N
2	1269	F	0.0N	34.0	11.3	6.64	12.2	0	0	54	45	1	0	0.0N
2	1272	F	0.0N	43.0	14.6	7.12	7.4	0	0	43	57	0	0	0.0N
2	1275	F	0.0N	40.5	13.8	7.03	8.1	0	0	38	62	0	0	0.0N
2	1284	F	0.0N	40.0	13.6	7.46	5.3	0	0	44	54	0	2	0.0N
2	1285	F	0.0N	42.0	14.2	8.17	19.6	0	0	39	61	0	0	0.0N
2	1286	F	0.0N	48.0	16.3	8.52	10.8	0	0	32	68	0	0	0.0N
2	1288	F	0.0N	42.0	14.4	7.32	9.3	0	0	43	57	0	0	0.0N
2	1295	F	0.0N	43.0	14.6	6.26	12.6	0	0	53	46	1	0	0.0N
GROUP MEANS			0.00N	41.56	14.10	7.31	10.66							0.00N
GROUP STD. DEV.			0.00N	3.90	1.39	0.75	4.37							0.00N
3	1341	F	0.0N	40.0	13.6	6.87	10.7	0	0	31	66	1	2	0.0N
3	1347	F	0.0N	41.0	13.9	7.85	15.5	0	0	55	45	0	0	0.0N
3	1349	F	0.0N	41.5	13.9	7.20	9.0	0	0	27	68	1	4	0.0N
3	1350	F	0.0N	45.0	15.0	8.31	5.8	0	0	17	82	1	0	0.0N
3	1354	F	0.0N	39.0	13.0	7.19	8.4	0	0	41	54	1	4	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

GROUP NUMBER	ANIMAL NUMBER	SEX	SED RATE MM/HR	HCT %	HGB GM%	RBC MILLS	WBC THS	DIFFERENTIAL							NUCL. RBC /100 WBC
								META %	BAND %	SEG %	LYMPH %	MONO %	EOSIN %	BASO %	
3	1361	F	0.0N	43.0	14.6	8.15	8.5	0	0	40	59	0	1	0	0.0N
GROUP MEANS			0.00N	41.58	14.00	7.59	9.65								0.00N
GROUP STD. DEV.			0.00N	2.15	0.71	0.59	3.27								0.00N
4	1410	F	0.0N	39.0	13.0	7.15	25.9	0	0	27	70	3	0	0	0.0N
4	1411	F	0.0N	41.0	13.8	7.85	7.6	0	0	37	63	0	0	0	0.0N
4	1413	F	0.0N	41.0	13.8	7.04	18.6	0	0	31	66	2	1	0	0.0N
4	1416	F	0.0N	42.0	14.2	8.05	21.1	0	0	11	82	1	6	0	0.0N
4	1424	F	0.0N	39.0	13.0	7.90	13.7	0	0	40	57	3	0	0	0.0N
4	1426	F	0.0N	40.0	13.6	7.39	21.4	0	0	31	69	0	0	0	0.0N
4	1427	F	0.0N	42.5	14.2	7.85	9.8	0	0	16	82	1	1	0	0.0N
4	1429	F	0.0N	43.0	14.6	6.39	26.0	0	0	69	29	1	1	0	0.0N
4	1443	F	0.0N	41.0	13.8	7.70	16.4	0	0	45	52	1	2	0	0.0N <sup>29</sup>
GROUP MEANS			0.00N	40.94	13.78	7.48	17.83 <sup>S+</sup>								0.00N
GROUP STD. DEV.			0.00N	1.42	0.53	0.54	6.56								0.00N

N = NO TEST

S+ = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

GROUP NUMBER	ANIMAL NUMBER	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
1	01085	8.0	0:00N	0.0N	ON	0.0N
1	01086	8.8	0:00N	0.0N	ON	0.0N
1	01087	8.7	0:00N	0.0N	ON	0.0N
1	01088	8.2	0:00N	0.0N	ON	0.0N
1	01089	8.4	0:00N	0.0N	ON	0.0N
1	01090	9.6	0:00N	0.0N	ON	0.0N
GROUP MEANS						
GROUP STD. DEV.		8.62	0:00.0N	0.00N	0.0N	0.00N
		0.6	0:00.0N	0.00N	0.0N	0.00N
2	01229	8.7	0:00N	0.0N	ON	0.0N
2	01230	9.0	0:00N	0.0N	ON	0.0N
2	01231	9.4	0:00N	0.0N	ON	0.0N
2	01232	8.8	0:00N	0.0N	ON	0.0N
2	01233	9.5	0:00N	0.0N	ON	0.0N
2	01234	8.7	0:00N	0.0N	ON	0.0N
GROUP MEANS						
GROUP STD. DEV.		9.02	0:00.0N	0.00N	0.0N	0.00N
		0.4	0:00.0N	0.00N	0.0N	0.00N
3	01301	9.2	0:00N	0.0N	ON	0.0N
3	01302	9.1	0:00N	0.0N	ON	0.0N
3	01303	8.9	0:00N	0.0N	ON	0.0N
3	01304	9.4	0:00N	0.0N	ON	0.0N
3	01305	9.3	0:00N	0.0N	ON	0.0N
3	01306	9.9	0:00N	0.0N	ON	0.0N
GROUP MEANS						
GROUP STD. DEV.		9.30 <sup>S+</sup>	0:00.0N	0.00N	0.0N	0.00N
		0.3	0:00.0N	0.00N	0.0N	0.00N
4	01373	9.0	0:00N	0.0N	ON	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

S+ = Significantly higher than control at  $p < 0.05$ .



TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

GROUP NUMBER	ANIMAL NUMBER	S E X	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
4	01374	M	9.4	0:00N	0.0N	0N	0.0N
4	01375	M	8.5	0:00N	0.0N	0N	0.0N
4	01376	M	8.2	0:00N	0.0N	0N	0.0N
4	01377	M	8.0	0:00N	0.0N	0N	0.0N
4	01378	M	8.4	0:00N	0.0N	0N	0.0N
GROUP MEANS			8.58	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.5	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

GROUP NUMBER	ANIMAL NUMBER	PROTHROMBIN E X SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
1	01157	F	8.5	0:00N	0.0N	0.0N
1	01158	F	8.7	0:00N	0.0N	0.0N
1	01159	F	8.3	0:00N	0.0N	0.0N
1	01160	F	9.4	0:00N	0.0N	0.0N
1	01161	F	9.2	0:00N	0.0N	0.0N
1	01162	F	9.0	0:00N	0.0N	0.0N
GROUP MEANS			8.85	0:00.0N	0.0N	0.00N
GROUP STD. DEV.			0.4	0:00.0N	0.0N	0.00N
2	01265	F	8.3	0:00N	0.0N	0.0N
2	01266	F	7.5	0:00N	0.0N	0.0N
2	01267	F	9.0	0:00N	0.0N	0.0N
2	01268	F	9.0	0:00N	0.0N	0.0N
2	01269	F	9.4	0:00N	0.0N	0.0N
2	01270	F	8.2	0:00N	0.0N	0.0N
GROUP MEANS			8.57	0:00.0N	0.0N	0.00N
GROUP STD. DEV.			0.7	0:00.0N	0.0N	0.00N
3	01337	F	8.4	0:00N	0.0N	0.0N
3	01338	F	8.8	0:00N	0.0N	0.0N
3	01339	F	9.2	0:00N	0.0N	0.0N
3	01340	F	9.2	0:00N	0.0N	0.0N
3	01341	F	8.4	0:00N	0.0N	0.0N
3	01342	F	9.1	0:00N	0.0N	0.0N
GROUP MEANS			8.85	0:00.0N	0.0N	0.00N
GROUP STD. DEV.			0.4	0:00.0N	0.0N	0.00N
4	01409	F	8.9	0:00N	0.0N	0.0N

----GROUP CONTINUED ON NEXT PAGE----

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK005

GROUP NUMBER	ANIMAL NUMBER	SEX	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
4	01410	F	8.5	0:00N	0.0N	0N	0.0N
4	01411	F	8.7	0:00N	0.0N	0N	0.0N
4	01412	F	7.9	0:00N	0.0N	0N	0.0N
4	01413	F	8.2	0:00N	0.0N	0N	0.0N
4	01414	F	8.3	0:00N	0.0N	0N	0.0N
GROUP MEANS			8.42	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.4	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 010

GROUP NUMBER	ANIMAL NUMBER	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
1	01085 M	7.8	0:00N	0.0N	0N	0.0N
1	01086 M	8.5	0:00N	0.0N	0N	0.0N
1	01087 M	8.9	0:00N	0.0N	0N	0.0N
1	01088 M	8.5	0:00N	0.0N	0N	0.0N
1	01089 M	8.6	0:00N	0.0N	0N	0.0N
1	01090 M	9.4	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.62	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.5	0:00.0N	0.00N	0.0N	0.00N
2	01229 M	8.4	0:00N	0.0N	0N	0.0N
2	01230 M	8.7	0:00N	0.0N	0N	0.0N
2	01231 M	9.5	0:00N	0.0N	0N	0.0N
2	01232 M	8.2	0:00N	0.0N	0N	0.0N
2	01233 M	7.8	0:00N	0.0N	0N	0.0N
2	01234 M	9.0	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.60	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.6	0:00.0N	0.00N	0.0N	0.00N
3	01301 M	10.4	0:00N	0.0N	0N	0.0N
3	01302 M	8.8	0:00N	0.0N	0N	0.0N
3	01303 M	9.1	0:00N	0.0N	0N	0.0N
3	01304 M	8.7	0:00N	0.0N	0N	0.0N
3	01305 M	9.5	0:00N	0.0N	0N	0.0N
3	01306 M	9.7	0:00N	0.0N	0N	0.0N
GROUP MEANS		9.37 St	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.6	0:00.0N	0.00N	0.0N	0.00N
4	01373 M	8.5	0:00N	0.0N	0N	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

St = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK010

GROUP NUMBER	ANIMAL NUMBER	S E X	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
4	01374	M	9.7	0:00N	0.0N	0N	0.0N
4	01375	M	9.4	0:00N	0.0N	0N	0.0N
4	01376	M	9.1	0:00N	0.0N	0N	0.0N
4	01377	M	9.3	0:00N	0.0N	0N	0.0N
4	01378	M	9.6	0:00N	0.0N	0N	0.0N
GROUP MEANS			9.27	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.4	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

S+ = Significantly higher than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 010

GROUP NUMBER	ANIMAL NUMBER	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATLETS THOUS.	RETICULOCYTES %
1	01157 F	8.5	0:00N	0.0N	0N	0.0N
1	01158 F	9.0	0:00N	0.0N	0N	0.0N
1	01159 F	9.1	0:00N	0.0N	0N	0.0N
1	01160 F	9.2	0:00N	0.0N	0N	0.0N
1	01161 F	8.6	0:00N	0.0N	0N	0.0N
1	01162 F	7.7	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.68	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.6	0:00.0N	0.00N	0.0N	0.00N
2	01265 F	8.4	0:00N	0.0N	0N	0.0N
2	01266 F	9.3	0:00N	0.0N	0N	0.0N
2	01267 F	8.8	0:00N	0.0N	0N	0.0N
2	01268 F	9.3	0:00N	0.0N	0N	0.0N
2	01269 F	9.1	0:00N	0.0N	0N	0.0N
2	01270 F	8.7	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.93	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.4	0:00.0N	0.00N	0.0N	0.00N
3	01337 F	9.2	0:00N	0.0N	0N	0.0N
3	01338 F	8.7	0:00N	0.0N	0N	0.0N
3	01339 F	9.1	0:00N	0.0N	0N	0.0N
3	01340 F	8.0	0:00N	0.0N	0N	0.0N
3	01341 F	9.4	0:00N	0.0N	0N	0.0N
3	01342 F	8.4	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.80	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.5	0:00.0N	0.00N	0.0N	0.00N
4	01409 F	9.3	0:00N	0.0N	0N	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 010

GROUP NUMBER	ANIMAL NUMBER	S	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATLETS THOUS.	RETICULOCYTES %
4	01410	F	8.8	0:00N	0.0N	0N	0.0N
4	01411	F	8.2	0:00N	0.0N	0N	0.0N
4	01412	F	9.2	0:00N	0.0N	0N	0.0N
4	01413	F	9.3	0:00N	0.0N	0N	0.0N
4	01414	F	9.0	0:00N	0.0N	0N	0.0N
GROUP MEANS			8.97	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.4	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK040

GROUP NUMBER	ANIMAL NUMBER	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
1	1085 M	8.4	0:00N	0.0N	0N	0.0N
1	1086 M	9.0	0:00N	0.0N	0N	0.0N
1	1087 M	8.7	0:00N	0.0N	0N	0.0N
1	1088 M	8.8	0:00N	0.0N	0N	0.0N
1	1089 M	7.9	0:00N	0.0N	0N	0.0N
1	1090 M	7.9	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.45	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.5	0:00.0N	0.00N	0.0N	0.00N
2	1229 M	9.0	0:00N	0.0N	0N	0.0N
2	1230 M	8.9	0:00N	0.0N	0N	0.0N
2	1231 M	7.6	0:00N	0.0N	0N	0.0N
2	1232 M	8.4	0:00N	0.0N	0N	0.0N
2	1233 M	8.2	0:00N	0.0N	0N	0.0N
2	1234 M	8.3	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.40	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.5	0:00.0N	0.00N	0.0N	0.00N
3	1301 M	8.4	0:00N	0.0N	0N	0.0N
3	1302 M	8.2	0:00N	0.0N	0N	0.0N
3	1303 M	8.3	0:00N	0.0N	0N	0.0N
3	1304 M	8.7	0:00N	0.0N	0N	0.0N
3	1305 M	9.2	0:00N	0.0N	0N	0.0N
3	1307 M	8.2	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.50	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.4	0:00.0N	0.00N	0.0N	0.00N
4	1373 M	9.1	0:00N	0.0N	0N	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST



TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 040

GROUP NUMBER	ANIMAL NUMBER	S E X	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
4	1374	M	8.6	0:00N	0.0N	0N	0.0N
4	1375	M	8.5	0:00N	0.0N	0N	0.0N
4	1376	M	8.1	0:00N	0.0N	0N	0.0N
4	1377	M	7.6	0:00N	0.0N	0N	0.0N
4	1379	M	8.7	0:00N	0.0N	0N	0.0N
GROUP MEANS			8.43	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.5	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK040

GROUP NUMBER	ANIMAL NUMBER	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
1	1158 F	5.3	0:00N	0.0N	0N	0.0N
1	1159 F	8.9	0:00N	0.0N	0N	0.0N
1	1160 F	6.4	0:00N	0.0N	0N	0.0N
1	1162 F	9.1	0:00N	0.0N	0N	0.0N
1	1163 F	8.6	0:00N	0.0N	0N	0.0N
1	1164 F	8.8	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.93	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.3	0:00.0N	0.00N	0.0N	0.00N
2	1265 F	8.2	0:00N	0.0N	0N	0.0N
2	1266 F	9.5	0:00N	0.0N	0N	0.0N
2	1267 F	8.7	0:00N	0.0N	0N	0.0N
2	1268 F	9.1	0:00N	0.0N	0N	0.0N
2	1269 F	7.9	0:00N	0.0N	0N	0.0N
2	1270 F	9.5	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.65	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.6	0:00.0N	0.00N	0.0N	0.00N
3	1337 F	8.3	0:00N	0.0N	0N	0.0N
3	1338 F	8.4	0:00N	0.0N	0N	0.0N
3	1339 F	8.9	0:00N	0.0N	0N	0.0N
3	1340 F	7.9	0:00N	0.0N	0N	0.0N
3	1341 F	8.9	0:00N	0.0N	0N	0.0N
3	1342 F	8.4	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.47 <sup>S-</sup>	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.4	0:00.0N	0.00N	0.0N	0.00N
4	1409 F	8.6	0:00N	0.0N	0N	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

S- = Significantly lower than control at  $p < 0.05$ .

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK040

GROUP NUMBER	ANIMAL NUMBER	S	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
4	1410	F	6.3	0:00N	0.0N	0N	0.0N
4	1411	F	6.5	0:00N	0.0N	0N	0.0N
4	1412	F	6.2	0:00N	0.0N	0N	0.0N
4	1413	F	7.5	0:00N	0.0N	0N	0.0N
4	1414	F	8.7	0:00N	0.0N	0N	0.0N
GROUP MEANS			6.47	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.6	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-12192 FOR 110 WEEKS  
WEEK 060

GROUP	ANIMAL	PROTHROMBIN	COAGULATION	MET-HGB	PLATELETS	RETICULOCYTES
NUMBER	NUMBER X	SECONDS	MIN:SEC	%	THOUS.	%
1	1035 M	3.4	0:00N	0.0N	0N	0.0N
1	1036 M	3.9	0:00N	0.0N	0N	0.0N
1	1037 M	7.9	0:00N	0.0N	0N	0.0N
1	1038 M	8.7	0:00N	0.0N	0N	0.0N
1	1039 M	7.5	0:00N	0.0N	0N	0.0N
1	1040 M	3.1	0:00N	0.0N	0N	0.0N
GROUP MEANS		3.25	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.5	0:00.0N	0.00N	0.0N	0.00N
2	1225 M	4.1	0:00N	0.0N	0N	0.0N
2	1230 M	3.5	0:00N	0.0N	0N	0.0N
2	1231 M	8.4	0:00N	0.0N	0N	0.0N
2	1232 M	8.3	0:00N	0.0N	0N	0.0N
2	1233 M	7.7	0:00N	0.0N	0N	0.0N
2	1234 M	7.7	0:00N	0.0N	0N	0.0N
GROUP MEANS		5.12	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.3	0:00.0N	0.00N	0.0N	0.00N
3	1301 M	7.5	0:00N	0.0N	0N	0.0N
3	1302 M	3.6	0:00N	0.0N	0N	0.0N
3	1303 M	7.8	0:00N	0.0N	0N	0.0N
3	1304 M	8.5	0:00N	0.0N	0N	0.0N
3	1305 M	7.8	0:00N	0.0N	0N	0.0N
3	1307 M	3.2	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.08	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.5	0:00.0N	0.00N	0.0N	0.00N
4	1373 M	9.7	0:00N	0.0N	0N	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 060

GROUP	ANIMAL	PROTHROMBIN	COAGULATION	MET-HGB	PLATELETS	RETICULOCYTES
NUMBER	X	SECONDS	MIN:SEC	%	THOUS.	%
4	1374	8.0	0:00N	0.0N	0N	0.0N
4	1375	8.3	0:00N	0.0N	0N	0.0N
4	1376	8.4	0:00N	0.0N	0N	0.0N
4	1377	7.7	0:00N	0.0N	0N	0.0N
4	1379	8.4	0:00N	0.0N	0N	0.0N
GROUP MEANS		8.25	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.4	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICR SWISS MICE RECEIVING SC-19102 FOR 110 WEEKS  
WEEK060

GROUP	ANIMAL	PROTHROMBIN	COAGULATION	MET-HGB	PLATELETS	RETICULOCYTES
NUMBER	NUMBER	SECONDS	MIN:SEC	%	THOUS.	%
1	1158	6.0	0:00N	0.0N	ON	0.0N
1	1159	7.2	0:00N	0.0N	ON	0.0N
1	1160	7.6	0:00N	0.0N	ON	0.0N
1	1162	7.7	0:00N	0.0N	ON	0.0N
1	1163	8.0	0:00N	0.0N	ON	0.0N
1	1164	8.2	0:00N	0.0N	ON	0.0N
GROUP MEANS		7.78	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.4	0:00.0N	0.00N	0.0N	0.00N
2	1255	8.3	0:00N	0.0N	ON	0.0N
2	1265	8.5	0:00N	0.0N	ON	0.0N
2	1267	8.2	0:00N	0.0N	ON	0.0N
2	1268	8.3	0:00N	0.0N	ON	0.0N
2	1269	8.0	0:00N	0.0N	ON	0.0N
2	1270	7.7	0:00N	0.0N	ON	0.0N
GROUP MEANS		8.17	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.3	0:00.0N	0.00N	0.0N	0.00N
3	1337	7.3	0:00N	0.0N	ON	0.0N
3	1338	7.7	0:00N	0.0N	ON	0.0N
3	1339	8.0	0:00N	0.0N	ON	0.0N
3	1340	8.3	0:00N	0.0N	ON	0.0N
3	1341	7.9	0:00N	0.0N	ON	0.0N
3	1342	7.7	0:00N	0.0N	ON	0.0N
GROUP MEANS		7.82	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.		0.3	0:00.0N	0.00N	0.0N	0.00N
4	1409	7.6	0:00N	0.0N	ON	0.0N

---GROUP CONTINUED ON NEXT PAGE---

N = NO TEST

TABLE NO. 2 - INDIVIDUAL HEMATOLOGICAL VALUES  
ICK SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 050

GROUP NUMBER	ANIMAL NUMBER	S E X	PROTHROMBIN SECONDS	COAGULATION MIN:SEC	MET-HGB %	PLATELETS THOUS.	RETICULOCYTES %
4	1410	F	3.8	0:00N	0.0N	0N	0.0N
4	1411	F	7.7	0:00N	0.0N	0N	0.0N
4	1412	F	7.8	0:00N	0.0N	0N	0.0N
4	1413	F	8.1	0:00N	0.0N	0N	0.0N
4	1414	F	8.3	0:00N	0.0N	0N	0.0N
GROUP MEANS			8.08	0:00.0N	0.00N	0.0N	0.00N
GROUP STD. DEV.			0.6	0:00.0N	0.00N	0.0N	0.00N

N = NO TEST

TABLE NO. 3 - INDIVIDUAL BLOOD CHEMISTRY VALUES  
 ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
 WEEK 110

GROUP NUMBER	ANIMAL NUMBER	S	GLUCOSE MG%	BUN MG%	SGPT R-F.	ALK. PHOS K-A. UNITS	BILIRUBIN			SGPT K. UNITS	BSP RET %, 30 MIN	P.P. GLU. %
							TOTAL MG%	DIRECT MG%	INDIRECT MG%			
1	1085	M	0.0N	0.0Q	28.0	26.5	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1087	M	0.0N	66.0	34.0	7.7	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1088	M	0.0N	0.0Q	21.0	20.7	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1089	M	0.0N	34.0	49.0	11.7	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1096	M	0.0N	0.0Q	67.0	17.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1103	M	0.0N	27.0	25.0	17.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1107	M	0.0N	0.0Q	49.0	12.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1110	M	0.0N	24.0	25.0	6.5	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1112	M	0.0N	0.0Q	25.0	5.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1116	M	0.0N	34.0	77.0	19.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	37.00	40.00	14.580	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	16.79	19.65	6.791	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
2	1229	M	0.0N	0.0Q	34.0	16.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1234	M	0.0N	40.0	38.0	13.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1240	M	0.0N	34.0	37.0	16.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1241	M	0.0N	0.0Q	28.0	63.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1249	M	0.0N	24.0	40.0	10.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1255	M	0.0N	0.0Q	38.0	142.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1257	M	0.0N	0.0Q	31.0	11.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1258	M	0.0N	0.0Q	26.0	4.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1260	M	0.0N	36.0	119.0	9.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1263	M	0.0N	43.0	47.0	30.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	35.40	43.80	31.770	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	7.27	27.12	42.331	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
3	1304	M	0.0N	56.0	41.0	8.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1305	M	0.0N	0.0Q	32.0	8.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1308	M	0.0N	0.0Q	31.0	6.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N

Q = QUANTITY NOT SUFFICIENT

---GROUP CONTINUED ON NEXT PAGE---  
 N = NO TEST



TABLE NO. 3 - INDIVIDUAL BLOOD CHEMISTRY VALUES  
 ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
 WEEK 110

GROUP NUMBER	ANIMAL NUMBER	S E X	GLUCOSE MG%	BUN MG%	SGPT R-F.	ALK.PHOS K-A. UNITS	-----BILIRUBIN-----			SGOT K. UNITS	BSP RET %, 30 MIN	P.P. GLU. MG%
							TOTAL MG%	DIRECT MG%	INDIRECT MG%			
3	1309	M	0.0N	0.0Q	0.0Q	0.0Q	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1313	M	0.0N	54.0	32.0	6.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1314	M	0.0N	0.0Q	37.0	20.7	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1317	M	0.0N	0.0Q	64.0	0.0Q	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1318	M	0.0N	0.0Q	51.0	9.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1324	M	0.0N	0.0Q	25.0	35.6	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1326	M	0.0N	0.0Q	27.0	32.2	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	55.00	37.78	15.962	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	1.41	12.58	11.997	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
4	1374	M	0.0N	0.0Q	25.0	17.6	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1376	M	0.0N	42.0	31.0	9.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1381	M	0.0N	91.0	41.0	15.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1387	M	0.0N	0.0Q	28.0	21.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1398	M	0.0N	0.0Q	68.0	0.0Q	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1404	M	0.0N	0.0Q	44.0	0.0Q	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	66.50	39.50	15.925	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	34.05	15.81	5.153	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N

Q = QUANTITY NOT SUFFICIENT

N = NO TEST

TABLE NO. 3 - INDIVIDUAL BLOOD CHEMISTRY VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

GROUP NUMBER	ANIMAL NUMBER	SEX	GLUCOSE MG%	BUN MG%	SGPT R-F.	ALK. PHOS K-A. UNITS	BILIRUBIN			SGOT K. UNITS	RSP RET %, 30 MIN	P.P. GLU 45%
							TOTAL MG%	DIRECT MG%	INDIRECT MG%			
1	1160	F	0.0N	58.0	41.0	15.6	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1165	F	0.0N	0.0Q	70.0	13.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1168	F	0.0N	0.0Q	43.0	6.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1172	F	0.0N	46.0	37.0	35.6	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1173	F	0.0N	106.0	28.0	17.5	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1176	F	0.0N	61.0	48.0	19.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1180	F	0.0N	46.0	54.0	6.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1183	F	0.0N	44.0	28.0	16.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1184	F	0.0N	0.0Q	48.0	17.5	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
1	1185	F	0.0N	0.0Q	51.0	13.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	60.17	44.80	16.130	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	23.53	12.57	8.047	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
2	1272	F	0.0N	60.0	34.0	39.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1275	F	0.0N	38.0	27.0	9.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1284	F	0.0N	0.0Q	35.0	11.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1285	F	0.0N	0.0Q	45.0	12.7	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1286	F	0.0N	36.0	25.0	16.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1288	F	0.0N	0.0Q	23.0	12.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
2	1295	F	0.0N	48.0	26.0	10.9	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	45.50	30.71 <sup>S-</sup>	16.271	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	11.00	7.76	10.634	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
3	1341	F	0.0N	101.0	35.0	35.6	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1347	F	0.0N	112.0	27.0	13.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1349	F	0.0N	0.0Q	25.0	17.2	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1350	F	0.0N	0.0Q	32.0	23.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1354	F	0.0N	0.0Q	22.0	6.5	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
3	1361	F	0.0N	49.0	25.0	17.5	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	87.33	27.67 <sup>S-</sup>	18.917	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	33.65	4.89	9.890	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N

Q = QUANTITY NOT SUFFICIENT

N = NO TEST

S- = S significantly lower than control at p < 0.05.

TABLE NO. 3 - INDIVIDUAL BLOOD CHEMISTRY VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

GROUP NUMBER	ANIMAL NUMBER	SEX	GLUCOSE MG%	BUN MG%	SGPT R-F.	ALK. PHOS K-A-UNITS	BILIRUBIN			SGOT K. UNITS	BSP RET %, 30 MIN	P. P. GLU. MG%
							TOTAL MG%	DIRECT MG%	INDIRECT MG%			
4	1410	F	0.0N	0.0Q	59.0	19.0	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1411	F	0.0N	52.0	25.0	14.8	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1413	F	0.0N	0.0Q	23.0	11.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1416	F	0.0N	0.0Q	43.0	15.2	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1424	F	0.0N	0.0Q	0.0Q	0.0Q	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1426	F	0.0N	36.0	37.0	21.3	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
4	1427	F	0.0N	0.0Q	35.0	15.4	0.00N	0.00N	0.00N	0.0N	0.00N	0.0N
GROUP MEANS			0.00N	44.00	37.00	16.183	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N
GROUP STD. DEV.			0.00N	11.31	13.15	3.478	0.000N	0.000N	0.00N	0.000N	0.0N	0.0N

Q = QUANTITY NOT SUFFICIENT

N = NO TEST

TABLE NO. 3 - INDIVIDUAL BLOOD CHEMISTRY VALUES  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

WEEK 110

GROUP NUMBER	ANIMAL NUMBER	S E X	L-PHENYLALANINE		GROUP NUMBER	ANIMAL NUMBER	S E X	L-PHENYLALANINE	
			MG/DL					MG/DL	
1	1085	M	1.51		1	1160	F	2.63	
1	1087	M	1.95		1	1164	F	2.33	
1	1088	M	2.10		1	1165	F	2.82	
1	1089	M	1.59		1	1168	F	2.15	
1	1103	M	1.94		1	1170	F	2.56	
1	1110	M	1.44		1	1172	F	2.27	
1	1112	M	1.50		1	1176	F	2.09	
1	1116	M	1.65		1	1180	F	1.81	
1	1152	M	1.90		1	1183	F	2.20	
1	1154	M	2.21		1	1184	F	2.30	
					1	1185	F	2.34	
GROUP MEANS			1.78					2.32	
GROUP STD. DEV.			0.27					0.28	
2	1229	M	2.40		2	1272	F	2.13	
2	1234	M	1.49		2	1275	F	1.99	
2	1240	M	1.79		2	1284	F	1.83	
2	1241	M	2.21		2	1285	F	2.26	
2	1245	M	1.87		2	1286	F	1.52	
2	1255	M	1.60		2	1288	F	1.52	
2	1257	M	1.77						
2	1258	M	1.75						
2	1260	M	1.48						
2	1263	M	2.22						
GROUP MEANS			1.86					1.88 <sup>S-</sup>	
GROUP STD. DEV.			0.32					0.31	

S- = Significantly lower than control at  $p < 0.05$ .

TABLE NO. 3 - CONTINUED

GROUP NUMBER	ANIMAL NUMBER	S E X	L-PHENYLALANINE MG/DL	GROUP NUMBER	ANIMAL NUMBER	S E X	L-PHENYLALANINE MG/DL
3	1304	M	1.59	3	1347	F	2.10
3	1308	M	1.51	3	1349	F	1.63
3	1313	M	1.50	3	1350	F	1.67
3	1314	M	1.77	3	1354	F	1.17
3	1318	M	1.82	3	1361	F	1.66
3	1326	M	1.49				
3	1328	M	1.68				
GROUP MEANS			1.62				1.65 <sup>S-</sup>
GROUP STD. DEV.			0.14				0.33
4	1374	M	1.24	4	1413	F	1.47
4	1376	M	1.95	4	1416	F	1.53
4	1381	M	1.81	4	1427	F	2.12
4	1387	M	1.96				
GROUP MEANS			1.74				1.71 <sup>S-</sup>
GROUP STD. DEV.			0.34				0.36

S- = Significantly lower than control at  $p < 0.05$ .

TABLE NO. 4 - URINE ANALYSIS  
ICR SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS  
WEEK 110

GROUP NO.	MOUSE NO.	SEX	S	P H	SUGAR	PROTEIN	OCCULT BLOOD	PHENYL-KETONES	MICROSCOPIC FINDINGS						
									RBC	WBC	EPITH.	AMORPH.	CRYS.	BACT.	
1	01085	M		6	0	1	2	1	10-15	3-6	0-2				
1	01087	M		6	0	1	2	0	3-5	1-3	0-2		FEW		
1	01088	M		6	0	2	1	1		0-2	0-3		FEW		
1	01089	M		6	0	1	2	1	0-3	0-5	0-3		FEW		
1	01096	M		5	0	3	3	0	8-10	0-2	0-1		FEW		
1	01103	M		6	0	2	2	1	10-15	0-2	0-2				
1	01107	M		5	0	2	3	0	6-10	0-4	2-3				
1	01110	M		6	0	3	1	1	12-15	1-3	1-4	LITTLE	FEW		
1	01112	M		N	N	N	N	1	N	N	N	N	N	N	
1	01116	M		6	0	1	2	1	6-9	0-2	0-1	LITTLE		FEW	
1	01160	F		6	0	2	2	1	4-6	0-1	0-2			FEW	
1	01165	F		5	0	1	2	0	8-10		0-3				
1	01168	F		6	0	1	1	0	2-4	0-1	0-1				
1	01172	F		Q	0	1	2	0	Q	Q	Q	Q	Q	Q	Q
1	01173	F		6	0	2	1	0	Q	Q	Q	Q	Q	Q	Q
1	01176	F		5	0	3	0	1	0-3	4-5	2-3		Q		MANY
1	01180	F		6	0	2	1	1	Q	Q	Q	Q	Q	Q	Q
1	01184	F		Q	Q	Q	2	1	Q	Q	Q	Q	Q	Q	Q
1	01185	F		6	0	2	2	0	4-8		0-2		FEW		
2	01229	M		5	0	2	2	1	3-8	0-2	3-4				
2	01234	M		6	0	2	2	1	8-10	3-5	0-1				
2	01240	M		6	0	2	2	1	6-12	2-3	0-2				
2	01241	M		5	0	2	2	2	15-20	1-4	1-3		FEW		
2	01249	M		6	0	1	2	2	30-40	0-4	0-3				
2	01255	M		6	0	3	2	0	12-15	0-2	0-2		FEW		
2	01257	M		5	0	2	2	1	6-8	2-3	4-7		FEW		
2	01258	M		N	N	N	N	1	N	N	N	N	N	N	N
2	01260	M		N	0	2	1	0	3-7	0-1	0-1		FEW		
2	01263	M		6	0	2	2	0	3-5	0-1	0-1		FEW		

N = NO TEST.  
Q = QUANTITY NOT SUFFICIENT.

TABLE NO. 4 - CONTINUED

GROUP NO.	MOUSE NO.	S E X	P H	SUGAR	PROTEIN	OCCULT BLOOD	PHENYL- KETONES	MICROSCOPIC FINDINGS					
								RBC	WBC	EPITH.	AMORPH.	CRYS.	BACT.
2	01275	F	6	0	1	2	1	8-10	0-1	0-1			
2	01284	F	6	0	1	1	1	3-4		0-2			
2	01285	F	5	0	1	2	0	1-6		0-3		FEW	
2	01286	F	6	0	1	1	2	Q	Q	Q	Q	Q	Q
2	01288	F	5	0	1	1	2	4-8	0-1	0-1			
2	01295	F	6	N	1	1	1	4-6		0-3			
3	01304	M	5	0	2	2	0	8-10	0-1	1-2		FEW	
3	01305	M	6	0	1	2	0	3-6	0-1	0-1			
3	01308	M	5	0	2	1	1	10-12	0-2	0-3		FEW	
3	01309	M	6	0	1	2	0	1-8	0-1	0-1			
3	01313	M	Q	Q	Q	Q	1	Q	Q	Q	Q	Q	Q
3	01317	M	6	0	2	2	0	5-8		0-3			
3	01318	M	5	0	2	3	0	15-20	1-3	0-1			
3	01324	M	5	0	1	1	0	8-12	1-2	0-2			
3	01326	M	Q	Q	Q	Q	1	Q	Q	Q	Q	Q	Q
3	01341	F	6	0	1	2	0	10-12	0-2	0-1			
3	01347	F	Q	Q	Q	Q	0	Q	Q	Q	Q	Q	Q
3	01349	F	5	0	2	1	0	3-7	0-3	0-2			
3	01350	F	Q	Q	Q	Q	0	Q	Q	Q	Q	Q	Q
3	01361	F	7	N	1	1	0	1-6	0-3	0-2		FEW	
4	01374	M	5	0	1	1	0	7-10	0-2	0-2			
4	01376	M	5	0	2	3	0	10-15	0-3	0-1		FEW	
4	01381	M	6	0	2	3	1	8-12	1-2	1-2			
4	01387	M	6	0	1	1	0	3-6	0-1	0-2			
4	01398	M	5	0	1	2	0	6-10	0-1	0-2			
4	01404	M	5	0	3	3	1	20-30	1-2	0-2		FEW	
4	01410	F	6	0	1	1	0	3-7	0-1	0-1		FEW	
4	01411	F	5	0	1	1	0	4-10		0-1	Q	Q	Q
4	01413	F	5	0	2	2	1	Q	Q	Q			
4	01426	F	5	0	2	2	1	10-15	0-3				
4	01427	F	6	0	2	2	0	Q	Q	Q	Q	Q	Q
4	01429	F	Q	Q	Q	Q	0	Q	Q	Q	Q	Q	Q
4	01443	F	6	0	1	1	0	8-10	1-2	0-1			

- 53 -

## REFERENCES FOR BIOCHEMICAL PROCEDURES

### HEMATOLOGY

- Hematocrit: Schalm, O. W., Veterinary Hematology, p. 193, 296, 309, 314.  
Hematology, USNM, NNMCM, p. 50.
- Hemoglobin: Schalm, O. W., Veterinary Hematology, p. 193, 296, 309, 314.  
Hematology, USMNS, NNMCM, p. 8-14.
- Erythrocyte Count: Coulter Electronics Model F Hematology, NNMCM, NMS, p. 17-19.
- Leukocyte Count: Coulter Electronics Model F Hematology, NNMCM, NMS, p. 22-23.
- Leukocyte Differential: Hematology, NNMCM, NMS, p. 23-26.
- Sedimentation Rate: Clinical Diagnosis by Laboratory Methods, P. 100-102.
- Total Thrombocyte Count: Phase Method Hematology, NNMCM, NMS p. 69-70.
- Reticulated Erythrocyte Count: Hematology, NNMCM, NMS, p. 42-43.
- Prothrombin Time: Simplastin Test Procedure, General Diagnostics Division,  
Warner-Chilcott Laboratories, Morris Plains, New Jersey.

### CLINICAL CHEMISTRY

- Blood Urea Nitrogen: SMA-12 Autoanalyzer Marsh et. al., Clin. Chem. 11:  
624-627, 1965. Micro Procedure: Autoanalyzer Method N-16a,  
Skeggs, L. T., Am. J. Clin. Pathol. 28, 311, 1957. Marsh, W. H.,  
Fingerhut, B., and Kirsch, E., Am. J. Clin. Pathol. 28, 681, 1957.
- Total Serum Protein: SMA-12 Autoanalyzer Standard N Method. Micro Procedure:  
Modified Kingsley Method, J. Biol. Chem., Vol. 131, 197, 1939.  
Weichselbaum, T. E., Amer. J. Clin. Pathol., 7, 40, 1946.
- Total Serum Albumin: SMA-12 Autoanalyzer Nishi, H. H., and Rhodes, A.,  
Automatron in Analytical Chemistry - Proceedings of the 1965  
Technicon Symposium Micro Procedure: "Methyl Orange" Microchemical  
Journal 7, 57-62 (1963), Adaptation of Procedure of Bracken and Klotz.
- Chloride: SMA-12 Autoanalyzer Skeggs, L. T., Jr., and Hochstrasser, H., Clin.  
Chem. 10: 918-936, 1964. Micro Procedure: "Chloridometer"  
Aminco-Cotlove Bulletin No. 751-A, American Instrument Co., Inc.,  
Silver Spring, Maryland.



REFERENCES FOR BIOCHEMICAL PROCEDURES (Continued)

CLINICAL CHEMISTRY - Continued

- Carbon Dioxide: SMA-12 Autoanalyzer Technicon Instruments Corp., Chauncey, New York, Skeggs, L. T., Jr., and Hochstrasser, H. Clin. Chem. 10: 918-936, 1964.
- Calcium: SMA-12 Autoanalyzer Kessler, G., and Wolfman, M., Clin. Chem. 10: 686-703, 1964. Micro Procedure: "Calcium Kit" Clinton Laboratories, 6010 Wilshire Boulevard, Los Angeles 36, California.
- Serum Glutamic-Pyruvic Transaminase: Sigma Technical Bulletin No. 505 Revised September, 1964. Sigma Chemical Company, 3500 De Kalb Street, St. Louis, Missouri, 63118.
- Serum Glutamic-Oxaloacetic Transaminase: SMA-12 Autoanalyzer Morganstern, et. al., Clin. Chem. 12: 95-111, 1966. Micro Procedure: "Trans AC" General Diagnostics Division, Warner-Chilcott Laboratories, Morris Plains, New Jersey.
- Serum Alkaline Phosphatase: SMA-12 Autoanalyzer Marsh et. al., Clin. Chem. 5, 119, 1959. Micro Procedure: "Phosphastrate" Warner-Chilcott Laboratories, Morris Plains, New Jersey.
- Serum Electrophoresis: Millipore Phoroslide System, Bulletin P-E-1, 1968. Phoroslide Electrophoresis System, Principles and Operating Instructions, 1968. Millipore Corp., Bedford, Massachusetts.
- BSP (Bromosulphalein): Seligson, P., and Marino, J., Standard Methods of Clinical Chemistry, Vol. II, 1958, 186-191.
- Blood Glucose: SMA-12 Autoanalyzer. Brown, M. E., Diabetes 10: 60-62, 1961. Bittner, D., and McCleary, M., Am. J. Clin. Path. 40: 423-424, Alst., 1963. Micro Procedure: Autoanalyzer Method N-16a, Modification of Hoffman, W. S., J. Biol. Chem. 120, 51, 1937.
- Total Serum Bilirubin: SMA-12 Autoanalyzer Jandrassik and Grof, Biochem. 7, 297: 81 (1938) as adapted by Gambino and Schreiber, Technicon Symposium (1964). Micro Procedure: Gambino, S. R., Standard Methods in Clinical Chemistry, Vol. V, 55-64, 1965.
- Sodium: SMA-12 Autoanalyzer Standard Method Micro Procedure: Autoanalyzer Method N-20a, Technicon Instrument Corp., Chauncey, New York, 1963.
- Potassium: Same as for sodium.

REFERENCES FOR BIOCHEMICAL PROCEDURES (Continued)

CLINICAL CHEMISTRY - Continued

Serum L-Phenylalanine: Hill, J. B., Summer, G. K., Pender, M. W., and Reszel, N. O., An Automated Procedure for Blood Phenylalanine. Clin. Chem. 11, 541, 1965.

URINE ANALYSIS

Specific Gravity and Microscopic Examination of Sediment: Urinalysis Manual, U. S. Naval Medical School, NNMC, Bethesda, Maryland

pH, Sugar, Ketones, Protein, Bilirubin, Occult Blood, and Urobilinogen: Labstix, Ames Company, Elkhart, Indiana.

Fasting Phenylketones: Phenistix Method, Ames Labs.

Table No. 5 - Ophthalmoscopic examinations

INITIAL EXAMINATION

Conducted at Week 4; the eyes of all 360 control and treated mice placed on study appeared grossly normal.

20-WEEK EXAMINATION

Performed on 352 control and treated mice. No compound-related ocular changes were seen in any of the treated mice. Gross eye changes were evident in two control mice and are listed below.

<u>Mouse No.</u>	<u>Sex</u>	<u>Group No.</u>	<u>Observation</u>
01129	M	1	Right Eye: Central corneal opacity
01209	F	1	Right Eye: Irregular opaque coating over entire corneal surface

The eyes of the remaining mice examined at 20 weeks appeared grossly normal

40-WEEK EXAMINATION

Performed on 331 control and treated mice. No compound-related eye changes were evident in any of the treated mice. Incidental changes were present in five control and seven treated mice and are listed below.

<u>Mouse No.</u>	<u>Sex</u>	<u>Group No.</u>	<u>Observation</u>
01129	M	1	Right Eye: Diffuse corneal opacity
01130	M	1	Right Eye: Moderate cataract
01137	M	1	Both Eyes: Central corneal opacity
01186	F	1	Right Eye: Diffuse corneal opacity
01223	F	1	Both Eyes: Central corneal opacity
01239	M	2	Right Eye: Central corneal opacity
01250	M	2	Both Eyes: Central corneal opacity
01252	M	2	Left Eye: Central corneal opacity
01273	F	2	Right Eye: Severe cataract
01310	M	3	Left Eye: Central corneal opacity
01383	M	4	Right Eye: Central corneal opacity
01409	F	4	Right Eye: Central corneal opacity

The eyes of the remaining mice examined at 40 weeks appeared grossly normal.

Table No. 5 - Continued

## 60-WEEK EXAMINATION

Performed on 299 control and treated mice. No compound-related eye changes were seen in any of the treated animals. Incidental changes were evident in six control and 17 treated mice and are listed below.

<u>Mouse No.</u>	<u>Sex</u>	<u>Group No.</u>	<u>Observation</u>
01090	M	1	Both Eyes: Central corneal opacity
01119	M	1	Both Eyes: Central corneal opacity
01137	M	1	Both Eyes: Central corneal opacity
01210	F	1	Right Eye: Central corneal opacity
01217	F	1	Right Eye: Central corneal opacity
01223	F	1	Both Eyes: Central corneal opacity
01238	M	2	Left Eye: Severe cataract
01252	M	2	Left Eye: Central corneal opacity
01273	F	2	Right Eye: Severe cataract
01275	F	2	Right Eye: Central corneal opacity
01276	F	2	Left Eye: Moderate cataract
01279	F	2	Right Eye: Central corneal opacity
01286	F	2	Both Eyes: Central corneal opacity
01300	F	2	Both Eyes: Central corneal opacity
01304	M	3	Right Eye: Central corneal opacity
01318	M	3	Both Eyes: Central corneal opacity
01347	F	3	Both Eyes: Central corneal opacity
01358	F	3	Right Eye: Central corneal opacity
01370	F	3	Both Eyes: Central corneal opacity
01383	M	4	Right Eye: Central corneal opacity
01384	M	4	Right Eye: Central corneal opacity
01431	F	4	Right Eye: Central corneal opacity
01441	F	4	Left Eye: Central corneal opacity

The eyes of the remaining mice examined at 60 weeks appeared grossly normal.

Table No. 5 - Continued

TERMINAL (110-WEEK) EXAMINATION

Performed on 103 surviving control and treated mice. No compound-related ocular abnormalities were present in any of the treated mice. Incidental eye changes were seen in 60 mice randomly scattered among all groups including the controls. A list of the terminal eye findings is presented below.

Mouse No.	Sex	Group No.	Observation
01085	M	1	Both Eyes: Cataract
01087	M	1	Both Eyes: Cataract
01089	M	1	Both Eyes: Cataract
01090	M	1	Both Eyes: Central corneal opacity
01107	M	1	Both Eyes: Cataract
01119	M	1	Both Eyes: Cataract; central corneal opacity
01123	M	1	Both Eyes: Cataract
01131	M	1	Both Eyes: Cataract
01145	M	1	Both Eyes: Cataract; central corneal opacity
01146	M	1	Left Eye: Cataract
01152	M	1	Both Eyes: Cataract
01154	M	1	Both Eyes: Cataract
01156	M	1	Both Eyes: Cataract
01158	F	1	Right Eye: Cataract
01164	F	1	Both Eyes: Central corneal opacity
01165	F	1	Both Eyes: Central corneal opacity
01168	F	1	Both Eyes: Cataract
01170	F	1	Both Eyes: Cataract
01173	F	1	Both Eyes: Cataract
01184	F	1	Both Eyes: Central corneal opacity
01185	F	1	Both Eyes: Central corneal opacity
01210	F	1	Right Eye: Central corneal opacity; Left Eye: Cataract
01211	F	1	Both Eyes: Central corneal opacity
01217	F	1	Both Eyes: Cataract
01218	F	1	Both Eyes: Cataract
01229	M	2	Both Eyes: Cataract
01240	M	2	Left Eye: Cataract
01241	M	2	Both Eyes: Cataract
01257	M	2	Both Eyes: Cataract
01258	M	2	Both Eyes: Cataract
01260	M	2	Both Eyes: Cataract
01263	M	2	Right Eye: Large corneal opacity
01267	F	2	Right Eye: Cataract; Left Eye: Central corneal opacity
01269	F	2	Both Eyes: Cataract
01272	F	2	Right Eye: Central corneal opacity
01275	F	2	Both Eyes: Central corneal opacity
01285	F	2	Both Eyes: Cataract
01286	F	2	Both Eyes: Central corneal opacity
01288	F	2	Both Eyes: Cataract

Table No. 5 - Continued

TERMINAL (110-WEEK) EXAMINATION - Continued

<u>Mouse No.</u>	<u>Sex</u>	<u>Group No.</u>	<u>Observation</u>
01304	M	3	Right Eye: Central corneal opacity
01309	M	3	Both Eyes: Cataract
01314	M	3	Right Eye: Central corneal opacity
01317	M	3	Both Eyes: Central corneal opacity
01318	M	3	Both Eyes: Central corneal opacity
01326	M	3	Both Eyes: Cataract
01331	M	3	Both Eyes: Cataract
01341	F	3	Left Eye: Cataract
01347	F	3	Left Eye: Cataract
01349	F	3	Both Eyes: Cataract
01361	F	3	Both Eyes: Cataract
01374	M	4	Left Eye: Cataract
01376	M	4	Both Eyes: Cataract
01398	M	4	Both Eyes: Cataract
01404	M	4	Both Eyes: Cataract
01413	F	4	Right Eye: Cataract
01416	F	4	Both Eyes: Cataract
01426	F	4	Both Eyes: Cataract
01427	F	4	Both Eyes: Cataract
01429	F	4	Both Eyes: Cataract
01443	F	4	Both Eyes: Central corneal opacity

The eyes of the remaining mice examined at termination appeared grossly normal.

Table No. 5 - Continued

PERSISTENT EYE ALTERATIONS

The mice which showed persistent eye alterations during the study were as follows:

GROUP NO. 1 (CONTROL): SEVEN MICE

- Male Mouse No. 01090 - Central corneal opacity (both eyes) at 60 and 110 weeks.  
Male Mouse No. 01119 - Central corneal opacity (both eyes) at Week 60; central corneal opacity and cataract (both eyes) at Week 110.  
Male Mouse No. 01129 - Central corneal opacity (right eye) at Week 20; diffuse corneal opacity (right eye) at Week 40\*.  
Male Mouse No. 01137 - Central corneal opacity (both eyes) at 40 and 60 weeks; found dead at Week 91.  
Female Mouse No. 01210 - Central corneal opacity (right eye) at Week 60; central corneal opacity (right eye) and cataract (left eye) at Week 110.  
Female Mouse No. 01217 - Central corneal opacity (right eye) at Week 60; cataract (both eyes) at Week 110.  
Female Mouse No. 01223 - Central corneal opacity (both eyes) at 40 and 60 weeks; found dead at Week 98.

GROUP NO. 2 (0.25 G/KG): FOUR MICE

- Male Mouse No. 01252 - Central corneal opacity (left eye) at 40 and 60 weeks; found dead at Week 63.  
Female Mouse No. 01273 - Cataract (right eye) at 40 and 60 weeks; found dead at Week 100.  
Female Mouse No. 01275 - Central corneal opacity (right eye) at Week 60; central corneal opacity (both eyes) at Week 110.  
Female Mouse No. 01286 - Central corneal opacity (both eyes) at 60 and 110 weeks.

GROUP NO. 3 (0.50 G/KG): THREE MICE

- Male Mouse No. 01304 - Central corneal opacity (right eye) at 60 and 110 weeks.  
Male Mouse No. 01318 - Central corneal opacity (both eyes) at 60 and 110 weeks.  
Female Mouse No. 01347 - Central corneal opacity (both eyes) at Week 60; cataract (left eye) at Week 110.

GROUP NO. 4 (1.00 G/KG): ONE MOUSE

- Male Mouse No. 01383 - Central corneal opacity (right eye) at 40 and 60 weeks; found dead at Week 74.

\* Grossly normal at Weeks 60 and 110.

Table No. 6  
GROSS NECROPSY INCIDENCE TABLE

TERMINAL SACRIFICE

ORGANS	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	22	11	14	6	19	7	6	9
PITUITARY								
Raised area	1*				1			
EYE								
Opaque		1						
Protruding		1			1			
SALIVARY GLAND								
Enlarged	1							
THYMUS								
Enlarged, firm, nodular	1							
LUNG								
Dark red areas	1				2			
Nodular	3	4	2	1				
Consolidated	3		1					
Foci, yellow or gray	1		2		4		1	1
Lobe chalky white			1					
HEART								
Enlarged		1						
Atria enlarged	2							
LIVER								
Pale								1
Yellowish or greenish tinge	1			1			1	1
Raised area	1	1						
Nodular	3	1	1	1	1			
Cystic		1	3		2			1
Red foci							1	
Dark red indentations	1							
Lobe enlarged			1					
GALLBLADDER								
Dark	2							
Distended		1						
SPLEEN								
Small	3	1	9	3	1	1	1	
Enlarged	3	1			3			
Margins translucent	1						1	2
Mottled							1	
Nodular	3						2	

\* Number of animals affected



- 63 -  
Table No. 6 - Continued  
GROSS NECROPSY INCIDENCE TABLE  
TERMINAL SACRIFICE

ORGANS	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	22	11	14	6	19	7	6	9
KIDNEYS								
Enlarged	2							
Small			1					
Greenish or yellowish tinge		1	1	1	1	1	1	2
Surface rough, indentations	1							
Cortex wide	1							
Cortex pale		1			1			
Cortex pitted	1			1				
Cortex granular	1				1			
Cortex cystic	6	1	5					1
Medulla wide				1				
Medulla dark red	3	1		1	7			
Poor differentiation between cortex and medulla	1				2			
Pelvis dilated	1		1	1				
Tissue mass	1							
STOMACH								
Wall thickened	1	2	2					1
Wall thin					1	1		
Lining smooth	3	1			4	1		
Ulcerated areas in lining		1						
PANCREAS								
Thickened	1	1	2					
Dark brown		2	1					
Granular						2		
Yellow or white foci	1	4	7	2	2	3	1	
CERVICAL LYMPH NODE								
Enlarged						1	1	
ABDOMINAL LYMPH NODE								
Enlarged	3				1			
MESENTERIC LYMPH NODE								
Enlarged	1	1	1		3			1
TESTIS								
Small, soft	4	2	3	2				
Enlarged	1							
EPIDIDYMIS								
Thickened	1	1						
PROSTATE								
Enlarged, firm	1							

- 64 -  
Table No. 6 - Continued  
GROSS NECROPSY INCIDENCE TABLE  
TERMINAL SACRIFICE

ORGANS	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	22	11	14	6	19	7	6	9
SEMINAL VESICLES								
Enlarged, firm	3		3					
Small	1		5	2				
Chalky white			1					
UTERUS								
Distended					15	4	4	3
Walls thickened					14	3	4	6
Nodular and/or cystic					13	5	6	2
OVARY								
Cystic					18	5	5	7
Nodular					1			
Tissue Mass						1		
FALLOPIAN TUBE								
Enlarged, firm, granular					1			2
SORES ON BODY	1				1	1		
NODULE IN INGUINAL AREA	1							
NODE AT SITE OF RIGHT ADRENAL					1			
RIGHT HIP JOINT ENLARGED	1							

GROSS NECROPSY INCIDENCE TABLE  
DEATHS

ORGANS	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals*	44	21	20	26	49	27	29	26
BRAIN								
Soft				1**				
Adhered to skull							1	
Indentations						1		
Red areas on lobe								1
Excess of cerebrospinal fluid					1			
Granular Tissue mass					1			
SKULL								
Lining nodular						1		
PITUITARY								
Adhered to skull							1	
Enlarged						1		
Darkened						2		
Raised area on surface					1			
INNER EAR								
Filled with fluid							1	
Hollow areas							1	
LACRIMAL GLAND								
Segmented	1							
White in color	1							
SALIVARY GLAND								
Enlarged	3			1		1		
Segmented	1							
Firm	2							
Covered with jelly-like substance	2							
Contains firm jelly-like cyst						1		

\* Seven mice (three males and two females in Group No. 1 and one male each in Groups No. 2 and No. 4) escaped during the study and were not recovered. For 17 mice (three males and two females in Group No. 1, three males and two females in Group No. 2, two males and one female in Group No. 3, and two males and two females in Group No. 4), severe autolysis precluded meaningful gross necropsy observations and microscopic evaluation due to unsuitability of tissues for histopathology. The mice which escaped and those mice lost to postmortem evaluation due to autolysis are not included in the "Number of Animals" column of this table.

\*\* Number of animals affected.

GROSS NECROPSY INCIDENCE TABLE  
DEATHS

ORGANS	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	44	21	20	26	49	27	29	26
EYE								
One eye missing	1							
ESOPHAGUS								
Distended					1			
THYMUS								
Enlarged	1	2	1		2	2	2	1
Cystic	1							2
Nodular		1	1		1			
Firm		1	1		1	1	1	
THORACIC CAVITY								
Contains fluid	9	3	2	4	3	3	2	4
LUNG								
Dark red areas	15	10	10	14	25	10	11	14
White areas on surface	2					3		
Pale		1						
Greenish tinge					1			
Mottled					1			
Consolidated areas	1	1		1			1	
Frothy appearance	3			1	1	2	1	
Distended	2			3			1	1
Depressed areas					1			
Nodular or raised areas	4	1	1	3	2	1	1	2
Surrounded by clot-like material	1							
Tissue mass	1							
HEART								
Enlarged		1					1	
Atrium enlarged	5	1		3	3	1	1	1
Atrium dark red		1					1	
Atrium mottled								1
Atrium nodular	1							1
Yellow foci	1							
Nodule on surface					1			
Surrounded by fatty nodules	1							

Table No. 6A

GROSS NECROPSY INCIDENCE TABLE

ORGANS	DEATHS							
	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	44	21	20	26	49	27	29	26
LIVER								
Enlarged, margins rounded	4			3	2	2	1	2
Thickened or firm	1	1			2		1	1
Surface rough	1				1			1
Indentations	1							
Adhered to stomach						1		
Dark in color	2		1	1	1	3		1
Pale	1					1	1	
Mottled				1				
Margins gray					1			
Margins translucent							1	
Nodular	3	2	1	1				
Cystic	2					1		1
Friable	1							
Raised areas	3		1		2		1	
Contains white areas	1		1					
Red, brown, or yellow foci	2	1	1	1	1	1		1
Tissue mass			1		1			
GALLBLADDER								
Enlarged					1	2		2
STOMACH								
Wall thickened	1		2		1	5	2	1
Wall thin	2		1	2			2	
Distended	1				1			
Contains dark material	1			3	2	2	1	1
Granular material adhered to lining				1		1	1	
Darkened areas on mucosa		2		1	3	1	1	
Lining smooth		1	1	3			2	
Ulcerated areas	1				4	3	3	2
Nodular				1				
PANCREAS								
Thickened	2							
Discolored				1				
SMALL INTESTINE								
Distended	3	3	1	1	1			
Mucosa dark red	1						1	
Walls thin	1				1			
Nodular						1		
Covered with jelly-like substance			1					
Contains pale or dark fluid	4	3	1	2	4		1	

Table No. 6A

GROSS NECROPSY INCIDENCE TABLE

ORGANS	DEATHS							
	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	44	21	20	26	49	27	29	26
LARGE INTESTINE								
Distended	2	3		1				1
Mucosa thin	1							
Mucosa dark red							1	
Contains pale fluid	1	1		1				
Contains dark material	1	2		1	3	1		1
SPLEEN								
Enlarged	6	4	3	3	13	6	10	8
Small	1	1					2	
Irregular shape		1			1	1		1
Firm							1	1
Soft								1
Cystic	1						1	
Nodular or raised areas	1	1	2	1	1	1	2	1
Mottled								1
Yellow foci			1				1	
KIDNEYS								
Enlarged	2		1	2				2
Soft	1							
Surface rough or nodular	3		1	3	3			2
Discolored	3		4	4	1	2	1	1
Red foci on surface	1		1			1		
Cystic				1	1			
Cortex wide				2	1		1	
Cortex narrow					1			
Cortex pale				1		1	1	2
Cortex striated			1	1		1		1
Cortex pitted			1			1	1	1
Poor differentiation between cortex and medulla			2	5	2	1	3	2
Medulla wide	3					1	1	
Medulla dark in color	8		4	2	2	3	1	3
Medulla contains fissures					1	1		
Medulla striated	2		1	2	1	1		1
Pelvis dilated	9	5	5	9	8	2	5	4
Firm nodule in pelvis	1							
Purulent material in pelvis			1					

Table No. 6A  
GROSS NECROPSY INCIDENCE TABLE

ORGANS	DEATHS							
	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	44	21	20	26	49	27	29	26
ADRENAL								
Dark in color	2	1	1	1			1	4
Enlarged							1	
Speckled				1			1	1
URINARY BLADDER								
Distended	4	1	1	3				
Contains dark fluid			1	1				
Contains cloudy yellow fluid	1							
Contains Calculi	1							
Wall thickened	1	1		1	1	1		
Nodular								1
Reddened areas on mucosa		1	1			1		
TESTES								
Small, soft	3	2		3				
PROSTATE								
Enlarged	3	1						
Firm	1	1						
Discolored		1		1				
SEMINAL VESICLES								
Enlarged	4	2	3	3				
Firm	1		1	1				
Soft				1				
Nodular	1							
Greenish tinge				1				
Margins transparent		1	1	1				
OVARY								
Enlarged					1	1		
Firm					2	2		
Nodular							2	
Cystic					14	6	7	6
White or covered with white foci					1	2		
Reddened or yellowish areas						1		1
Adhered to abdominal wall					1		1	
Tissue mass							1	1

Table No. 6A

GROSS NECROPSY INCIDENCE TABLE

DEATHS

ORGANS	MALES				FEMALES			
	GROUP NO.				GROUP NO.			
	1	2	3	4	1	2	3	4
Number of Animals	44	21	20	26	49	27	29	26
UTERUS								
Distended or enlarged					16	9	3	13
Filled with fluid					5	1	1	4
Walls thickened					12	5	6	4
Lumpy appearance					1		1	
Nodular					2	3	1	3
Firm						1		
Cystic					14	9	11	9
Tortuous					1			
Discolored					5		3	2
Prolapsed							1	
Tissue mass					1	1	4	1
ABDOMINAL CAVITY								
Contains fluid		1	1	3	2		1	1
PERITONEUM								
Nodular					1			
BRONCHIAL LYMPH NODES								
Enlarged	1							
RENAL LYMPH NODES								
Enlarged	1							
CERVICAL LYMPH NODES								
Enlarged		1					1	
Firm		1						
MESENTERIC LYMPH NODES								
Enlarged	7	3	1	1	6	3	4	5
Discolored	3	2	1		4	2		2
ALL LYMPH NODES								
Enlarged	2	1	1			2	3	2
Firm		1	1				2	1
Gelatinous Material								
Adhered to Abdominal Wall		1						
Jelly-like Pink and Gray Nodules in Abdominal Cavity								1
Gelatinous Material in Subcutaneous Tissue	1			3				2



Table No. 6A

GROSS NECROPSY INCIDENCE TABLE

DEATHS

ORGANS	MALES				GROUP NUMBER		FEMALES			
	GROUP NO.						GROUP NO.			
	1	2	3	4	1	2	3	4		
Number of Animals	44	21	20	26					49	27 29 26
MUSCLES AND TISSUES										
Covered with gelatinous substance	2	1	1	1						
Abscesses or Sores on Body			1		3			1		
BACK										
Soft dark deposit of Tissue							1			
LEG										
Nodular					1					
FUR										
Red stains on abdomen			1							

TABLE NO. 7- MEAN TERMINAL BODY WEIGHTS, ORGAN WEIGHTS, ORGAN/BODY WEIGHT RATIO, AND STANDARD DEVIATIONS FOR MALE AND FEMALE ALBINO MICE.

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

GROUP NUMBER	SEX	BODY WEIGHT			THYROID				HEART			
		N	WEIGHT G.	S G.	WEIGHT G.	S G.	RATIO %	S %	WEIGHT G.	S G.	RATIO %	S %
1	M	22	31	3	0.008	0.002	0.03	0.01	0.21	0.05	0.68	0.14
2	M	11	34 <sup>S+</sup>	2	0.009	0.003 <sup>10/</sup>	0.03	0.01 <sup>10/</sup>	0.23	0.05	0.68	0.15
3	M	14	31	2	0.008	0.002	0.03	0.01	0.21	0.03	0.68	0.10 <sup>72</sup>
4	M	6	32	3	0.010	0.003	0.033	0.007	0.21	0.05	0.66	0.12
1	F	19	30	4	0.007	0.002	0.03	0.01	0.17	0.04	0.58	0.12
2	F	7	30	4	0.007	0.002 <sup>6/</sup>	0.03	0.01 <sup>6/</sup>	0.18	0.04	0.62	0.11
3	F	6	31	2	0.012 <sup>S+</sup>	0.004	0.04 <sup>S+</sup>	0.01	0.19	0.03	0.62	0.12
4	F	9	28	3	0.011 <sup>S+</sup>	0.003	0.04 <sup>S+</sup>	0.01	0.19	0.02	0.68	0.10

S+ = Significantly higher than control at  $p < 0.05$

/ = N for mean so designated

TABLE NO. 7- MEAN TERMINAL BODY WEIGHTS, ORGAN WEIGHTS, ORGAN/BODY WEIGHT RATIOS, AND STANDARD DEVIATIONS FOR MALE AND FEMALE ALBINO MICE

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

GROUP NUMBER	BODY WEIGHT				LIVER				KIDNEYS			
	SEX	N	WEIGHT G.	S G.	WEIGHT G.	S G.	RATIO %	S %	WEIGHT G.	S G.	RATIO %	S %
1	M	22	31	3	1.82	0.57	5.9	1.6	0.71	0.13 <sup>21/</sup>	2.3	0.4 <sup>21/</sup>
2	M	11	34 <sup>S+</sup>	2	1.77	0.58	5.3	2.0	0.79	0.32	2.3	1.0
3	M	14	31	2	1.61	0.39 <sup>13/</sup>	5.2	1.3 <sup>13/</sup>	0.71	0.07	2.3	0.2
4	M	6	32	3	1.71	0.23	5.4	0.5	0.72	0.11	2.3	0.3
1	F	19	30	4	1.64	0.31	5.5	0.9	0.50	0.08 <sup>18/</sup>	1.7	0.2 <sup>18/</sup>
2	F	7	30	4	1.53	0.17	5.2	0.9	0.51	0.10	1.7	0.4
3	F	6	31	2	1.45	0.10	4.8	0.4	0.54	0.05	1.8	0.2
4	F	9	28	3	1.71	0.25	6.1	1.0	0.55	0.07	2.0	0.3

S+ = Significantly higher than control at  $p < 0.05$ 

/ = N for mean so designated

TABLE NO. 7- MEAN TERMINAL BODY WEIGHTS, ORGAN WEIGHTS, ORGAN/BODY WEIGHT RATIOS, AND STANDARD DEVIATIONS FOR MALE AND FEMALE ALBINO MICE

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

GROUP NUMBER	SEX	N	BODY WEIGHT		ADRENALS				TESTES			
			WEIGHT G.	S G.	WEIGHT G.	S G.	RATIO %	S %	WEIGHT G.	S G.	RATIO %	S %
1	M	22	31	3	0.009	0.003	0.030	0.012	0.31	0.07 <sup>21/</sup>	1.0	0.3 <sup>21/</sup>
2	M	11	34 <sup>S+</sup>	2	0.010	0.002	0.029	0.006	0.32	0.07	0.94	0.22 <sup>74</sup>
3	M	14	31	2	0.010	0.002	0.033	0.007	0.31	0.07	1.0	0.23
4	M	6	32	3	0.011	0.004	0.036	0.015	0.30	0.09	0.93	0.23
1	F	19	30	4	0.013	0.003 <sup>18/</sup>	0.045	0.008 <sup>18/</sup>				
2	F	7	30	4	0.012	0.002	0.040	0.009				
3	F	6	31	2	0.012	0.002	0.038	0.006				
4	F	9	28	3	0.013	0.001	0.047	0.008				

S+ = Significantly higher than control at  $p < 0.05$

   / = N for mean so designated

TABLE NO. 7- MEAN TERMINAL BODY WEIGHTS, ORGAN WEIGHTS, ORGAN/BODY WEIGHT RATIO, AND STANDARD DEVIATIONS FOR MALE AND FEMALE ALBINO MICE

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

GROUP NUMBER	SEX	N	BODY WEIGHT		SEM. VESICLE			PROSTATE		
			WEIGHT G.	S G.	WEIGHT G.	S G.	RATIO %	S G.	WEIGHT G.	RATIO %
1	M	22	31	3	0.61	0.48	1.9	0.03	0.06	0.2
2	M	11	34 <sup>S+</sup>	2	0.54	0.13	1.6	0.02	0.05	0.2
3	M	14	31	2	0.67	0.53	2.1	0.03	0.05	0.2
4	M	6	32	3	0.40	0.28	1.2	0.02	0.05	0.2

- 75 -

S+ = Significantly higher than control at  $p < 0.05$

TABLE NO. 7 - MEAN TERMINAL BODY WEIGHTS, ORGAN WEIGHTS, ORGAN/BODY WEIGHT RATIOS, AND STANDARD DEVIATIONS FOR MALE AND FEMALE ALBINO MICE

SWISS MICE RECEIVING SC-19192 FOR 110 WEEKS

GROUP NUMBER	SEX	BODY WEIGHT			OVARIES			UTERUS				
		N	WEIGHT G.	S G.	WEIGHT G.	S G.	RATIO %	WEIGHT G.	S G.	RATIO %		
1	F	19	30	4	0.108	0.082 <sup>18/</sup>	0.35	0.24 <sup>18/</sup>	2.34	1.57	7.5	4.4
2	F	7	30	4	0.082	0.075 <sup>6/</sup>	0.26	0.18 <sup>6/</sup>	1.83	1.64	5.9	5.1
3	F	6	31	2	0.074	0.035 <sup>5/</sup>	0.25	0.12 <sup>5/</sup>	2.75	1.10	8.9	3.1
4	F	9	28	3	0.062 <sup>S-</sup>	0.024	0.22	0.08	2.00	2.99	6.4	8.3

S- = Significantly lower than control at  $p < 0.05$

$$/ = N \text{ for mean so designated}$$

KEY FOR TABLE NO. 8

P = Present

N = No Section

A = Autolysis

X = Not Remarkable

1 = Minimal

2 = Slight

3 = Moderate

4 = Moderately Severe/High

5 = Severe/High

TABLE NO. 8

PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(22) <sup>a</sup> Sacrificed																					
BRAIN																							
Mineral Deposition																							
Meningioma																							
Hemorrhage																							
Reticulum Cell Sarcoma																							
Perivascular Cuffing																							
Lymphosarcoma																							
PITUITARY																							
THYROID																							
Amyloid																							
Nonsuppurative Thyroiditis																							
Adenomatous Hyperplasia																							
ADRENAL																							
Cortical Hyperplasia																							
Amyloid																							
Cortical Hypertrophy																							
Cortical Atrophy																							
Cortical Adenoma																							

a = total number survivors



Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(22)		(44) <sup>b</sup>		Deaths											
		Sacrificed															
BRAIN																	
Mineral Deposition																	
Meningioma																	
Hemorrhage																	
Reticulum Cell Sarcoma	P																
Perivascular Cuffing																	
Lymphosarcoma																	
PITUITARY																	
THYROID																	
Amyloid																	
Nonsuppurative Thyroiditis																	
Adenomatous Hyperplasia																	
ADRENAL																	
Cortical Hyperplasia																	
Amyloid																	
Cortical Hypertrophy																	
Cortical Atrophy																	
Cortical Adenoma																	
Lymphosarcoma																	

b = total number of nonsurvivors for which one or more tissues were available for histologic preparation

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(44)																				
		Deaths																				
		01117	01118	01121	01122	01124	01126	01130	01131	01132	01133	01134	01135	01136	01137	01138	01139	01140	01141	01142	01143	
BRAIN		X	X	X	X	X	X		X		X	A	X	X	X	X	X	X	X	X	X	
Mineral Deposition								2		2												
Meningioma																						
Hemorrhage																						
Reticulum Cell Sarcoma																						
Perivascular Cuffing																						
Lymphosarcoma																						
								P														
PITUITARY		X	N	N	N	X	X	X	X	X	X	A	X	X	X	X	X	X	X	X		
THYROID		A	N				X	X	X	X	X	A	X	A	A		X	X	X	N		
Amyloid				3	3	2	X	X	X	X	X	A	X	A	A	4	X	X	X	N	2	
Nonsuppurative Thyroiditis																						
Adenomatous Hyperplasia																						
ADRENAL		N					X					A	X		N		X	X		X		
Cortical Hyperplasia			1	2				1	1	1	1										2	
Amyloid				2	4	4								3		2			2		2	
Cortical Hypertrophy																						
Cortical Atrophy																						
Cortical Adenoma																						

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males		Animal No.		(44)		Deaths		
		01144	01147	01148	01149	01151	01153	01155
BRAIN		X	X	X	X	X	X	
Mineral Deposition								2
Meningioma								
Hemorrhage								
Reticulum Cell Sarcoma								
Perivascular Cuffing								
Lymphosarcoma								
PITUITARY		N	X	X	X	X	X	X
THYROID		A	X			A	A	X
Amyloid				3	2			
Nonsuppurative Thyroiditis								
Adenomatous Hyperplasia								
ADRENAL			X			N	X	
Cortical Hyperplasia				2				2
Amyloid		3		2	3			
Cortical Hypertrophy								
Cortical Atrophy								
Cortical Adenoma								
Lymphosarcoma								P

Table No. 8 - Continued  
PROJECT NO. 700-260  
DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	01085	01087	01088	01089	01091	01092	01096	01103	01107	01110	01111	01112	01116	01119	01123	01128	01129	01145	01146	01152
HEART				X			X		X	X	X	X				X	X	X		X	X
Nonsuppurative Myocarditis								4					3	2					4		
Amyloid	2		3		1	4													2		
Arteritis																					
Angioma																					
Epicarditis																					
Mesothelioma								4													
Thrombosis																					
Lymphosarcoma																					
Reticulum Cell Sarcoma																					
PANCREAS		X	X		X	X			X					X					X	X	X
Lymphosarcoma							P														
Cystic Ducts																					
Nonsuppurative Pancreatitis																					
Reticulum Cell Sarcoma										2	1	1									
Mononuclear Infiltration				2																	
Atrophy																					
Amyloid																					
Arteritis																					
Islet Cell Hyperplasia																					
Islet Cell Tumor																					

(22)

Sacrificed

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No	(22)											(44)										
		Sacrificed											Deaths										
HEART		01154	01156	07086	01090	07093	01095	07097	07098	07099	07100	07101	07102	07105	07106	07108	07109	07113	07114	07115			
Nonsuppurative Myocarditis				X		X	X								X	X	X	X	X	X			
Amyloid			3							2	2	3		1									
Arteritis			2					3															
Angioma																							
Epicarditis								3															
Mesothelioma																							
Thrombosis			2		4					4		4											
Lymphosarcoma													P										
Reticulum Cell Sarcoma	P																						
PANCREAS		X	X	A	A	P	X	A	X	X	X	X	P	A	A	X	X	A		X			
Lymphosarcoma																							
Cystic Ducts																							
Nonsuppurative Pancreatitis																							
Reticulum Cell Sarcoma																							
Mononuclear Infiltration																							
Atrophy																							
Amyloid																							
Arteritis																							
Islet Cell Hyperplasia																							
Islet Cell Tumor																							

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)  
Deaths

Animal No.

Group I - Males

01117 01118 01121 01122 01124 01126 01130 01131 01132 01133 01134 01135 01136 01137 01138 01139 01140 01141 01142 01143

HEART

Nonsuppurative Myocarditis

Amyloid

Arteritis

Angioma

Epicarditis

Mesothelioma

Thrombosis

Lymphosarcoma

Reticulum Cell Sarcoma

PANCREAS

Lymphosarcoma

Cystic Ducts

Nonsuppurative Pancreatitis

Reticulum Cell Sarcoma

Mononuclear Infiltration

Atrophy

Amyloid

Arteritis

Islet Cell Hyperplasia

Islet Cell Tumor

X X

3

4

2

2

3

X

X

X

X

X

A

X

4

X

X

X

X

X

X

X

X

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

X

3

3

3

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	(44)					
	Deaths					
	01144	01147	01148	01149	01151	01153
Group I - Males	Animal No.					
HEART						
Nonsuppurative Myocarditis		X	2	X	X	X
Amyloid	2					
Arteritis						2
Angioma						
Epicarditis						
Mesothelioma						
Thrombosis			3			
Lymphosarcoma						
Reticulum Cell Sarcoma						
PANCREAS						
Lymphosarcoma	X	X	X	X	X	X
Cystic Ducts						
Nonsuppurative Pancreatitis						
Reticulum Cell Sarcoma						
Mononuclear Infiltration						
Atrophy						
Amyloid						
Arteritis						
Islet Cell Hyperplasia						
Islet Cell Tumor						

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 86 -



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	(22) Sacrificed		(44) Deaths																
	Animal No		01086	01090	01093	01095	01097	01098	01099	01100	01101	01102	01105	01106	01108	01109	01113	01114	01115
LUNG			X		2		X	X			2			X	2		X	X	X
Interstitial Pneumonitis		2																	
Peribronchial Lymphoid Hyperplasia	2																		
Perivascular Lymphoid Hyperplasia																			
Adenoma	P			P		P			P	P			P			P			
Epithelial Hyperplasia																			
Amyloid										2									
Alveolar Macrophages																			
Adenocarcinoma																			
Pneumonia																			
Thrombosis																			
Mesothelioma																			
Metastatic Tumor																			
Pigment																			
Lymphosarcoma													P						
Reticulum Cell Sarcoma	P																		
LYMPH NODE																			
Amyloid		X												A		X			N
Lymphoid Hyperplasia																			
Lymphosarcoma					P							P							
Reticulum Cell Sarcoma	P																		
Hemorrhage																			
Adenitis																			
Angioma																			
R.E. Hyperplasia																			
Arteritis																			
Angiosarcoma																			P

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)

Deaths

Group I - Males	Animal No.	01117	01118	01121	01122	01124	01126	01130	01131	01132	01133	01134	01135	01136	01137	01138	01139	01140	01141	01142	01143
LUNG																					
Interstitial Pneumonitis			2							3		A				X		X			
Peribronchial Lymphoid Hyperplasia		2	2							3											
Perivascular Lymphoid Hyperplasia		2		2						3											1
Adenoma								P	P						P						
Epithelial Hyperplasia																					
Amyloid																					
Alveolar Macrophages																					
Adenocarcinoma										3											
Pneumonia																					
Thrombosis																					
Mesothelioma											P										
Metastatic Tumor																					
Pigment																					
Lymphosarcoma								P											3		
Reticulum Cell Sarcoma																					
LYMPH NODE																					
Amyloid				3					X	A	N		A	A	A			X	X		2
Lymphoid Hyperplasia																					
Lymphosarcoma								P													
Reticulum Cell Sarcoma																					
Hemorrhage																					
Adenitis																					
Angioma																					
R.E. Hyperplasia			3																		
Arteritis			3																		
Angiosarcoma																					

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)  
Deaths  
Animal No.

Group I - Males

LUNG	X						
Interstitial Pneumonitis		2	1				
Peribronchial Lymphoid Hyperplasia		2	1				
Perivascular Lymphoid Hyperplasia						2	
Adenoma		2			P		
Epithelial Hyperplasia							
Amyloid							
Alveolar Macrophages						2	
Adenocarcinoma							
Pneumonia							
Thrombosis							
Mesothelioma							
Metastatic Tumor							
Pigment							
Lymphosarcoma							
Reticulum Cell Sarcoma							
LYMPH NODE	X	N				X	N
Amyloid							
Lymphoid Hyperplasia			2	3			
Lymphosarcoma							
Reticulum Cell Sarcoma							
Hemorrhage							2
Adenitis							
Angioma							
R.E. Hyperplasia							
Arteritis							
Angiosarcoma							

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(22) Sacrificed	
LIVER	01085	X	
Amyloid	01088	1	
Necrosis/Caudate Lobe	01091		
Pericholangitis	01092	2	
Vacuolation	01096	2	
Necrosis	01103		
Acute Hepatitis	01107		
Nodular Hyperplasia	01110	X	
Nonsuppurative Hepatitis	01111	1	
Mononuclear Infiltration	01112		
Hepatoma	01116	2	
Sinusoidal Infiltrate	01119		
Angiosarcoma	01123	X	
Thrombosis	01128	1	
Lymphosarcoma	01129		
Reticulum Cell Sarcoma	01145	3	
Cyst	01146		
Cytomegaly	01152		
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			
Angiectasis			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No	(22)		(44)		Deaths	
		Sacrificed		Deaths			
LIVER							
Amyloid		2					
Necrosis/Caudate Lobe							
Pericholangitis							
Vacuolation							
Necrosis							
Acute Hepatitis							
Nodular Hyperplasia							
Nonsuppurative Hepatitis		2					
Mononuclear Infiltration		2					
Hepatoma							
Sinusoidal Infiltrate							
Angiosarcoma							
Thrombosis							
Lymphosarcoma							
Reticulum Cell Sarcoma							
Cyst							
Cytomegaly							
Bile Duct Carcinoma							
Metastatic Sarcoma							
Angioma							
Angiectasis							
	01154						
	01156						
	01086		2				
	01090		A				
	01093						
	01095						
	01097		3				
	01098		A				
	01099		A				
	01100			1			
	01101						
	01102						
	01105		A	2			
	01106		A				
	01108					2	
	01109				X		
	01113				A		
	01114				X		
	01115				X		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(44)	Deaths	01143	01142	01141	01140	01139	01138	01137	01136	01135	01134	01133	01132	01131	01130	01126	01124	01122	01121	01118	01117
LIVER																							
Amyloid																							
Necrosis/Caudate Lobe																							
Pericholangitis																							
Vacuolation																							
Necrosis																							
Acute Hepatitis																							
Nodular Hyperplasia																							
Nonsuppurative Hepatitis																							
Mononuclear Infiltration																							
Hepatoma																							
Sinusoidal Infiltrate																							
Angiosarcoma																							
Thrombosis																							
Lymphosarcoma																							
Reticulum Cell Sarcoma																							
Cyst																							
Cytomegaly																							
Bile Duct Carcinoma																							
Metastatic Sarcoma																							
Angioma																							
Angiectasis																							

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)

Deaths

Animal No.	01144	01147	01148	01149	01151	01153	01155
------------	-------	-------	-------	-------	-------	-------	-------

Group I - Males

LIVER							
Amyloid	2		2	2	X	X	
Necrosis/Caudate Lobe							
Pericholangitis							
Vacuolation							
Necrosis		2					4
Acute Hepatitis							
Nodular Hyperplasia							
Nonsuppurative Hepatitis							
Mononuclear Infiltration	2						
Hepatoma							
Sinusoidal Infiltrate							
Angiosarcoma							
Thrombosis							
Lymphosarcoma							
Reticulum Cell Sarcoma							P
Cyst							
Cytomegaly							
Bile Duct Carcinoma							
Metastatic Sarcoma							
Angioma							
Angiectasis							

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(22)

Group I - Males	Animal No.	Sacrificed
GALL BLADDER		
Lymphosarcoma		
Acute Cholecystitis		
KIDNEY		
Interstitial Nephritis		
Regenerative Epithelium		
Dilated Pelvis		
Perivascular Mononuclear Infiltration		
Tubular Dilatation		
Glomerular Amyloid		
Interstitial Amyloid		
Mineral Deposition		
Lymphosarcoma		
Pyelonephritis		
Arteritis		
Pigment/Tubular		
Reticulum Cell Sarcoma		
Adenocarcinoma		
STOMACH		
Gastritis		
Ulceration		
Lymphosarcoma		
Metastatic Tumor		
Amyloid		
Carcinoma		
Mucosal Hyperplasia		
Adenocarcinoma		



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No		(22) Sacrificed		(44) Deaths															
	01154	01156	01086	01090	01093	01095	01097	01098	01099	01100	01101	01102	01105	01106	01108	01109	01113	01114	01115	
GALL BLADDER	X	X	A	A	A	A	N	A	A	X	X	P	A	N	X					
Lymphosarcoma																				
Acute Cholecystitis																				
KIDNEY																				
Interstitial Nephritis	2	3		3			A	A		2			A	A	2	A	A			
Regenerative Epithelium	2	3						3												
Dilated Pelvis			2										2							
Perivascular Mononuclear Infiltration	4	4	2	2		2	2		2	3			3		3	1	2	2	2	
Tubular Dilatation																				
Glomerular Amyloid	2	5	3	4		4	4	4		4			4							
Interstitial Amyloid																				
Mineral Deposition								2												
Lymphosarcoma												P								
Pyelonephritis																				
Arteritis					2		3				3									
Pigment/Tubular																				
Reticulum Cell Sarcoma	P																			
Adenocarcinoma																				
STOMACH																				
Gastritis		X	A	A	X	X	A		X		X		A	A	X	A	A	X	X	
Ulceration																				
Lymphosarcoma																				
Metastatic Tumor																				
Amyloid																				

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 96 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Deaths (44)						Animal No.
	01144	01147	01148	01149	01151	01153	01155
Group I - Males							
GALL BLADDER							
Lymphosarcoma	N	A	X	A	A	A	A
Acute Cholecystitis							
KIDNEY							
Interstitial Nephritis	2	X			X	X	2
Regenerative Epithelium							2
Dilated Pelvis							
Perivascular Mononuclear Infiltration	2			2			2
Tubular Dilatation							
Glomerular Amyloid	4		3	4			
Interstitial Amyloid							
Mineral Deposition	2		2				
Lymphosarcoma							
Pyelonephritis							
Arteritis							
Pigment/Tubular							
Reticulum Cell Sarcoma							
Adenocarcinoma							
STOMACH							
Gastritis	A	X			A	X	X
Ulceration							
Lymphosarcoma							
Metastatic Tumor							
Amyloid							
Carcinoma			2				
Mucosal Hyperplasia				3			
Adenoma							

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(22)

Group I - Males	Animal No.	Sacrificed	01085	01087	01088	01089	01091	01092	01096	01103	01107	01110	01111	01112	01116	01119	01123	01128	01129	01145	01146	01152
SMALL INTESTINE			X	X	1	X	X	X	3	3	X	X	X	X	X	2	X	X	X	3	X	X
Amyloid																						
Mucosal Erosion																						
Enteritis																						
Hemorrhage																						
LARGE INTESTINE			X	X	P	X		X	X	X	X	P	X	X	X	X	X	X	X	X	X	X
Nematodiasis																						
Lymphosarcoma																						
Amyloid							2															
Hemorrhage																						
SPLEEN			X	X	X	X	X		2	X	X	X		3	X		2	X	X		4	X
Extramedullary Hematopoiesis																						
Angiosarcoma																						
Angioma																						
Reticulum Cell Sarcoma													P									
Amyloid									1											3		
Lymphoid Depletion																						
Lymphosarcoma																						
R.E. Hyperplasia																						
Congestion																						
Thrombosis																						
Lymphoid Hyperplasia																						
Macrophages																						

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No	(22)		(44)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
		Sacrificed				Deaths																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														
SMALL INTESTINE		X																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(44) Deaths																			
		01117	01118	01121	01122	01124	01126	01130	01131	01132	01133	01134	01135	01136	01137	01138	01139	01140	01141	01142	01143
SMALL INTESTINE		A	X		A	A	A	X	A	A	X	A	A	A	A	A	A	N	A	X	
Amyloid				3	2	2				3						3					3
Mucosal Erosion																					
Enteritis																					
Hemorrhage																					
LARGE INTESTINE		A	X	X	A	A	X	X	X	X	X	A	A	A	A		X	X		A	
Nematodiasis																					
Lymphosarcoma																					
Amyloid						P										P					P
Hemorrhage																					
SPLEEN		A	X		X		X			X		A			X			N	X		X
Extramedullary Hematopoiesis				2									P								
Angiosarcoma																					
Angioma																					
Reticulum Cell Sarcoma																					
Amyloid						5								4		2	3				
Lymphoid Depletion								P													
Lymphosarcoma																					
R.E. Hyperplasia																					2
Congestion																					
Thrombosis																					
Lymphoid Hyperplasia									2		3		5								
Macrophages																					

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(44)

Deaths  
Animal No.

Group I - Males

SMALL INTESTINE	01144	A	A	A	3	A	A	X
Amyloid	01147	A	A	A				
Mucosal Erosion	01148	A	A					
Enteritis	01149							
Hemorrhage	01151							
	01153							
	01155							
LARGE INTESTINE								
Nematodiasis		A	X	P				P
Lymphosarcoma								
Amyloid								
Hemorrhage								
SPLEEN								
Extramedullary Hematopoiesis		X						
Angiosarcoma			X	X				
Angioma								
Reticulum Cell Sarcoma								P
Amyloid								
Lymphoid Depletion								
Lymphosarcoma								
R.E. Hyperplasia								
Congestion								
Thrombosis								
Lymphoid Hyperplasia								
Macrophages								

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(22)

[illegible]



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	TESTIS	(22)		(44)														Animal No		
		Sacrificed		Deaths																
	Amyloid	01154	01156	01086	01090	01093	01095	01097	01098	01099	01100	01101	01102	01105	01106	01108	01109	01113	01114	01115
	Mineralization		2	3	X	X		A			2			A	X	X	X		X	X
	Atrophy							5	2			1		3						
	Hyospermatogenesis							2						1				2		
	Interstitial Cell Hyperplasia	2	3	3			4	4			2			2				2		
	Arteritis	2		2																
	Lymphosarcoma												P							
	Epididymitis																			
	Interstitial Cell Tumor																			
	Dilation/Epididymis																			
	Mesothelioma	3																		
	PROSTATE																			
	Nonsuppurative Prostatitis																			
	Acute Prostatitis	X	X	X		X	X	A	N	N	X	X		A	X	N	X	A	X	X
	Hemorrhage																			
	Arteritis																			
	Reticulum Cell Sarcoma																			
	Lymphosarcoma												P							
	SEMINAL VESICLE																			
	Glandular Dilatation	X		A	A	X		A	A	A	X	X		A	A	X	A	A	A	A
	Perivascular Mononuclear Infiltration						3													
	Arteritis																			
	Acute Vesiculitis																			
	Lymphosarcoma																			
	Atrophy																			
	Reticulum Cell Sarcoma		4				3						P							

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)

Deaths

Animal No.

Group I - Males

01117 01118 01121 01122 01124 01126 01130 01131 01132 01133 01134 01135 01136 01137 01138 01139 01140 01141 01142 01143

TESTIS

Amyloid  
Mineralization  
Atrophy  
Hypospermatogenesis  
Interstitial Cell Hyperplasia  
Arteritis  
Lymphosarcoma  
Epididymitis  
Interstitial Cell Tumor  
Dilation/Epididymis  
Mesothelioma

PROSTATE

Nonsuppurative Prostatitis  
Acute Prostatitis  
Hemorrhage  
Arteritis  
Reticulum Cell Sarcoma  
Lymphosarcoma

SEMINAL VESICLE

Glandular Dilatation  
Perivascular Mononuclear Infiltration  
Arteritis  
Acute Vesiculitis  
Lymphosarcoma  
Atrophy  
Reticulum Cell Sarcoma

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)

Deaths

TESTIS	Animal No.	01744	01747	01748	01749	01751	01753	01755
Group I - Males		X		3	N	X	X	X
Amyloid								
Mineralization								
Atrophy								
Hypospermatogenesis			1	3				
Interstitial Cell Hyperplasia								
Arteritis								
Lymphosarcoma								
Epididymitis								
Interstitial Cell Tumor								
Dilation/Epididymis								
Mesothelioma								
PROSTATE								
Nonsuppurative Prostatitis		X	X	X	X	X	A	X
Acute Prostatitis								
Hemorrhage								
Arteritis								
Reticulum Cell Sarcoma								
Lymphosarcoma								
SEMINAL VESICLE								
Glandular Dilatation		A	X	A	X	X	A	X
Perivascular Mononuclear Infiltration								
Arteritis								
Acute Vesiculitis								
Lymphosarcoma								
Atrophy								
Reticulum Cell Sarcoma								

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(22)

Group I - Males	Animal No.	Sacrificed	01085	01087	01088	01089	01091	01092	01096	01103	01107	01110	01111	01112	01116	01119	01123	01128	01129	01145	01146	01152
SALIVARY GLAND	Mononuclear Infiltration		2	1		X	X				X	1	2	X	2	X	1	X	X	2	X	X
	Amyloid				1				3	3					3							
	Lymphosarcoma																					
	Adenitis							2														
URINARY BLADDER	Mononuclear Infiltration		1	1			X	2	1		1		2	X		X	2				X	X
	Acute Cystitis																					
	Lymphosarcoma																					
	Nonsuppurative Cystitis																					
	Mucosal Separation																					
	Hemorrhage																					
	Arteritis																					
	Epithelial Hyperplasia																					
NERVE			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	Reticulum Cell Sarcoma																					

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No	(22)		(44)		Deaths			
		Sacrificed							
SALIVARY GLAND	01154	2	X						01115
									01114
									01113
									01109
									01108
									01106
									01105
									01102
									01101
									01100
URINARY BLADDER	01096	2	X						01099
									01098
									01097
									01095
									01093
									01090
									01086
NERVE	01156		X						01106
									01105
									01102
									01101
									01100
									01099
									01098
									01097
									01095
									01093
RETICULUM CELL SARCOMA	01154	P	X						01106
									01105
									01102
									01101
									01100
									01099
									01098
									01097
									01095
									01093

SALIVARY GLAND  
Mononuclear Infiltration  
Amyloid  
Lymphosarcoma  
Adenitis

URINARY BLADDER  
Mononuclear Infiltration  
Acute Cystitis  
Lymphosarcoma  
Nonsuppurative Cystitis  
Mucosal Separation  
Hemorrhage  
Arteritis  
Epithelial Hyperplasia

NERVE  
Reticulum Cell Sarcoma

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males		Deaths		(44)		Animal No.	
SALIVARY GLAND	Mononuclear Infiltration	A	X	X	X	01117	01143
	Amyloid					01118	01142
	Lymphosarcoma					01121	01141
	Adenitis					01122	01140
						01124	01139
						01126	01138
						01130	01137
						01131	01136
						01132	01135
						01133	01134
URINARY BLADDER	Mononuclear Infiltration	A	1	X	X	01117	01143
	Acute Cystitis					01118	01142
	Lymphosarcoma					01121	01141
	Nonsuppurative Cystitis					01122	01140
	Mucosal Separation					01124	01139
	Hemorrhage					01126	01138
	Arteritis					01130	01137
	Epithelial Hyperplasia					01131	01136
						01132	01135
						01133	01134
NERVE	Reticulum Cell Sarcoma	X	X	X	X	01117	01143
						01118	01142

Table No. 3 - Continued  
PROJECT NO. 700-260  
DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(44)  
Deaths

Animal No.	01144	01147	01148	01149	01151	01153	01155
Group I - Males							
SALIVARY GLAND							
Mononuclear Infiltration					X	X	1
Amyloid	3		2	3			
Lymphosarcoma							
Adenitis		X					
URINARY BLADDER							
Mononuclear Infiltration	2	A	1	1	A	A	2
Acute Cystitis							
Lymphosarcoma							
Nonsuppurative Cystitis					3		
Mucosal Separation							
Hemorrhage							
Arteritis							
Epithelial Hyperplasia							
NERVE							
Reticulum Cell Sarcoma	X	X	X	X	X	X	X

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(22) Sacrificed	01085	01087	01088	01089	01091	01092	01096	01103	01107	01110	01111	01112	01116	01119	01123	01128	01129	01145	01146	01152
MUSCLE			X	X	X	X	X	X	X	X	3	X	X	X	2	X	X	X	X	X	X	X
Myositis																						
Lymphosarcoma																						
Reticulum Cell Sarcoma																						
Sarcoma																						
Parasite																						
EYE			X		X	X	X		X	X		X	X	X	X	X	X	X	X			X
Dacryoadenitis																						
Ophthalmitis																						
Retinal Degeneration								3			3									3	2	
Keratitis																						
Lymphosarcoma																						
Lens Vacuolation																						
Lacrimal Gland Hyperplasia				1																		
BONE			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Fibroplasia																						
BONE MARROW																						
Hematogenic Activity			4	4	4	4	4	5	4	4	4	4	4	4	5	4	4	4	4	5	4	4
Lymphosarcoma																						
Angiectasis																						
Osteomyelitis																						



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No	(22)		(44)		Deaths			
		Sacrificed							
	01154								01115
	01156								01114
MUSCLE									01113
Myositis	X								01109
Lymphosarcoma									01108
Reticulum Cell Sarcoma	P								01106
Sarcoma									01105
Parasite									01102
									01101
EYE									01100
Dacryoadenitis	X								01099
Ophthalmitis	X								01098
Retinal Degeneration									01097
Keratitis									01095
Lymphosarcoma									01093
Lens Vacuolation									01090
Lacrimal Gland Hyperplasia									01086
BONE									
Fibroplasia	X								
BONE MARROW									
Hematogenic Activity	4								
Lymphosarcoma									
Angiectasis									
Osteomyelitis									

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(44)																							
		Deaths																							
MUSCLE																									
Myositis																									
Lymphosarcoma																									
Reticulum Cell Sarcoma																									
Sarcoma																									
Parasite																									
EYE																									
Dacryoadenitis																									
Ophthalmitis																									
Retinal Degeneration																									
Keratitis																									
Lymphosarcoma																									
Lens Vacuolation																									
Lacrimal Gland Hyperplasia																									
BONE																									
Fibroplasia																									
BONE MARROW																									
Hematogenic Activity																									
Lymphosarcoma																									
Angiectasis																									
Osteomyelitis																									

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(44)

Animal No. Deaths

Group I - Males

MUSCLE	01144	01147	01148	01149	01151	01153	01155
Myositis	X	X	X	X	X	X	X
Lymphosarcoma							
Reticulum Cell Sarcoma							
Sarcoma							
Parasite							
EYE	A	X	A	X	A	A	
Dacryoadenitis							
Ophthalmitis							
Retinal Degeneration							
Keratitis							
Lymphosarcoma							2
Lens Vacuolation							
Lacrimal Gland Hyperplasia							
BONE	X	X	X	X	X	X	X
Fibroplasia							
BONE MARROW							
Hematogenic Activity	4	2	4	4	3	4	4
Lymphosarcoma							
Angiectasis							
Osteomyelitis							

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	Animal No.	(22)																					
		Sacrificed																					
MAMMARY GLAND																							
Acinar Tissue *																							
Ductal Tissue *																							
Mastitis																							
SPINAL CORD																							
Lymphosarcoma																							
SKIN																							
Parasite																							
Acute Dermatitis																							
Lymphangiectasis																							
Edema																							
TISSUE MASS																							
Lymphosarcoma																							
Undiff. Sarcoma																							
MESENTERY																							
Peritonitis																							
Arteritis																							
Lymphosarcoma																							
Sarcoma																							

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260  
DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Males	(22)		(44)																
	Sacrificed		Deaths																
Animal No	01154	01156	01086	01090	01093	01095	01097	01098	01099	01100	01101	01102	01105	01106	01108	01109	01113	01114	01115
MAMMARY GLAND																			
Acinar Tissue *	N		N	N	N	N		N	N	N	N	N	N	N	N	N	N	N	N
Ductal Tissue *	N	1	N	N	N	N	2	N	N	N	N	N	N	N	N	N	N	N	N
Mastitis																			
SPINAL CORD	X	X	N	X	X	X	X	X	X	X	X		X	X	X	X	X	X	X
Lymphosarcoma												P							
SKIN																			
Parasite																			
Acute Dermatitis																			
Lymphangiectasis																			
Edema																			
TISSUE MASS																			
Lymphosarcoma																			
Undiff. Sarcoma																			
MESENTERY																			
Peritonitis																			
Arteritis																			
Lymphosarcoma																			
Sarcoma																			

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)

Deaths

Group I - Males	Animal No.	01177	01118	01121	01122	01124	01126	01130	01131	01132	01133	01134	01135	01136	01137	01138	01139	01140	01141	01142	01143
MAMMARY GLAND																					
Acinar Tissue *		N	N	N	N			N	N	N	N	N	N	N	N	N	N	N	N	N	N
Ductal Tissue *		N	N	N	N	1	1	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Mastitis																					
SPINAL CORD		X	X	X	X	X	X	X	N	N	X	N	X	X	X	X	X	N	X	X	X
Lymphosarcoma																					
SKIN																					
Parasite																					
Acute Dermatitis																					
Lymphangiectasis																					
Edema																					
TISSUE MASS																					
Lymphosarcoma																					
Undiff. Sarcoma																					
MESENTERY																					
Peritonitis																					
Arteritis																					
Lymphosarcoma																					
Sarcoma																					

P

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(44)  
Deaths

Group I - Males

MAMMARY GLAND  
Acinar Tissue \*  
Ductal Tissue \*  
Mastitis

SPINAL CORD  
Lymphosarcoma

SKIN  
Parasite  
Acute Dermatitis  
Lymphangiectasis  
Edema

TISSUE MASS  
Lymphosarcoma  
Undiff. Sarcoma

MESENTERY  
Peritonitis  
Arteritis  
Lymphosarcoma  
Sarcoma

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim.No.	(11) <sup>a</sup> Sacrificed										(21) <sup>b</sup> Deaths								
		01229	01234	01240	01241	01245	01249	01255	01257	01258	01260	01263	01231	01230	01232	01233	01235	01236	01237	01243
Group II - Males																				
BRAIN																				
Mineral Deposition	1												1	2	X	2	2	X		X
Meningioma																				
Hemorrhage																				
Reticulum Cell Sarcoma																				
Perivascular Cuffing																				
Lymphosarcoma																				
Degeneration, Traumatic																				
PITUITARY																			P	
THYROID																				
Amyloid																				
Nonsuppurative Thyroiditis																				
Adenomatous Hyperplasia																				
ADRENAL																				
Cortical Hyperplasia																				
Amyloid																				
Cortical Hypertrophy																				
Cortical Atrophy																				
Cortical Adenoma																				

a = total number survivors

b = total number of nonsurvivors for which one or more tissues were available for histologic preparation



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(21)

Deaths

Group II - Males	01244	01246	01247	01248	01251	01252	01253	01254	01256	01259	01261	01262	01264
Anim.No.	X	X	2		X	X	X	X	X	1	X	X	X

BRAIN

Mineral Deposition  
Meningioma  
Hemorrhage  
Reticulum Cell Sarcoma  
Perivascular Cuffing  
Lymphosarcoma  
Degeneration, Traumatic  
PITUITARY

THYROID

Amyloid  
Nonsuppurative Thyroiditis  
Adenomatous Hyperplasia

ADRENAL

Cortical Hyperplasia  
Amyloid  
Cortical Hypertrophy  
Cortical Atrophy  
Cortical Adenoma  
Lymphosarcoma

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Antm. No.	(11) Sacrificed											(21) Deaths										
	01229																						
	01234																						
	01240																						
	01241																						
	01245																						
	01249																						
	01255																						
	01257																						
	01258																						
	01260																						
	01263																						
HEART																							
Nonsuppurative Myocarditis	2																						
Amyloid																							
Arteritis																							
Angioma																							
Epicarditis																							
Mesothelioma																							
Thrombosis																							
Lymphosarcoma																							
Reticulum Cell Sarcoma																							
PANCREAS																							
Lymphosarcoma																							
Cystic Ducts																							
Nonsuppurative Pancreatitis																							
Reticulum Cell Sarcoma																							
Mononuclear Infiltration																							
Atrophy																							
Amyloid																							
Arteritis																							
Islet Cell Hyperplasia																							
Islet Cell Tumor																							

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Antm. No.	Deaths	(21)
HEART			
Nonsuppurative Myocarditis			
Amyloid			
Arteritis			
Angioma			
Epicarditis			
Mesothelioma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
PANCREAS			
Lymphosarcoma			
Cystic Ducts			
Nonsuppurative Pancreatitis			
Reticulum Cell Sarcoma			
Mononuclear Infiltration			
Atrophy			
Amyloid			
Arteritis			
Islet Cell Hyperplasia			
Islet Cell Tumor			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Anim. No.	(11) Sacrificed											(21) Deaths						
	01229	01234	01240	01241	01245	01249	01255	01257	01258	01260	01263	01231	01230	01232	01233	01235	01236	01237	01243
LUNG																			
Interstitial Pneumonitis												X							
Peribronchial Lymphoid Hyperplasia	3	2	1	2	2														
Perivascular Lymphoid Hyperplasia																			
Adenoma																			
Epithelial Hyperplasia																			
Amyloid																			
Alveolar Macrophages																			
Adenocarcinoma																			
Pneumonia																			
Thrombosis																			
Mesothelioma																			
Metastatic Tumor																			
Pigment																			
Lymphosarcoma																			
Reticulum Cell Sarcoma																			
LYMPH NODE																			
Amyloid																			
Lymphoid Hyperplasia																			
Lymphosarcoma																			
Reticulum Cell Sarcoma																			
Hemorrhage																			
Adenitis																			
Angioma																			
R.E. Hyperplasia																			
Arteritis																			
Angiosarcoma																			

P

Table No. 3 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Anim. No.	Deaths	(21)
LUNG			
Interstitial Pneumonitis			
Peribronchial Lymphoid Hyperplasia			
Perivascular Lymphoid Hyperplasia			
Adenoma			
Epithelial Hyperplasia			
Amyloid			
Alveolar Macrophages			
Adenocarcinoma			
Pneumonia			
Thrombosis			
Mesothelioma			
Metastatic Tumor			
Pigment			
Lymphosarcoma			
Reticulum Cell Sarcoma			
LYMPH NODE			
Amyloid			
Lymphoid Hyperplasia			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Hemorrhage			
Adenitis			
Angioma			
R.E. Hyperplasia			
Arteritis			
Angiosarcoma			



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(21)

Group II - Males	Antm.No.	Deaths	
LIVER	01244		A
Amyloid	01248		
Necrosis/Caudate Lobe	01251		
Pericholangitis	01252		
Vacuolation	01253		4
Necrosis	01254		
Acute Hepatitis	01256		
Nodular Hyperplasia	01259		
Nonsuppurative Hepatitis	01261		
Mononuclear Infiltration	01262		
Hepatoma	01264		
Sinusoidal Infiltrate			
Angiosarcoma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Cyst			
Cytomegaly			
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			P
Angiectasis			

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(11)

(21)  
Deaths

## Sacrificed

Antim. No.

**Group II - Males**

01229  
01234  
01240  
01241  
01245  
01249  
01255  
01257  
01258  
01260  
01263  
01231  
01230  
01232  
01233  
01235  
01236  
01237  
01243

GALL BLADDER  
Lymphosarcoma  
Acute Cholecystitis

## KIDNEY

Interstitial Nephritis  
 Regenerative Epithelium  
 Dilated Pelvis  
 Perivascular Mononuclear Infiltration  
 Tubular Dilatation  
 Glomerular Amyloid  
 Interstitial Amyloid  
 Mineral Deposition  
 Lymphosarcoma  
 Pyelonephritis  
 Arteritis  
 Pigment/Tubular  
 Reticulum Cell Sarcoma  
 Adenocarcinoma

A 2 2 5 1

## STOMACH

Gastritis  
Ulceration  
Lymphosarcoma  
Metastatic Tumor  
Amyloid  
Carcinoma  
Mucosal Hyperplasia  
Aden



Table No. 8 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Anim. No.	Deaths	(21)
GALL BLADDER			
Lymphosarcoma			
Acute Cholecystitis			
KIDNEY			
Interstitial Nephritis			
Regenerative Epithelium			
Dilated Pelvis			
Perivascular Mononuclear Infiltration			
Tubular Dilatation			
Glomerular Amyloid			
Interstitial Amyloid			
Mineral Deposition			
Lymphosarcoma			
Pyelonephritis			
Arteritis			
Pigment/Tubular			
Reticulum Cell Sarcoma			
Adenocarcinoma			
STOMACH			
Gastritis			
Ulceration			
Lymphosarcoma			
Metastatic Tumor			
Amyloid			
Carcinoma			
Mucosal Hyperplasia			
Adenoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Antm. No.	Sacrificed											Deaths							
		01229	01234	01240	01241	01245	01249	01255	01257	01258	01260	01263	01231	01230	01232	01233	01235	01236	01237	01243
SMALL INTESTINE																				
Amyloid		X	2	2	X	2	X	4	X	X	X	X	A	A	X					
Mucosal Erosion																				
Enteritis																				
Hemorrhage																				
LARGE INTESTINE																				
Nematodiasis		X	X	X	X	X	X	N	P	X	X	X	A	A	X					
Lymphosarcoma																				
Amyloid																				
Hemorrhage																				
SPLEEN																				
Extramedullary Hematopoiesis																				
Angiosarcoma		X	X	X	X		X	X	X	X	X	X								
Angioma																				
Reticulum Cell Sarcoma																				
Amyloid																				
Lymphoid Depletion																				
Lymphosarcoma																				
R.E. Hyperplasia																			P	
Congestion																				
Thrombosis																				
Lymphoid Hyperplasia																				
Macrophages																				

2

P

5

3

3

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Antm.No.	(21) Deaths	
SMALL INTESTINE			
Amyloid	01244		A
Mucosal Erosion	01246		
Enteritis	01247		
Hemorrhage	01248		
LARGE INTESTINE			
Nematodiasis	01251		
Lymphosarcoma	01252		
Amyloid	01253		
Hemorrhage	01254		
SPLEEN			
Extramedullary Hematopoiesis			
Angiosarcoma			
Angioma			
Reticulum Cell Sarcoma			
Amyloid			
Lymphoid Depletion			
Lymphosarcoma			
R.E. Hyperplasia			
Congestion			
Thrombosis			
Lymphoid Hyperplasia			
Macrophages			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Antm. No.	Sacrificed (11)	Deaths (21)
TESTIS			
Amyloid		X	A
Mineralization			
Atrophy	2		3
Hypospermatogenesis		2	
Interstitial Cell Hyperplasia	3	4	3
Arteritis			
Lymphosarcoma			
Epididymitis			
Interstitial Cell Tumor		1	
Dilation/Epididymis		2	
Mesothelioma	3		
PROSTATE			
Nonsuppurative Prostatitis			A
Acute Prostatitis	2		
Hemorrhage			
Arteritis			
Reticulum Cell Sarcoma			
Lymphosarcoma			
SEMINAL VESICLE			
Glandular Dilatation			A
Perivascular Mononuclear Infiltration	X		
Arteritis			
Acute Vesiculitis			
Lymphosarcoma		2	
Atrophy			
Reticulum Cell Sarcoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim. No.	(21) Deaths	
Group II - Males	01244		
TESTIS	01246		
Amyloid	01247		
Mineralization	01248		
Atrophy	01251		
Hypospermatogenesis	01252		
Interstitial Cell Hyperplasia	01253		
Arteritis	01254		
Lymphosarcoma	01255		
Epididymitis	01256		
Interstitial Cell Tumor	01259		
Dilation/Epididymis	01261		
Mesothelioma	01262		
	01264		
PROSTATE			
Nonsuppurative Prostatitis			
Acute Prostatitis			
Hemorrhage			
Arteritis			
Reticulum Cell Sarcoma			
Lymphosarcoma			
SEMINAL VESICLE			
Glandular Dilatation			
Perivascular Mononuclear Infiltration			
Arteritis			
Acute Vesiculitis			
Lymphosarcoma			
Atrophy			
Reticulum Cell Sarcoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim. No.	(11) Sacrificed											(21) Deaths							
		01229	01234	01240	01241	01245	01249	01255	01257	01258	01260	01263	01231	01230	01232	01233	01235	01236	01237	01243
Group II - Males																				
SALIVARY GLAND																				
Mononuclear Infiltration	2																			
Amyloid																				
Lymphosarcoma																				
Adenitis																				
URINARY BLADDER																				
Mononuclear Infiltration	2	2	2	X			2	X	1		1		A	A	A	A	1	A	X	X
Acute Cystitis																				
Lymphosarcoma																				
Nonsuppurative Cystitis																				
Mucosal Separation	4	4	4		2		3		2	3	3	2								
Hemorrhage																				
Arteritis																				
Epithelial Hyperplasia																				
NERVE																				
Reticulum Cell Sarcoma																				

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(21)

Deaths	01264	01262	01261	01259	01256	01254	01253	01252	01251	01248	01247	01246	01244	Anim. No.
--------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-----------

Group II - Males

SALIVARY GLAND  
Mononuclear Infiltration  
Amyloid  
Lymphosarcoma  
Adenitis

URINARY BLADDER  
Mononuclear Infiltration  
Acute Cystitis  
Lymphosarcoma  
Nonsuppurative Cystitis  
Mucosal Separation  
Hemorrhage  
Arteritis  
Epithelial Hyperplasia

NERVE  
Reticulum Cell Sarcoma

3

A X A A X A A X A A A

2

1

1

A

X

A

A

A

A

A

A

A

A

A

A

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim. No.	(11) Sacrificed	(21) Deaths
Group II - Males	01229	01241	01231
	01234	01240	01263
	01237	01249	01260
	01236	01255	01258
	01235	01257	01233
	01232	01245	01230
	01231	01241	01237
	01230	01240	01236
	01229	01234	01243
MUSCLE			
Myositis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Sarcoma			
Parasite			
EYE			
Dacryoadenitis			
Ophthalmitis			
Retinal Degeneration			
Keratitis			
Lymphosarcoma			
Lens Vacuolation			
Lacrimal Gland Hyperplasia			
BONE			
Fibroplasia			
BONE MARROW			
Hematogenic Activity			
Lymphosarcoma			
Angiectasis			
Osteomyelitis			



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(21)

Deaths

Anim. No.

01244  
01246  
01247  
01248  
01251  
01252  
01253  
01254  
01256  
01259  
01261  
01262  
01264

Group II - Males

MUSCLE

Myositis  
Lymphosarcoma  
Reticulum Cell Sarcoma  
Sarcoma  
Parasite

EYE

Dacryoadenitis  
Ophthalmitis  
Retinal Degeneration  
Keratitis  
Lymphosarcoma  
Lens Vacuolation  
Lacrimal Gland Hyperplasia

BONE

Fibroplasia

BONE MARROW

Hematogenic Activity  
Lymphosarcoma  
Angiectasis  
Osteomyelitis

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Group II - Males	An tm. No.	(11)											(21)							
			Sacrificed											Deaths							
			01229	01234	01240	01241	01245	01249	01255	01257	01258	01260	01263	01231	01230	01232	01233	01235	01236	01237	01243
MAMMARY GLAND																					
Acinar Tissue *		N																			
Ductal Tissue *		N																			
Mastitis																					
SPINAL CORD																					
Lymphosarcoma																					
SKIN																					
Parasite																					
Acute Dermatitis																					
Lymphangiectasis																					
Edema																					
TISSUE MASS																					
Lymphosarcoma																					
Undiff. Sarcoma																					
MESENTERY																					
Peritonitis																					
Arteritis																					
Lymphosarcoma																					
Sarcoma																					

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260  
DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim. No.	(21)	
		Deaths	
Group II - Males			
MAMMARY GLAND			
Acinar Tissue			
Ductal Tissue			
Mastitis			
SPINAL CORD			
Lymphosarcoma			
SKIN			
Parasite			
Acute Dermatitis			
Lymphangiectasis			
Edema			
TISSUE MASS			
Lymphosarcoma			
Undiff. Sarcoma			
MESENTERY			
Peritonitis			
Arteritis			
Lymphosarcoma			
Sarcoma			
	01244		
	01246		
	01247		
	01248		
	01251		
	01252		
	01253		
	01254		
	01256		
	01259		
	01261		
	01262		
	01264		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Males	Anlm. No.	(14) <sup>a</sup> Sacrificed														(20) <sup>b</sup> Deaths				
		01304	01305	01308	01309	01313	01314	01317	01318	01324	01326	01328	01331	01332	01333	01301	01302	01303	01311	01315
BRAIN																				
Mineral Deposition		1	X		X	X	X	X	X	X	X	X	X	X		X	X	X		X
Meningioma				1											2				2	
Hemorrhage																				
Reticulum Cell Sarcoma																				
Perivascular Cuffing																				
Lymphosarcoma																				
Degeneration, Traumatic																				
PITUITARY		X	X	X	X	X	X	X	N	X	X	X	N	N	N	N	N	X	N	N
THYROID																				
Amyloid	X	X		2	1	X	X		3	X	X	X	X	X	X	X	N	A	3	4
Nonsuppurative Thyroiditis			1					1												
Adenomatous Hyperplasia																				
ADRENAL																				
Cortical Hyperplasia	1	2		2	X	1	X	2		1		2	2	3		1	A			2
Amyloid	2		3	2				2	3									2	2	2
Cortical Hypertrophy																				
Cortical Atrophy																				
Cortical Adenoma																				

a = total number survivors

b = total number of nonsurvivors for which one or more tissues were available for histologic preparation



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Males	Anim. No.	(14) Sacrificed	(20) Deaths
HEART			
Nonsuppurative Myocarditis			
Amyloid			
Arteritis			
Angioma			
Epicarditis			
Mesothelioma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
PANCREAS			
Lymphosarcoma			
Cystic Ducts			
Nonsuppurative Pancreatitis			
Reticulum Cell Sarcoma			
Mononuclear Infiltration			
Atrophy			
Amyloid			
Arteritis			
Islet Cell Hyperplasia			
Islet Cell Tumor			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(20)

Group III- Males	Deaths	01321	01327	01329	01330	01336	01306	01307	01310	01312	01316	01319	01320	01322	01325	01335
HEART		X	X	X												
Nonsuppurative Myocarditis																
Amyloid					3	3										
Arteritis						3										
Angioma																
Epicarditis																
Mesothelioma																
Thrombosis																
Lymphosarcoma						2								P		
Reticulum Cell Sarcoma																
PANCREAS		X	X	X	X	X										
Lymphosarcoma																
Cystic Ducts																
Nonsuppurative Pancreatitis																
Reticulum Cell Sarcoma																
Mononuclear Infiltration																
Atrophy																
Amyloid																
Arteritis																
Islet Cell Hyperplasia																
Islet Cell Tumor																

Anim. No.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III- Males	Anim. No.	(14) Sacrificed														(20) Deaths				
		01304	01305	01308	01309	01313	01314	01317	01318	01324	01326	01328	01331	01332	01333	01301	01302	01303	01311	01315
LUNG																				
Interstitial Pneumonitis				3						1										
Peribronchial Lymphoid Hyperplasia		2	2	3	1			2		2	1		3							
Perivascular Lymphoid Hyperplasia								2			1	2								
Adenoma				P					P											
Epithelial Hyperplasia																				
Amyloid																				
Alveolar Macrophages				3									3							
Adenocarcinoma																				
Pneumonia																				
Thrombosis																				
Mesothelioma																				
Metastatic Tumor																				
Pigment																				
Lymphosarcoma																				
Reticulum Cell Sarcoma																				
LYMPH NODE																				
Amyloid																				
Lymphoid Hyperplasia																	2			
Lymphosarcoma																			P	
Reticulum Cell Sarcoma																				
Hemorrhage																				
Adenitis																				
Angioma																				
R.E. Hyperplasia																				
Arteritis																				
Anch-sarcoma																	2			



## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III- Males	Anim. No.	Deaths
LUNG		
Interstitial Pneumonitis		
Peribronchial Lymphoid Hyperplasia		
Perivascular Lymphoid Hyperplasia		
Adenoma		
Epithelial Hyperplasia		
Amyloid		
Alveolar Macrophages		
Adenocarcinoma		
Pneumonia		
Thrombosis		
Mesothelioma		
Metastatic Tumor		
Pigment		
Lymphosarcoma		
Reticulum Cell Sarcoma		
LYMPH NODE		
Amyloid		
Lymphoid Hyperplasia		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Hemorrhage		
Adenitis		
Angioma		
R.E. Hyperplasia		
Arteritis		
Angiosarcoma		

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 144 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(20)

Group III- Males	Antim. No.	Deaths	
LIVER			
Amyloid			
Necrosis/Caudate Lobe			
Pericholangitis			
Vacuolation			
Necrosis			
Acute Hepatitis			
Nodular Hyperplasia			
Nonsuppurative Hepatitis			
Mononuclear Infiltration			
Hepatoma			
Sinusoidal Infiltrate			
Angiosarcoma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Cyst			
Cytomegaly			
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			
Angiectasis			
	01321	2	
	01327	2	
	01329	X	
	01330	2	
	01336	2	
	01306		
	01307		
	01310		
	01312		
	01316		
	01319		P
	01320		
	01322		
	01325		
	01335		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III- Males	Anim.No.	(14) Sacrificed														(20) Deaths				
		01304	01305	01308	01309	01313	01314	01317	01318	01324	01326	01328	01331	01332	01333	01301	01302	01303	01311	01315
GALL BLADDER		X														A	A	N	A	A
Lymphosarcoma																				
Acute Cholecystitis																				
KIDNEY																A	A	A		
Interstitial Nephritis				2																
Regenerative Epithelium			2	2			1	2						1	2					
Dilated Pelvis									2	2	2	2	2	1						
Perivascular Mononuclear Infiltration		2	1	4	2	2	2	3		2	2	2	2		2	2	3	2	1	
Tubular Dilatation																				
Glomerular Amyloid		2		4	2	2			3		4									
Interstitial Amyloid					3	2		3												
Mineral Deposition																				
Lymphosarcoma								1	1		1									
Pyelonephritis																				
Arteritis																				
Pigment/Tubular																1				
Reticulum Cell Sarcoma																				
Adenocarcinoma																				
STOMACH		X	X	X	X	X	X		X	X	X	X	X		X		A	X	X	
Gastritis																				
Ulceration																				
Lymphosarcoma																				
Metastatic Tumor																				
Amyloid																				
Carcinoma																				
Mucosal Hyperplasia																				
Ader																				



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III- Males	Anim. No.	(14) Sacrificed														(20) Deaths				
		01304	01305	01308	01309	01313	01314	01317	01318	01324	01326	01328	01331	01332	01333	01301	01302	01303	01311	01315
SMALL INTESTINE																				
Amyloid		X	X	3	X	X	X	X	3	X	2		X	X	X	A	A	A	A	A
Mucosal Erosion																				
Enteritis																				
Hemorrhage																				
LARGE INTESTINE																				
Nematodiasis		X	P	X	X	X	X	X	X	X	X	X	X	X	X	X	A	X	A	A
Lymphosarcoma																				
Amyloid																				
Hemorrhage																				
SPLEEN																				
Extramedullary Hematopoiesis		X			X	X	X		2	X	X	X	X	X	X	X		A	X	
Angiosarcoma																				
Angioma																		P		
Reticulum Cell Sarcoma																				
Amyloid				2													2			4
Lymphoid Depletion																				
Lymphosarcoma																				
R.E. Hyperplasia																				
Congestion																				
Thrombosis																				
Lymphoid Hyperplasia			2																4	
Macrophages																				

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(20)

- 149 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III- Males	Anim. No.	(14) Sacrificed														(20) Deaths				
		01304	01305	01308	01309	01313	01314	01317	01318	01324	01326	01328	01331	01332	01333	01301	01302	01303	01311	01315
TESTIS																				
Amyloid		X			X						X					A		X		X
Mineralization				1		1		2				4					4			
Atrophy																	3			
Hypospermatogenesis																				
Interstitial Cell Hyperplasia	3		1			2	4	1				4	2	3	3		4		1	
Arteritis																				
Lymphosarcoma						1											4			
Epididymitis										3										
Interstitial Cell Tumor																				
Dilation/Epididymis																				
Mesothelioma																				
PROSTATE																				
Nonsuppurative Prostatitis									N	2						N	A	X	X	X
Acute Prostatitis		X	X	X	X	X	X	X			X	X	X	X	X					
Hemorrhage																				
Arteritis																				
Reticulum Cell Sarcoma																				
Lymphosarcoma																				
SEMINAL VESICLE																				
Glandular Dilatation		X	X	X	X		X	X			X	X	X	X	X	N	A	A	X	A
Perivascular Mononuclear Infiltration						3			5											3
Arteritis																				
Acute Vesiculitis																				
Lymphosarcoma																				
Atrophy																				
Re jium Cell Sarcoma																				



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	01321	01327	01329	01330	01336	01306	01307	01310	01312	01316	01319	01320	01322	01325	01335
Group III- Males															
TESTIS	X		X		X										
Amyloid		3		5											
Mineralization		2		2											
Atrophy															
Hypospermatogenesis		1		5											
Interstitial Cell Hyperplasia															
Arteritis															
Lymphosarcoma															
Epididymitis															
Interstitial Cell Tumor															
Dilation/Epididymis		3													
Mesothelioma															
PROSTATE	X	N	X		X										
Nonsuppurative Prostatitis															
Acute Prostatitis				3											
Hemorrhage															
Arteritis															
Reticulum Cell Sarcoma															
Lymphosarcoma															
SEMINAL VESICLE															
Glandular Dilatation	3	2	X	A	A										
Perivascular Mononuclear Infiltration															
Arteritis															
Acute Vesiculitis															
Lymphosarcoma															
Atrophy															
Reticulum Cell Sarcoma															

(20)

Deaths

Anim. No.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Males	Anim. No.	(14)														(20)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
		Sacrificed														Deaths																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
	01 304																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		</

SALIVARY GLAND  
Mononuclear Infiltration  
Amyloid  
Lymphosarcoma  
Adenitis

URINARY BLADDER  
Mononuclear Infiltration  
Acute Cystitis  
Lymphosarcoma  
Nonsuppurative Cystitis  
Mucosal Separation  
Hemorrhage  
Arteritis  
Epithelial Hyperplasia

NERVE  
Reticulum Cell Sarcoma

Table No. 8 - Continued

PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim. No.	(20)																			
		Deaths																			
Group III- Males		01321	01327	01329	01330	01336	01306	01307	01310	01312	01316	01319	01320	01322	01325	01335					

SALIVARY GLAND  
 Mononuclear Infiltration  
 Amyloid  
 Lymphosarcoma  
 Adenitis

URINARY BLADDER  
 Mononuclear Infiltration  
 Acute Cystitis  
 Lymphosarcoma  
 Nonsuppurative Cystitis  
 Mucosal Separation  
 Hemorrhage  
 Arteritis  
 Epithelial Hyperplasia

NERVE  
 Reticulum Cell Sarcoma

2  
 X  
 A  
 A  
 A  
 X  
 A  
 X  
 A  
 A  
 X  
 A  
 A  
 A  
 A  
 A  
 1  
 1  
 1  
 3  
 P  
 2

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III- Males	Antm. No.	(14) Sacrificed	(20) Deaths
	01304	01313	01301
	01305	01308	01302
	01308	01317	01303
	01309	01318	01311
		01324	01315
		01326	
		01328	
		01331	
		01332	
		01333	
MUSCLE			
Myositis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Sarcoma			
Parasite			
EYE			
Dacryoadenitis			
Ophthalmitis			
Retinal Degeneration			
Keratitis			
Lymphosarcoma			
Lens Vacuolation			
Lacrimal Gland Hyperplasia			
BONE			
Fibroplasia			
BONE MARROW			
Hematogenic Activity			
Lymphosarcoma			
Angiectasis			
Osteomyelitis			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Deaths (20)	Anim. No.
Group III- Males		
MUSCLE		
Myositis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Sarcoma		
Parasite		
EYE		
Dacryoadenitis		
Ophthalmitis		
Retinal Degeneration		
Keratitis		
Lymphosarcoma		
Lens Vacuolation		
Lacrimal Gland Hyperplasia		
BONE		
Fibroplasia		
BONE MARROW		
Hematogenic Activity		
Lymphosarcoma		
Angiectasis		
Osteomyelitis		

X

01321  
01327  
01329  
01330  
01336  
01306  
01307  
01310  
01312  
01316  
01319  
01320  
01322  
01325  
01335

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Anim. No.	(14) Sacrificed	(20) Deaths
Group III- Males	01304	01314	01301
	01305	01309	01302
	01308	01313	01333
	01310	01318	01332
	01317	01324	01331
	01326	01328	01303
	01328	01331	01311
	01333	01332	01315
MAMMARY GLAND			
Acinar Tissue			
Ductal Tissue			
Mastitis			
SPINAL CORD			
Lymphosarcoma			
SKIN			
Parasite			
Acute Dermatitis			
Lymphangiectasis			
Edema			
TISSUE MASS			
Lymphosarcoma			
Undiff. Sarcoma			
MESENTERY			
Peritonitis			
Arteritis			
Lymphosarcoma			
Sarcoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Antm. No.	(20) Deaths	
Group III- Males	01321	01327	01329
	01330	01336	01306
	01307	01310	01312
	01316	01319	01320
	01322	01325	01335
MAMMARY GLAND			
Acinar Tissue			
Ductal Tissue			
Mastitis			
SPINAL CORD			
Lymphosarcoma			
SKIN			
Parasite			
Acute Dermatitis			
Lymphangiectasis			
Edema			
TISSUE MASS			
Lymphosarcoma			
Undiff. Sarcoma			
MESENTERY			
Peritonitis			
Arteritis			
Lymphosarcoma			
Sarcoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(6)a Sacrificed						(26)b Deaths											
		01374	01376	01381	01387	01398	01404	01375	01377	01378	01379	01409	01382	01383	01384	01385	01386	01388	01389
BRAIN																			
Mineral Deposition							1												
Meningioma																			
Hemorrhage																			
Reticulum Cell Sarcoma																			
Perivascular Cuffing																			
Lymphosarcoma																			
PITUITARY																			
THYROID																			
Amyloid																			
Nonsuppurative Thyroiditis																			
Adenomatous Hyperplasia																			
ADRENAL																			
Cortical Hyperplasia																			
Amyloid																			
Cortical Hypertrophy																			
Cortical Atrophy																			
Cortical Adenoma																			
Lymphosarcoma																			

a = total number survivors

b = total number of nonsurvivors for which one or more tissues were available for histologic preparation



### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	(26)	Deaths
Group IV - Males		
BRAIN		
Mineral Deposition	X	2
Meningioma	X	2
Hemorrhage	X	2
Reticulum Cell Sarcoma	X	2
Perivascular Cuffing	X	2
Lymphosarcoma	X	2
PITUITARY		
THYROID		
Amyloid	X	2
Nonsuppurative Thyroiditis	X	3
Adenomatous Hyperplasia	X	3
ADRENAL		
Cortical Hyperplasia	X	3
Amyloid	X	3
Cortical Hypertrophy	X	3
Cortical Atrophy	X	3
Cortical Adenoma	X	3

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(6)						(26)											
		Sacrificed						Deaths											
		01374	01376	01381	01387	01398	01404	01375	01377	01378	01379	01409	01382	01383	01384	01385	01386	01388	01389
HEART		X			X							X	2	2	1	X		X	X
Nonsuppurative Myocarditis				1			2												
Amyloid			4	4		2		2			2								
Arteritis									1	3	2			3			3		
Angioma																			
Epicarditis																			
Mesothelioma																			
Thrombosis																			
Lymphosarcoma													3						
Reticulum Cell Sarcoma																			
PANCREAS																			
Lymphosarcoma			X		X	X		X	X	N	X	X	X	X	A	X	X	X	X
Cystic Ducts																			
Nonsuppurative Pancreatitis																			
Reticulum Cell Sarcoma																			
Mononuclear Infiltration				2															
Atrophy																			
Amyloid							2												
Arteritis																			
Islet Cell Hyperplasia	3						2												4
Islet Cell Tumor																			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)  
Deaths

Animal No.

Group IV - Males

	01390	01392	01393	01394	01395	01396	01397	01399	01401	01402	01403	01405	01407	01408
HEART														
Nonsuppurative Myocarditis	3	2		X		2	X	X			X	X	2	2
Amyloid	3					3			2	3			3	
Arteritis			3		1									
Angioma														
Epicarditis														
Mesothelioma														
Thrombosis														
Lymphosarcoma	4	3				3			4				3	4
Reticulum Cell Sarcoma														
PANCREAS														
Lymphosarcoma	X	X	X	X	N	X	X	A	X	X	X	X	A	A
Cystic Ducts														
Nonsuppurative Pancreatitis														
Reticulum Cell Sarcoma														
Mononuclear Infiltration														
Atrophy														
Amyloid														
Arteritis														
Islet Cell Hyperplasia														2
Islet Cell Tumor														

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Group IV - Males	Animal No.	(6)						(26)					
			Sacrificed			Deaths								
		01374												
		01376												
		01381												
		01387												
		01398												
		01404												
		01375												
		01377												
		01378												
		01379												
		01409												
		01382												
		01383												
		01384												
		01385												
		01386												
		01388												
		01389												
LUNG														
Interstitial Pneumonitis														
Peribronchial Lymphoid Hyperplasia														
Perivascular Lymphoid Hyperplasia														
Adenoma														
Epithelial Hyperplasia														
Amyloid														
Alveolar Macrophages														
Adenocarcinoma														
Pneumonia														
Thrombosis														
Mesothelioma														
Metastatic Tumor														
Pigment														
Lymphosarcoma														
Reticulum Cell Sarcoma														
LYMPH NODE														
Amyloid														
Lymphoid Hyperplasia														
Lymphosarcoma														
Reticulum Cell Sarcoma														
Hemorrhage														
Adenitis														
Angioma														
R.E. Hyperplasia														
Arteritis														
Angiosarcoma														

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	Deaths	(26)
LUNG			
Interstitial Pneumonitis			
Peribronchial Lymphoid Hyperplasia			
Perivascular Lymphoid Hyperplasia			
Adenoma			
Epithelial Hyperplasia			
Amyloid			
Alveolar Macrophages			
Adenocarcinoma			
Pneumonia			
Thrombosis			
Mesothelioma			
Metastatic Tumor			
Pigment			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Lymph Node			
Amyloid			
Lymphoid Hyperplasia			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Hemorrhage			
Adenitis			
Angioma			
R.E. Hyperplasia			
Arteritis			
Angiosarcoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(6) Sacrificed	(26) Deaths
LIVER	01374	1	
Amyloid	01376	2	
Necrosis/Caudate Lobe	01381	3	
Pericholangitis	01387	X	
Vacuolation	01398	2	
Necrosis	01404	4	
Acute Hepatitis			
Nodular Hyperplasia			
Nonsuppurative Hepatitis			
Mononuclear Infiltration			
Hepatoma			
Sinusoidal Infiltrate			
Angiosarcoma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Cyst			
Cytomegaly			
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			
Angiectasis			
	01375	A	
	01377	X	
	01378	A	
	01379	A	
	01409	X	
	01382		1
	01383		2
	01384		3
	01385		X
	01386		3
	01388		X
	01389		A

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(26)

Group IV - Males	Animal No.	Deaths
LIVER		
Amyloid	3	
Necrosis/Caudate Lobe		
Pericholangitis		
Vacuolation	2	
Necrosis		
Acute Hepatitis		
Nodular Hyperplasia		
Nonsuppurative Hepatitis	1	
Mononuclear Infiltration		
Hepatoma		
Sinusoidal Infiltrate		
Angiosarcoma		
Thrombosis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Cyst		
Cytomegaly		
Bile Duct Carcinoma		
Metastatic Sarcoma		
Angioma		
Angiectasis		

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(6)						Deaths
		Sacrificed						
GALL BLADDER								
Lymphosarcoma								
Acute Cholecystitis								
KIDNEY								
Interstitial Nephritis								
Regenerative Epithelium								
Dilated Pelvis								
Perivascular Mononuclear Infiltration								
Tubular Dilatation								
Glomerular Amyloid								
Interstitial Amyloid								
Mineral Deposition								
Lymphosarcoma								
Pyelonephritis								
Arteritis								
Pigment/Tubular								
Reticulum Cell Sarcoma								
Adenocarcinoma								
STOMACH								
Gastritis								
Ulceration								
Lymphosarcoma								
Metastatic Tumor								
Amyloid								
Carcinoma								
Mucosal Hyperplasia								
Adenocarcinoma								



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)

Group IV - Males	Animal No.	Deaths	01390	01392	01393	01394	01395	01396	01397	01399	01401	01402	01403	01405	01407	01408
GALL BLADDER																
Lymphosarcoma			A	X	A	A	A	A	A		X	A	A		A	A
Acute Cholecystitis																
KIDNEY				X												
Interstitial Nephritis			3		3		A	A		A	1	3	A		2	
Regenerative Epithelium			3		3							3				
Dilated Pelvis					3				2						2	
Perivascular Mononuclear Infiltration						1	2			2	2		2		2	1
Tubular Dilatation																
Glomerular Amyloid			3				4	4		4	4	4			5	
Interstitial Amyloid			4													
Mineral Deposition														1		1
Lymphosarcoma																
Pyelonephritis																
Arteritis																
Pigment/Tubular								3								
Reticulum Cell Sarcoma																
Adenocarcinoma																
STOMACH																
Gastritis			X	X		X	A	X	A	A		X	X	X	X	A
Ulceration																
Lymphosarcoma					1											
Metastatic Tumor																
Amyloid																
Carcinoma																
Mucosal Hyperplasia																
Adenoma																

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(6)						(26)												
		Sacrificed						Deaths												
Group IV - Males		01374	01376	01381	01387	01398	01404	01375	01377	01378	01379	01409	01382	01383	01384	01385	01386	01388	01389	
SMALL INTESTINE		X	3	3	X	X	X	A	N	A	A	A	X	2	A	A	A	X	A	
Amyloid																				
Mucosal Erosion																				
Enteritis																				
Hemorrhage																				
LARGE INTESTINE		X	X	X	X	X	X	X	A	A	X	A	X	X	A	X	A	X	A	
Nematodiasis																				
Lymphosarcoma																				
Amyloid																				
Hemorrhage									P											
SPLEEN		X			X	X	X	X	X	A		X	X		X	X			N	
Extramedullary Hematopoiesis																				
Angiosarcoma																				
Angioma																				
Reticulum Cell Sarcoma																				
Amyloid			3	1																
Lymphoid Depletion																				
Lymphosarcoma																				
R.E. Hyperplasia																				
Congestion																				
Thrombosis																				
Lymphoid Hyperplasia																				
Macrophages																				

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	Deaths	01390	01392	01393	01394	01395	01396	01397	01399	01401	01402	01403	01405	01407	01408
SMALL INTESTINE																
Amyloid	X				X	X	A	A	A	A	A	A	A	A	A	A
Mucosal Erosion												3				
Enteritis																
Hemorrhage								2								
LARGE INTESTINE																
Nematodiasis				X		A	N	A	A	A		X		A	A	A
Lymphosarcoma	P				P						P		P		P	P
Amyloid																
Hemorrhage																
SPLEEN																
Extramedullary Hematopoiesis				X	X		N		X	A			X			X
Angiosarcoma																
Angioma																
Reticulum Cell Sarcoma																
Amyloid																
Lymphoid Depletion								2			1	1		P		2
Lymphosarcoma	3															
R.E. Hyperplasia																
Congestion																
Thrombosis																
Lymphoid Hyperplasia																
Macrophages																

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(6) Sacrificed	(26) Deaths	
Group IV - Males	01374	X		01375
TESTIS	01376	X		01377
Amyloid	01381	X		01378
Mineralization	01387			01379
Atrophy	01398			01382
Hypospermatogenesis	01404	X		01383
Interstitial Cell Hyperplasia				01384
Arteritis				01385
Lymphosarcoma				01386
Epididymitis				01388
Interstitial Cell Tumor				01389
Dilation/Epididymis				
Mesothelioma				
PROSTATE				
Nonsuppurative Prostatitis				
Acute Prostatitis				
Hemorrhage				
Arteritis				
Reticulum Cell Sarcoma				
Lymphosarcoma				
SEMINAL VESICLE				
Glandular Dilatation				
Perivascular Mononuclear Infiltration				
Arteritis				
Acute Vesiculitis				
Lymphosarcoma				
Atrophy				
Reticulum Cell Sarcoma				

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males		(26) Deaths													
	Animal No.	01390	01392	01393	01394	01395	01396	01397	01399	01401	01402	01403	01405	01407	01408
TESTIS															
Amyloid		2	2		X	X	4	X	X		3	X	X		A
Mineralization											2			4	2
Atrophy															
Hyospermatogenesis		1	2	2			4			4	4			4	2
Interstitial Cell Hyperplasia															
Arteritis															
Lymphosarcoma															
Epididymitis															
Interstitial Cell Tumor															
Dilatation/Epididymis															
Mesothelioma															
PROSTATE															
Nonsuppurative Prostatitis		X	1												
Acute Prostatitis															
Hemorrhage															
Arteritis															
Reticulum Cell Sarcoma															
Lymphosarcoma															
SEMINAL VESICLE															
Glandular Dilatation		X	X		A	A	A	A	A	X	A	X	X	A	A
Perivascular Mononuclear Infiltration								3							
Arteritis															
Acute Vesiculitis															
Lymphosarcoma															
Atrophy															
Reticulum Cell Sarcoma															

2

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(6)						(26)					
		Sacrificed						Deaths					
	01374												
	01376		3										
	01381		2										
	01387		2	2									
	01398				2								
	01404				2								
	01375					3							
	01377						X						
	01378						A						
	01379								X				
	01409												
	01382												
	01383												
	01384												
	01385												
	01386												
	01388												
	01389												
SALIVARY GLAND		X											
Mononuclear Infiltration													
Amyloid													
Lymphosarcoma													
Adenitis													
URINARY BLADDER		X											
Mononuclear Infiltration													
Acute Cystitis													
Lymphosarcoma													
Nonsuppurative Cystitis													
Mucosal Separation													
Hemorrhage													
Arteritis													
Epithelial Hyperplasia													
NERVE		X											
Reticulum Cell Sarcoma													

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 173 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(6)						(26)												
		Sacrificed						Deaths												
Group IV - Males		01374	01376	01381	01387	01398	01404	01375	01377	01378	01379	01409	01382	01383	01384	01385	01386	01388	01389	
MUSCLE		X	X	X	N	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Myositis																				
Lymphosarcoma																				
Reticulum Cell Sarcoma																				
Sarcoma																				
Parasite																				
EYE		X	X	X	X		X	A	A	A	A	A	A		A	X	X	X	X	
Dacryoadenitis																				
Ophthalmitis						2														
Retinal Degeneration						2					3		2							
Keratitis																				
Lymphosarcoma																				
Lens Vacuolation																				
Lacrimal Gland Hyperplasia																				
BONE		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Fibroplasia																				
BONE MARROW																				
Hematogenic Activity		4	4	4	4	4	5	4	4	A	4	4	4	4	4	4	4	4	4	3
Lymphosarcoma																				
Angiectasis																				
Osteomyelitis																				



## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

[illegible]

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(6)						(26)					
		Sacrificed						Deaths					
	01374	N	N										
	01376	N	N										
	01381	N	N										
	01387	N	N										
	01398	N	N										
	01404						2						
MAMMARY GLAND													
	Acinar Tissue *												
	Ductal Tissue *												
	Mastitis												
SPINAL CORD													
	Lymphosarcoma	X	X	X	X	X	X	X	X	X	X	X	X
SKIN													
	Parasite												
	Acute Dermatitis												
	Lymphangiectasis												
	Edema												
TISSUE MASS													
	Lymphosarcoma												
	Undiff. Sarcoma												
MESENTERY													
	Peritonitis												
	Arteritis												
	Lymphosarcoma												
	Sarcoma												

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Males	Animal No.	(26) Deaths												
MAMMARY GLAND														
Acinar Tissue *		N	N	N	N	N	N	N	N	N	N	N	N	N
Ductal Tissue *		N	N	N	N	N	N	N	N	N	N	N	N	N
Mastitis														
SPINAL CORD														
Lymphosarcoma		X	X	X	N	X	X	X	A	X	X	X	N	X
SKIN														
Parasite			P											A
Acute Dermatitis														
Lymphangiectasis														
Edema			2											2
TISSUE MASS														
Lymphosarcoma														
Undiff. Sarcoma														
MESENTERY														
Peritonitis														
Arteritis														
Lymphosarcoma														
Sarcoma														

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(19)<sup>a</sup>  
Sacrificed

Group I - Females	Animal No.	01160	01164	01165	01168	01170	01172	01173	01176	01180	01183	01184	01185	01187	01189	01210	01215	01218	01220	01228
BRAIN																				
Mineral Deposition	1		X	X	X	X	X	X	X	X	2	X	X	X	1	X	2	X	X	X
Meningioma																				
Hemorrhage																				
Reticulum Cell Sarcoma																				
Perivascular Cuffing																				
Lymphosarcoma																				
PITUITARY		X	X	X	X	X	X	X	X	X	X	X	N	X	X	X	X	X	X	X
THYROID																				
Amyloid	N	N	N	X	X	X	X	2	3		X	X	X	2	X	X	X	X	X	X
Nonsuppurative Thyroiditis								2		1										
Adenomatous Hyperplasia																				
ADRENAL					X															
Cortical Hyperplasia	1	1	3	3		2	3	2	2	3	2	2	2	2	2	1	4	2	2	2
Amyloid																				
Cortical Hypertrophy	1	1	3			2		2	2		3			2						
Cortical Atrophy																				
Cortical Adenoma																				
Lymphosarcoma																				

a = total number survivors

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Group I - Females	Animal No.	(49) <sup>b</sup>																			
			Deaths																			
BRAIN																						
Mineral Deposition																						
Meningioma																						
Hemorrhage																						
Reticulum Cell Sarcoma																						
Perivascular Cuffing																						
Lymphosarcoma																						
PITUITARY																						
THYROID																						
Amyloid																						
Nonsuppurative Thyroiditis																						
Adenomatous Hyperplasia																						
ADRENAL																						
Cortical Hyperplasia																						
Amyloid																						
Cortical Hypertrophy																						
Cortical Atrophy																						
Cortical Adenoma																						
Lymphosarcoma																						

b = total number of nonsurvivors for which one or more tissues were available for histologic preparation

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
BRAIN			X	X	N	X	X	X	X	X	X	X	X	X	X		X	X	X	X	X
Mineral Deposition																					
Meningioma																					
Hemorrhage																					
Reticulum Cell Sarcoma																					
Perivascular Cuffing																					
Lymphosarcoma																					
PITUITARY			N	X		X	X	X	X	N	X	A	X	X	X			X	X	X	X
THYROID			N	N		X	A	A	X	N			A	X	X			X		N	X
Amyloid											4										
Nonsuppurative Thyroiditis																					
Adenomatous Hyperplasia																			4		
ADRENAL			A				X			X		A	X			X					
Cortical Hyperplasia				1		2		1	3		3			3	2		3	2	2	2	2
Amyloid			3																		
Cortical Hypertrophy																					
Cortical Atrophy																					
Cortical Adenoma																					

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(49) Deaths									
		01213	01216	01217	01219	01222	01223	01224	01225	01226	01227
Group I - Females											
BRAIN											
Mineral Deposition		X	X	X	X	X	X	X	X	X	X
Meningioma											
Hemorrhage											
Reticulum Cell Sarcoma											
Perivascular Cuffing											
Lymphosarcoma											
PITUITARY											
		N	X	X	X	X	X	X	X	X	X
THYROID											
Amyloid		X	X	A	N	A	X	A	X	N	A
Nonsuppurative Thyroiditis								3			
Adenomatous Hyperplasia											
ADRENAL											
Cortical Hyperplasia		2	3	2	X	2	1	2	N	3	3
Amyloid		2		2		2		4			
Cortical Hypertrophy											
Cortical Atrophy											
Cortical Adenoma											
Lymphosarcoma											

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 182 -



### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 183 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
HEART			X	X	X	X	X		X	N		X	X	X	X	X	4	X			X
Nonsuppurative Myocarditis											2						5				
Amyloid																					
Arteritis																					
Angioma																					
Epicarditis																					
Mesothelioma																					
Thrombosis																					
Lymphosarcoma								P									4				
Reticulum Cell Sarcoma																					
PANCREAS			A	A	X	X	X		X	N	X	A	X	X	X	X		X		P	A
Lymphosarcoma																					
Cystic Ducts																					
Nonsuppurative Pancreatitis																					
Reticulum Cell Sarcoma																					
Mononuclear Infiltration																					
Atrophy																					
Amyloid																					
Arteritis																					
Islet Cell Hyperplasia																					
Islet Cell Tumor																					

Table No. 8 - Continued  
PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	Deaths (49)
HEART		
Nonsuppurative Myocarditis		
Amyloid		
Arteritis		
Angioma		
Epicarditis		
Mesothelioma		
Thrombosis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
PANCREAS		
Lymphosarcoma		
Cystic Ducts		
Nonsuppurative Pancreatitis		
Reticulum Cell Sarcoma		
Mononuclear Infiltration		
Atrophy		
Amyloid		
Arteritis		
Islet Cell Hyperplasia		
Islet Cell Tumor		

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(19) Sacrificed
LUNG	01160	X
Interstitial Pneumonitis	01164	3
Peribronchial Lymphoid Hyperplasia	01165	2
Perivascular Lymphoid Hyperplasia	01166	2
Adenoma	01167	
Epithelial Hyperplasia	01168	X
Amyloid	01169	X
Alveolar Macrophages	01170	X
Adenocarcinoma	01171	
Pneumonia	01172	2
Thrombosis	01173	2
Mesothelioma	01174	2
Metastatic Tumor	01175	2
Pigment	01176	2
Lymphosarcoma	01177	
Reticulum Cell Sarcoma	01178	
LYMPH NODE	01179	
Amyloid	01180	X
Lymphoid Hyperplasia	01181	
Lymphosarcoma	01182	P
Reticulum Cell Sarcoma	01183	
Hemorrhage	01184	
Adenitis	01185	
Angioma	01186	
R.E. Hyperplasia	01187	
Arteritis	01188	
Angiosarcoma	01189	

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01157	01158	01159	01161	01162	01163	01166	01169	01171	01174	01175	01177	01178	01179	01181	01182	01186	01188	01190	01191
LUNG			X			A			X	X	X			X		A	X	A	A			
Interstitial Pneumonitis																						
Peribronchial Lymphoid Hyperplasia							2															
Perivascular Lymphoid Hyperplasia													2									
Adenoma				2	2																	
Epithelial Hyperplasia															2						P	
Amyloid																						
Alveolar Macrophages																						
Adenocarcinoma																						
Pneumonia																						
Thrombosis																						
Mesothelioma																						
Metastatic Tumor												P										
Pigment																						
Lymphosarcoma								P								P						
Reticulum Cell Sarcoma																						
LYMPH NODE																						
Amyloid			A	X	N	A	A			X		X			X	A						
Lymphoid Hyperplasia																						
Lymphosarcoma																						
Reticulum Cell Sarcoma								P														
Hemorrhage																						
Adenitis													2						3			
Angioma																						
R.E. Hyperplasia																						
Arteritis																						
Angiosarcoma																						

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
LUNG			A	X		X	X				X	X	X		X	X		X	X		
Interstitial Pneumonitis																					
Peribronchial Lymphoid Hyperplasia									2					2							2
Perivascular Lymphoid Hyperplasia									2								2				
Adenoma																					
Epithelial Hyperplasia					3																
Amyloid																					
Alveolar Macrophages														2							
Adenocarcinoma																					
Pneumonia																					
Thrombosis																					
Mesothelioma																					
Metastatic Tumor																					
Pigment																					
Lymphosarcoma								P		P											
Reticulum Cell Sarcoma																					
LYMPH NODE																					
Amyloid				X	X				X				A			X				X	
Lymphoid Hyperplasia																			3		
Lymphosarcoma										P											
Reticulum Cell Sarcoma																					
Hemorrhage																					
Adenitis											3										
Angioma																					
R.E. Hyperplasia																					2
Arteritis																					
Angiosarcoma																					

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	Deaths (49)									
		01213	01216	01217	01219	01222	01223	01224	01225	01226	01227
Group I - Females											
LUNG											
Interstitial Pneumonitis				X	X			X		X	X
Peribronchial Lymphoid Hyperplasia											
Perivascular Lymphoid Hyperplasia			2				2		2		
Adenoma		2	2								
Epithelial Hyperplasia											
Amyloid		2									
Alveolar Macrophages							3				
Adenocarcinoma											
Pneumonia											
Thrombosis											
Mesothelioma											
Metastatic Tumor						P					
Pigment											
Lymphosarcoma											
Reticulum Cell Sarcoma											
LYMPH NODE											
Amyloid				A	X		X			X	X
Lymphoid Hyperplasia				3		4					
Lymphosarcoma									4		
Reticulum Cell Sarcoma											
Hemorrhage											
Adenitis			P								
Angioma		3									
R.E. Hyperplasia											
Arteritis											
Angiosarcoma											

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(19) Sacrificed
LIVER		
Amyloid		
Necrosis/Caudate Lobe		
Pericholangitis	2	
Vacuolation		
Necrosis		
Acute Hepatitis		
Nodular Hyperplasia		
Nonsuppurative Hepatitis	2	
Mononuclear Infiltration	2	
Hepatoma		
Sinusoidal Infiltrate		
Angiosarcoma		
Thrombosis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Cyst		
Cytomegaly		
Bile Duct Carcinoma		
Metastatic Sarcoma		
Angioma		
Angiectasis		



Table No. 8 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	
LIVER	01157	X	A
	01158	A	A
	01159	A	A
	01161	A	A
	01162		3
	01163		P
	01166	X	
	01169		2
	01171	X	
	01174	X	
	01175	X	
	01177	X	
	01178	X	
	01179	A	
	01181		P
	01182	A	
	01186	A	
	01188	A	
	01190	X	
	01191		3
Amyloid			
Necrosis/Caudate Lobe			
Pericholangitis			
Vacuolation			
Necrosis			
Acute Hepatitis			
Nodular Hyperplasia			
Nonsuppurative Hepatitis			
Mononuclear Infiltration			
Hepatoma			
Sinusoidal Infiltrate			
Angiosarcoma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Cyst			
Cytomegaly			
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			
Angiectasis			3

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths																		
		01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
LIVER		A	A		A	X		X	A	A	X			X	X	A	X		A	X
Amyloid																				
Necrosis/Caudate Lobe																				
Pericholangitis																				
Vacuolation																				
Necrosis																				
Acute Hepatitis																				
Nodular Hyperplasia																				
Nonsuppurative Hepatitis											3									
Mononuclear Infiltration																				
Hepatoma																				
Sinusoidal Infiltrate																				
Angiosarcoma																				
Thrombosis																				
Lymphosarcoma																				
Reticulum Cell Sarcoma																				
Cyst																				
Cytomegaly																				
Bile Duct Carcinoma																				
Metastatic Sarcoma																				
Angioma																				
Angiectasis																				

P

P

2

2

2

3

Table No. 8 - Continued  
PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	Deaths	(49)
LIVER			
Amyloid			
Necrosis/Caudate Lobe			
Pericholangitis			
Vacuolation			
Necrosis			
Acute Hepatitis			
Nodular Hyperplasia			
Nonsuppurative Hepatitis			
Mononuclear Infiltration			
Hepatoma			
Sinusoidal Infiltrate			
Angiosarcoma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Cyst			
Cytomegaly			
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			
Angiectasis			



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01157	01158	01159	01161	01162	01163	01166	01169	01171	01174	01175	01177	01178	01179	01181	01182	01186	01188	01190	01191
GALL BLADDER			A	A	A	A	A	A	A	A	A	X	A	A	A	A	A	A	A	A		
Lymphosarcoma					N	A																
Acute Cholecystitis																						
KIDNEY			A	A	A	A	A	A	A	A	X	X				A	A	A	A	A	X	A
Interstitial Nephritis				2		A	2								3							2
Regenerative Epithelium				2											3							
Dilated Pelvis																						
Perivascular Mononuclear Infiltration			2				2					1		2	1	2	2		3			2
Tubular Dilatation																						
Glomerular Amyloid							5												5			5
Interstitial Amyloid				4														4	5			3
Mineral Deposition																			4			
Lymphosarcoma																						
Pyelonephritis								P														
Arteritis																						
Pigment/Tubular																						
Reticulum Cell Sarcoma																						
Adenocarcinoma																						
STOMACH			X	X	A	A		X	X	X	X	X	X	X	X	A	A	X	X	A	A	A
Gastritis																						
Ulceration																						
Lymphosarcoma																						
Metastatic Tumor																						
Amyloid																						
Carcinoma																						
Mucosal Hyperplasia																						
Adenoma																						

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
GALL BLADDER			A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
Lymphosarcoma																					
Acute Cholecystitis																					
KIDNEY			A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
Interstitial Nephritis																					
Regenerative Epithelium																					
Dilated Pelvis																					
Perivascular Mononuclear Infiltration																					
Tubular Dilatation																					
Glomerular Amyloid																					
Interstitial Amyloid																					
Mineral Deposition																					
Lymphosarcoma																					
Pyelonephritis																					
Arteritis																					
Pigment/Tubular																					
Reticulum Cell Sarcoma																					
Adenocarcinoma																					
STOMACH			A	A	X	X	A	X	X	A		A	X	X	X	X	X	X	X	A	X
Gastritis																					
Ulceration																					
Lymphosarcoma																					
Metastatic Tumor																					
Amyloid																					
Carcinoma																					
Mucosal Hyperplasia																					
Adenoma																					

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	(49) Deaths										Animal No.
	01213	01216	01217	01219	01222	01223	01224	01225	01226	01227	
Group I - Females											
GALL BLADDER											
Lymphosarcoma	A	A	A	A	A	A	A	A	X	A	
Acute Cholecystitis											
KIDNEY											
Interstitial Nephritis	A		2		3	X	3	X	4	2	
Regenerative Epithelium									3		
Dilated Pelvis											
Perivascular Mononuclear Infiltration	2	2	2	2			2		2	2	
Tubular Dilatation											
Glomerular Amyloid	3	5	5		3		5		4	4	
Interstitial Amyloid		3	3		3		4		4		
Mineral Deposition											
Lymphosarcoma											
Pyelonephritis											
Arteritis											
Pigment/Tubular											
Reticulum Cell Sarcoma		P									
Adenocarcinoma											
STOMACH											
Gastritis	X	X	X	X	X	X	X		X	X	
Ulceration											
Lymphosarcoma											
Metastatic Tumor											
Amyloid											
Carcinoma											
Mucosal Hyperplasia											
Adenoma											

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(19)

Sacrificed

Group I - Females	Animal No.	01160	01164	01165	01168	01170	01172	01173	01176	01180	01183	01184	01185	01187	01189	01210	01215	01218	01220	01228
SMALL INTESTINE		1	1	X	X	4	2	2	4	X	2	X	2	2	X		X	X	X	X
Amyloid																				
Mucosal Erosion																				
Enteritis																				
Hemorrhage																				
LARGE INTESTINE		P	X	X	X	X	X	X	X	X	X	P	X	X	X	P	X	X	X	X
Nematodiasis																				
Lymphosarcoma																				
Amyloid																				
Hemorrhage																				
SPLEEN		3		3	X		3	2	3	X	X	X	X		X	3	X	X	X	X
Extramedullary Hematopoiesis																				
Angiosarcoma																				
Angioma																				
Reticulum Cell Sarcoma			P																	
Amyloid																				
Lymphoid Depletion																				
Lymphosarcoma																				
R.E. Hyperplasia																				
Congestion																				
Thrombosis																				
Lymphoid Hyperplasia																				
Macrophages																				



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths	01157	01158	01159	01161	01162	01163	01166	01169	01171	01174	01175	01177	01178	01179	01181	01182	01186	01188	01190	01191
SMALL INTESTINE			A	A	A	A	A	A	N	X		X	A	X	X	A		A	A	A	A	A
Amyloid																						
Mucosal Erosion																						
Enteritis																						
Hemorrhage											3								5			3
LARGE INTESTINE			X	P	A	A	A	X	P	X		X	X	X	X	A		A				
Nematodiasis																						
Lymphosarcoma																						
Amyloid																						
Hemorrhage											3											
SPLEEN			A	X	A	A			N			X	X			A					X	
Extramedullary Hematopoiesis																						
Angiosarcoma																						
Angioma																						
Reticulum Cell Sarcoma																						
Amyloid							3															2
Lymphoid Depletion			3								3											
Lymphosarcoma																						
R.E. Hyperplasia								P						4			P					
Congestion																						
Thrombosis																						
Lymphoid Hyperplasia										4												
Macrophages															3							3

Table No. 8 - Continued

PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths															
		01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208
SMALL INTESTINE																	
Amyloid		A	A	X	A	A	A	A	A	A	A	A	A	A	X	X	A
Mucosal Erosion										4							
Enteritis																	
Hemorrhage																	3
LARGE INTESTINE																	
Nematodiasis		A	X	X	X	A	A	X	A	X	A	A	A	A	P	P	X
Lymphosarcoma		P															
Amyloid																	
Hemorrhage																	
SPLEEN																	
Extramedullary Hematopoiesis		A			X	A		X			A				X	X	A
Angiosarcoma																	
Angioma																	
Reticulum Cell Sarcoma																	
Amyloid										2		3		3			2
Lymphoid Depletion																	
Lymphosarcoma																	
R.E. Hyperplasia																	P
Congestion																	
Thrombosis																	
Lymphoid Hyperplasia			3	4													
Macrophages													2				

Table No. 8 - Continued  
PROJECT NO. 700-260

Group I - Females	Animal No.	(49)	Deaths
	01213	X	
	01216	P	
	01217	A	
	01219	A	
	01222	A	4
	01223	X	
	01224	A	3
	01225	A	
	01226		2
	01227		2
SMALL INTESTINE			
Amyloid			
Mucosal Erosion			
Enteritis			
Hemorrhage			
Reticulum Cell Sarcoma			
LARGE INTESTINE			
Nematodiasis			
Lymphosarcoma			
Amyloid			
Hemorrhage			
SPLEEN			
Extramedullary Hematopoiesis			
Angiosarcoma			
Angioma			
Reticulum Cell Sarcoma			
Amyloid			
Lymphoid Depletion			
Lymphosarcoma			
R.E. Hyperplasia			
Congestion			
Thrombosis			
Lymphoid Hyperplasia			
Macrophages			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(19) Sacrificed	01160	01164	01165	01168	01170	01172	01173	01176	01180	01183	01184	01185	01187	01189	01210	01215	01218	01220	01228
OVARY																					
Cystic Follicles			P	P	P	P	P	P	P	P	P	P	P		P	X	P	P	P	P	X
Hemorrhagic Cyst																					
Mineralization														2							
Arteritis																					
Lymphosarcoma																					
Reticulum Cell Sarcoma							P														
Granulosa Cell Tumor																					
Amyloid			2				2		2		2	3	4	4			2				
UTERUS																					
Glandular Dilatation			4	4		3		3	3	4	4	4	3	3	4	N	3	4	2	3	4
Glandular Hyperplasia			2		2	P	3	2	3	2	3	3			4		2	3	2	2	2
Polyp																					
Thrombosis					3	3					4	4									3
Acute Endometritis																					
Angioma													P								
Angiosarcoma																					
Endometriosis																					
Leiomyosarcoma																					
Carcinoma / Scirrhus					P						P										
Angiectasis																					
Arteritis																					
Lymphosarcoma																					
Hemorrhage																					
Leiomyoma																					
Reticulum Cell Sarcoma					3	3												P			3

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(49)

Group I - Females	Animal No.	Deaths	01157	01158	01159	01161	01162	01163	01166	01169	01171	01174	01175	01177	01178	01179	01181	01182	01186	01188	01190	01191
OVARY			P	N	A	N	P	P	P	P		X	P	P	P			A	A		P	P
Cystic Follicles																						
Hemorrhagic Cyst																						
Mineralization							P		P	P												
Arteritis																						
Lymphosarcoma																						
Reticulum Cell Sarcoma																						
Granulosa Cell Tumor																						
Amyloid																						
UTERUS			X		A			2	A	2	1	3	2	X					4			3
Glandular Dilatation																						
Glandular Hyperplasia																						
Polyp				3			3	3													2	A
Thrombosis			2																		3	
Acute Endometritis																						
Angioma																						
Angiosarcoma																						
Endometriosis																						
Leiomyosarcoma																						
Carcinoma / Scirrhous																						
Angiectasis																						
Arteritis																						
Lymphosarcoma																						
Hemorrhage																						
Leiomyoma																						
Reticulum Cell Sarcoma																						

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49)															
		Deaths															
OVARY																	
Cystic Follicles																	
Hemorrhagic Cyst																	
Mineralization																	
Arteritis																	
Lymphosarcoma																	
Reticulum Cell Sarcoma																	
Granulosa Cell Tumor																	
Amyloid																	
UTERUS																	
Glandular Dilatation																	
Glandular Hyperplasia																	
Polyp																	
Thrombosis																	
Acute Endometritis																	
Angioma																	
Angiosarcoma																	
Endometriosis																	
Leiomyosarcoma																	
Carcinoma / Scirrhous																	
Angiectasis																	
Arteritis																	
Lymphosarcoma																	
Hemorrhage																	
Leiomyoma																	
Reticulum Cell Sarcoma																	

Table No. 8 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	Deaths (49)
OVARY		
Cystic Follicles		
Hemorrhagic Cyst		
Mineralization		
Arteritis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Granulosa Cell Tumor		
Amyloid		
UTERUS		
Glandular Dilatation		
Glandular Hyperplasia		
Polyp		
Thrombosis		
Acute Endometritis		
Angioma		
Angiosarcoma		
Endometriosis		
Leiomyosarcoma		
Carcinoma / Scirrhus		
Angiectasis		
Arteritis		
Lymphosarcoma		
Hemorrhage		
Leiomyoma		
Reticulum Cell Sarcoma		

Table No. 8 - Continued  
PROJECT NO. 700-260

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(19)

## Sacrificed

	Animal No.	Sacrificed
Group I - Females		
VAGINA	X N X X X X X X X X X X X P	P
Acute Vaginitis		
Carcinoma		
Hemorrhage		
SALIVARY GLAND		
Mononuclear Infiltration	X	
Amyloid		
Lymphosarcoma		
Adenitis		
URINARY BLADDER		
Mononuclear Infiltration	X	
Acute Cystitis		
Lymphosarcoma		
Nonsuppurative Cystitis		
Mucosal Separation		
Hemorrhage		
Arteritis		
Epithelial Hyperplasia		
NERVE		
Reticulum Cell Sarcoma		



Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	Deaths (49)																			
		01157	01158	01159	01161	01162	01163	01166	01169	01171	01174	01175	01177	01178	01179	01181	01182	01186	01188	01190	01191
VAGINA			X	X		X	X	X	X	X	X	X	X	X		X				A	A
Acute Vaginitis																				A	
Carcinoma																					
Hemorrhage																					
SALIVARY GLAND					A			X		X		X	2	X	X			X		X	
Mononuclear Infiltration		X	X																		
Amyloid				2		3	3										4	2			2
Lymphosarcoma																					
Adenitis																					
URINARY BLADDER					A		A	A	A	A	2	2	3	2	A	N	A		A	A	A
Mononuclear Infiltration		A	3	A		2					2	2	2	2						2	
Acute Cystitis																					
Lymphosarcoma																					
Nonsuppurative Cystitis																					
Mucosal Separation																					
Hemorrhage																					
Arteritis																					
Epithelial Hyperplasia																					
NERVE																					
Reticulum Cell Sarcoma		X	X	X	A	X	X	X	X	X	X	X	X	X		X	X	X	X	X	X

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths																		
		01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
VAGINA		A	A	X	X	X	X	X	N			X	X		X	X	X	X	X	X
Acute Vaginitis																				
Carcinoma																				
Hemorrhage																				
SALIVARY GLAND																				
Mononuclear Infiltration																				
Amyloid																				
Lymphosarcoma																				
Adenitis																				
URINARY BLADDER																				
Mononuclear Infiltration																				
Acute Cystitis																				
Lymphosarcoma																				
Nonsuppurative Cystitis																				
Mucosal Separation																				
Hemorrhage																				
Arteritis																				
Epithelial Hyperplasia																				
NERVE																				
Reticulum Cell Sarcoma																				

## DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	Deaths
VAGINA		
Acute Vaginitis	X	X
Carcinoma	X	X
Hemorrhage	X	X
SALIVARY GLAND		
Mononuclear Infiltration	1	1
Amyloid	2	4
Lymphosarcoma		
Adenitis		
URINARY BLADDER		
Mononuclear Infiltration	1	2
Acute Cystitis		
Lymphosarcoma		
Nonsuppurative Cystitis		
Mucosal Separation		
Hemorrhage		
Arteritis		
Epithelial Hyperplasia		
NERVE		
Reticulum Cell Sarcoma	X	X

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(19) Sacrificed																		
		01160	01164	01165	01168	01170	01172	01173	01176	01180	01183	01184	01185	01187	01189	01210	01215	01218	01220	01228
MUSCLE																				
Myositis																				
Lymphosarcoma																				
Reticulum Cell Sarcoma																				
Sarcoma																				
Parasite																				
EYE																				
Dacryoadenitis																				
Ophthalmitis																				
Retinal Degeneration																				
Keratitis																				
Lymphosarcoma																				
Lens Vacuolation																				
Lacrimal Gland Hyperplasia																				
BONE																				
Fibroplasia																				
BONE MARROW																				
Hematogenic Activity																				
Lymphosarcoma																				
Angiectasis																				
Osteomyelitis																				

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

[illegible]

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(49) Deaths																		
		01192	01193	01194	01195	01196	01197	01198	01199	01200	01201	01203	01204	01205	01206	01207	01208	01209	01211	01212
Group I - Females																				
MUSCLE																				
Myositis		X	X	X	X	2		X		X	A	X	X	X	X	X	X	X	X	X
Lymphosarcoma																				
Reticulum Cell Sarcoma									P											
Sarcoma																				
Parasite																				
EYE																				
Dacryoadenitis		A	A	X	A	A	A	A	A	A	A	A	X	A		X	X	A	A	A
Ophthalmitis																				
Retinal Degeneration																				
Keratitis																				
Lymphosarcoma																				
Lens Vacuolation																				
Lacrimal Gland Hyperplasia																				
BONE																				
Fibroplasia		X	X	X	X	X	X	X	X		X	X	X	X	X	X	X	X	X	X
BONE MARROW										3										
Hematogenic Activity		A				A					A			A					A	5
Lymphosarcoma																				
Angiectasis																				
Osteomyelitis									P											

3

3

P

Table No. 8 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths
MUSCLE		
Myositis	X	X
Lymphosarcoma		
Reticulum Cell Sarcoma		
Sarcoma		
Parasite		
		3
EYE		
Dacryoadenitis	A	A
Ophthalmitis		
Retinal Degeneration		
Keratitis		
Lymphosarcoma		
Lens Vacuolation		
Lacrimal Gland Hyperplasia		
	2	
BONE		
Fibroplasia	X	X
BONE MARROW		
Hematogenic Activity	A	A
Lymphosarcoma		
Angiectasis		
Osteomyelitis		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(19) Sacrificed																		
		01160	01164	01165	01168	01170	01172	01173	01176	01180	01183	01184	01185	01187	01189	01210	01215	01218	01220	01228
MAMMARY GLAND																				
Acinar Tissue							2			3	N	1		N	1		2	1	1	2
Ductal Tissue			N		2	N	2	2	2	3	N	3	2	N	2	2	2	3	2	2
Mastitis	2	N	N	2	3	N	2			2										
SPINAL CORD																				
Lymphosarcoma	X	X	X	X	X	N	X	X	X	X	X	X	X	X	X	X	X	X	X	X
SKIN																				
Parasite																				
Acute Dermatitis																				
Lymphangiectasis																				
Edema																				
TISSUE MASS																				
Lymphosarcoma																				
Undiff. Sarcoma																				
MESENTERY																				
Peritonitis																				
Arteritis																				
Lymphosarcoma																				
Sarcoma																				

\* N in this instance indicates acinar/ductal tissue not present in section examined.



Table No. 8 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group I - Females	Animal No.	(49) Deaths
MAMMARY GLAND		
Acinar Tissue	1	
Ductal Tissue	2	
Mastitis	3	
SPINAL CORD		
Lymphosarcoma	X	
SKIN		
Parasite		
Acute Dermatitis		
Lymphangiectasis		
Edema		
TISSUE MASS		
Lymphosarcoma		
Undiff. Sarcoma		
MESENTERY		
Peritonitis		
Arteritis		
Lymphosarcoma		
Sarcoma		

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(49)

Group I - Females	Animal No.	Deaths	01212	01211	01209	01208	01207	01206	01205	01204	01203	01201	01200	01199	01198	01197	01196	01195	01194	01193	01192
MAMMARY GLAND																					
Acinar Tissue			N						N			N					N		N	N	N
Ductal Tissue									N	2	2	N		2	2	1	N	2	N	N	N
Mastitis															2						
SPINAL CORD																					
Lymphosarcoma																					
SKIN																					
Parasite																					
Acute Dermatitis																					
Lymphangiectasis																					
Edema																					
TISSUE MASS																					
Lymphosarcoma																					
Undiff. Sarcoma																					
MESENTERY																					
Peritonitis																					
Arteritis																					
Lymphosarcoma																					
Sarcoma																					

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(49) Deaths									
		01213	01216	01217	01219	01222	01223	01224	01225	01226	01227
Group I - Females											
MAMMARY GLAND											
Acinar Tissue *	N		2		2	N		N	N		
Ductal Tissue *	N	2	2	2	3	N	2	N	N	3	2
Mastitis											
SPINAL CORD											
Lymphosarcoma	N	X	X	X	X	N	X	X	X	X	X
SKIN											
Parasite											
Acute Dermatitis											
Lymphangiectasis											
Edema											
TISSUE MASS											
Lymphosarcoma											
Undiff. Sarcoma											
MESENTERY											
Peritonitis											
Arteritis											
Lymphosarcoma											
Sarcoma											

P

\*N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT NO. 700260  
DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	Animal No.	(7) <sup>a</sup> Sacrificed	(27) <sup>b</sup> Deaths	01272	01275	01284	01285	01286	01288	01295	01265	01267	01269	01294	01300	01266	01268	01271	01273	01274	01276	01277
BRAIN				X																		
Mineral Deposition																						
Meningioma																						
Hemorrhage																						
Reticulum Cell Sarcoma																						
Perivascular Cuffing																						
Lymphosarcoma																						
Degeneration, Traumatic																						
PITUITARY																						
THYROID																						
Amyloid																						
Nonsuppurative Thyroiditis																						
Adenomatous Hyperplasia																						
ADRENAL																						
Cortical Hyperplasia																						
Amyloid																						
Cortical Hypertrophy																						
Cortical Atrophy																						
Cortical Adenoma																						
Lymphosarcoma																						

a = total number survivors  
b = total number of nonsurvivors for which one or more tissues were available for histologic preparation

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(27) Deaths														
Group II - Females		01279	01281	01283	01282	01287	01289	01290	01291	01292	01293	01296	01297	01298	01299	01280
BRAIN		X	X	X	X	X	X	1	X	1	X	X	X	X	P	X
Mineral Deposition																
Meningioma																
Hemorrhage																
Reticulum Cell Sarcoma																
Perivascular Cuffing																
Lymphosarcoma																
Degeneration, Traumatic																
PITUITARY																
THYROID																
Amyloid																
Nonsuppurative Thyroiditis																
Adenomatous Hyperplasia																
ADRENAL																
Cortical Hyperplasia																
Amyloid																
Cortical Hypertrophy																
Cortical Atrophy																
Cortical Adenoma																
Lymphosarcoma																

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(7) Sacrificed	(27) Deaths
Group II - Females			
HEART			
Nonsuppurative Myocarditis			
Amyloid			
Arteritis			
Angioma			
Epicarditis			
Mesothelioma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			
PANCREAS			
Lymphosarcoma			
Cystic Ducts			
Nonsuppurative Pancreatitis			
Reticulum Cell Sarcoma			
Mononuclear Infiltration			
Atrophy			
Amyloid			
Arteritis			
Islet Cell Hyperplasia			
Islet Cell Tumor			
	01272	X	
	01275	X	
	01284	X	
	01285	3	
	01286	X	
	01288	X	
	01295	X	
	01265	X	
	01267	3	
	01269	X	
	01294	2	
	01300	3	
	01266		
	01268		
	01271		
	01273		
	01274		
	01276		
	01277		

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	Animal No.	(27) Deaths	
HEART			
Nonsuppurative Myocarditis	01279		
Amyloid	01281		
Arteritis	01283		
Angioma	01282		
Epicarditis	01287		
Mesothelioma	01289		
Thrombosis	01290		
Lymphosarcoma	01291		
Reticulum Cell Sarcoma	01292		
	01293		
	01296		
	01297		
	01298		
	01299		
	01280		
PANCREAS			
Lymphosarcoma			P
Cystic Ducts			
Nonsuppurative Pancreatitis			
Reticulum Cell Sarcoma			
Mononuclear Infiltration			
Atrophy			
Amyloid			
Arteritis			
Islet Cell Hyperplasia			
Islet Cell Tumor			

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(7) Sacrificed	(27) Deaths
Group II - Females			
LUNG			
Interstitial Pneumonitis	X		
Peribronchial Lymphoid Hyperplasia		2	
Perivascular Lymphoid Hyperplasia			
Adenoma		P	
Epithelial Hyperplasia			
Amyloid			
Alveolar Macrophages			
Adenocarcinoma			
Pneumonia			
Thrombosis			
Mesothelioma			
Metastatic Tumor			
Pigment			
Lymphosarcoma			
Reticulum Cell Sarcoma			
LYMPH NODE			
Amyloid			
Lymphoid Hyperplasia			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Hemorrhage			
Adenitis			
Angioma			
R.E. Hyperplasia			
Arteritis			
Angiosarcoma			
	01272	01275	01284
	01285	01286	01288
	01295	01265	01267
	01269	01294	01300
	01271	01273	01274
	01276	01277	



Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	Animal No.	(27) Deaths	
LUNG	01279		
Interstitial Pneumonitis	01281		
Peribronchial Lymphoid Hyperplasia	01283	A	
Perivascular Lymphoid Hyperplasia	01282		
Adenoma	01287		
Epithelial Hyperplasia	01289		
Amyloid	01290	X	
Alveolar Macrophages	01292		
Adenocarcinoma	01293	X	
Pneumonia	01296		
Thrombosis	01297		
Mesothelioma	01298		
Metastatic Tumor	01299		
Pigment	01280		
Lymphosarcoma			
Reticulum Cell Sarcoma			
LYMPH NODE			
Amyloid			
Lymphoid Hyperplasia			
Lymphosarcoma			P
Reticulum Cell Sarcoma			
Hemorrhage			
Adenitis			
Angioma			
R.E. Hyperplasia			
Arteritis			
Angiosarcoma			

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	Animal No.	(7) Sacrificed	(27) Deaths
LIVER	01272	X	
Amyloid	01275	X	
Necrosis/Caudate Lobe	01284	X	
Pericholangitis	01285	2	
Vacuolation	01286	X	
Necrosis	01288	X	
Acute Hepatitis	01295	X	
Nodular Hyperplasia	01265	2	
Nonsuppurative Hepatitis	01267	2	
Mononuclear Infiltration	01269		
Hepatoma	01272	2	
Sinusoidal Infiltrate	01275		
Angiosarcoma	01284		
Thrombosis	01285		
Lymphosarcoma	01286		
Reticulum Cell Sarcoma	01288		
Cyst	01295		
Cytomegaly	01265		
Bile Duct Carcinoma	01267		
Metastatic Sarcoma	01269		
Angioma	01272		
Angiectasis	01275		
	01276		
	01277		
	01278		
	01279		
	01280		
	01281		
	01282		
	01283		
	01284		
	01285		
	01286		
	01287		
	01288		
	01289		
	01290		
	01291		
	01292		
	01293		
	01294		
	01295		
	01296		
	01297		
	01298		
	01299		
	01300		
	01301		
	01302		
	01303		
	01304		
	01305		
	01306		
	01307		
	01308		
	01309		
	01310		
	01311		
	01312		
	01313		
	01314		
	01315		
	01316		
	01317		
	01318		
	01319		
	01320		
	01321		
	01322		
	01323		
	01324		
	01325		
	01326		
	01327		
	01328		
	01329		
	01330		
	01331		
	01332		
	01333		
	01334		
	01335		
	01336		
	01337		
	01338		
	01339		
	01340		
	01341		
	01342		
	01343		
	01344		
	01345		
	01346		
	01347		
	01348		
	01349		
	01350		
	01351		
	01352		
	01353		
	01354		
	01355		
	01356		
	01357		
	01358		
	01359		
	01360		
	01361		
	01362		
	01363		
	01364		
	01365		
	01366		
	01367		
	01368		
	01369		
	01370		
	01371		
	01372		
	01373		
	01374		
	01375		
	01376		
	01377		
	01378		
	01379		
	01380		
	01381		
	01382		
	01383		
	01384		
	01385		
	01386		
	01387		
	01388		
	01389		
	01390		
	01391		
	01392		
	01393		
	01394		
	01395		
	01396		
	01397		
	01398		
	01399		
	01400		
	01401		
	01402		
	01403		
	01404		
	01405		
	01406		
	01407		
	01408		
	01409		
	01410		
	01411		
	01412		
	01413		
	01414		
	01415		
	01416		
	01417		
	01418		
	01419		
	01420		
	01421		
	01422		
	01423		
	01424		
	01425		
	01426		
	01427		
	01428		
	01429		
	01430		
	01431		
	01432		
	01433		
	01434		
	01435		
	01436		
	01437		
	01438		
	01439		
	01440		
	01441		
	01442		
	01443		
	01444		
	01445		
	01446		
	01447		
	01448		
	01449		
	01450		
	01451		
	01452		
	01453		
	01454		
	01455		
	01456		
	01457		
	01458		
	01459		
	01460		
	01461		
	01462		
	01463		
	01464		
	01465		
	01466		
	01467		
	01468		
	01469		
	01470		
	01471		
	01472		
	01473		
	01474		
	01475		
	01476		
	01477		
	01478		
	01479		
	01480		
	01481		
	01482		
	01483		
	01484		
	01485		
	01486		
	01487		
	01488		
	01489		
	01490		
	01491		
	01492		
	01493		
	01494		
	01495		
	01496		
	01497		
	01498		
	01499		
	01500		
	01501		
	01502		
	01503		
	01504		
	01505		
	01506		
	01507		
	01508		
	01509		
	01510		
	01511		
	01512		
	01513		
	01514		
	01515		
	01516		
	01517		
	01518		
	01519		
	01520		
	01521		
	01522		
	01523		
	01524		
	01525		
	01526		
	01527		
	01528		
	01529		
	01530		
	01531		
	01532		
	01533		
	01534		
	01535		
	01536		
	01537		
	01538		
	01539		
	01540		
	01541		
	01542		
	01543		
	01544		
	01545		
	01546		
	01547		
	01548		
	01549		
	01550		
	01551		
	01552		
	01553		
	01554		
	01555		
	01556		
	01557		
	01558		
	01559		
	01560		
	01561		
	01562		
	01563		
	01564		
	01565		
	01566		
	01567		
	01568		
	01569		
	01570		
	01571		
	01572		
	01573		
	01574		
	01575		
	01576		
	01577		
	01578		
	01579		
	01580		
	01581		
	01582		
	01583		
	01584		
	01585		
	01586		
	01587		
	01588		
	01589		
	01590		
	01591		
	01592		
	01593		
	01594		
	01595		
	01596		
	01597		
	01598		
	01599		
	01600		
	01601		
	01602		
	01603		
	01604		
	01605		
	01606		
	01607		
	01608		
	01609		
	01610		
	01611		
	01612		
	01613		
	01614		
	01615		
	01616		
	01617		
	01618		
	01619		
	01620		
	01621		
	01622		
	01623		
	01624		
	01625		
	01626		
	01627		
	01628		
	01629		
	01630		
	01631		
	01632		
	01633		
	01634		
	01635		
	01636		
	01637		
	01638		
	01639		
	01640		
	01641		
	01642		
	01643		
	01644		
	01645		
	01646		
	01647		
	01648		
	01649		
	01650		
	01651		
	01652		
	01653		
	01654		
	01655		
	01656		
	01657		
	01658		
	01659		
	01660		
	01661		
	01662		
	01663		
	01664		
	01665		
	01666		
	01667		
	01668		
	01669		
	01670		
	01671		
	01672		
	01673		
	01674		
	01675		
	01676		
	01677		
	01678		
	01679		
	01680		
	01681		
	01682		
	01683		
	01684		
	0168		

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	Animal No.	Deaths (27)	01279	01281	01283	01282	01287	01289	01290	01291	01292	01293	01296	01297	01298	01299	01280
LIVER						X					X						
Amyloid																	
Necrosis/Caudate Lobe																	
Pericholangitis																	
Vacuolation																	
Necrosis																	
Acute Hepatitis																	
Nodular Hyperplasia																	
Nonsuppurative Hepatitis																	3
Mononuclear Infiltration																	
Hepatoma																	3
Sinusoidal Infiltrate																	
Angiosarcoma																	
Thrombosis																	
Lymphosarcoma																	
Reticulum Cell Sarcoma																	
Cyst																	
Cytomegaly																	
Bile Duct Carcinoma																	
Metastatic Sarcoma																	
Angioma																	
Angiectasis																	

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Group II - Females	Animal No.	(7)							(27)						
			Sacrificed							Deaths						
GALL BLADDER		01272	X	X	X	X	X	X	X	01275	X	X	X	X	X	01277
Lymphosarcoma		01275								01276						01276
Acute Cholecystitis		01284								01273						01273
		01285								01271						01271
		01286								01268						01268
		01288								01300						01300
		01295								01294						01294
		01267								01269						01269
		01265								01267						01267
		01295								01265						01265
		01288								01295						01295
		01286								01286						01286
		01285								01285						01285
		01284								01284						01284
		01275								01275						01275
		01272								01272						01272
KIDNEY																
Interstitial Nephritis																
Regenerative Epithelium																
Dilated Pelvis																
Perivascular Mononuclear Infiltration																
Tubular Dilatation																
Glomerular Amyloid																
Interstitial Amyloid																
Mineral Deposition																
Lymphosarcoma																
Pyelonephritis																
Arteritis																
Pigment/Tubular																
Reticulum Cell Sarcoma																
Adenocarcinoma																
STOMACH																
Gastritis																
Ulceration																
Lymphosarcoma																
Metastatic Tumor																
Amyloid																
Carcinoma																
Mucosal Hyperplasia																
Adenoma																

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(27)

	Animal No.	Deaths	
Group II - Females	01279		
GALL BLADDER	01281		
Lymphosarcoma	01283		
Acute Cholecystitis	01282		
	01287		
	01289		
	01290		
	01291		
	01292		
	01293		
	01296		
	01297		
	01298		
	01299		
	01280		
KIDNEY			
Interstitial Nephritis			
Regenerative Epithelium			
Dilated Pelvis			
Perivascular Mononuclear Infiltration			
Tubular Dilatation			
Glomerular Amyloid			
Interstitial Amyloid			
Mineral Deposition			
Lymphosarcoma			
Pyelonephritis			
Arteritis			
Pigment/Tubular			
Reticulum Cell Sarcoma			
Adenocarcinoma			
STOMACH			
Gastritis			
Ulceration			
Lymphosarcoma			
Metastatic Tumor			
Amyloid			
Carcinoma			
Mucosal Hyperplasia			
Adenoma			

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(7) Sacrificed	(27) Deaths
Group II - Females			
SMALL INTESTINE			
Amyloid	X		
Mucosal Erosion			
Enteritis			
Hemorrhage			
LARGE INTESTINE			
Nematodiasis			
Lymphosarcoma			
Amyloid			
Hemorrhage			
SPLEEN			
Extramedullary Hematopoiesis			
Angiosarcoma			
Angioma			
Reticulum Cell Sarcoma			
Amyloid			
Lymphoid Depletion			
Lymphosarcoma			
R.E. Hyperplasia			
Congestion			
Thrombosis			
Lymphoid Hyperplasia			
Macrophages			

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	Animal No.	(27) Deaths	
SMALL INTESTINE	01279		
Amyloid	01281		
Mucosal Erosion	01283		
Enteritis	01282		
Hemorrhage	01287		
	01289		
	01290		
	01291		
	01292		
	01293		
	01296		A A
	01297		
	01298		
	01299		A
	01280		
LARGE INTESTINE			
Nematodiasis			
Lymphosarcoma			
Amyloid			
Hemorrhage			
SPLEEN			
Extramedullary Hematopoiesis			
Angiosarcoma			
Angioma			
Reticulum Cell Sarcoma			
Amyloid			
Lymphoid Depletion			
Lymphosarcoma			
R.E. Hyperplasia			
Congestion			
Thrombosis			
Lymphoid Hyperplasia			
Macrophages			

2

3

P

P

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group II - Females	(7) Sacrificed										(27) Deaths									
	Animal No.	01272	01275	01284	01285	01286	01288	01295	01265	01267	01269	01294	01300	01266	01268	01271	01273	01274	01276	01277
OVARY																				
Cystic Follicles		P	P	P	X	P	P	P	X	P	P		P				P		P	P
Hemorrhagic Cyst			P	P		P	P	P		P	P						P			
Mineralization			P	P																
Arteritis																				
Lymphosarcoma																				
Reticulum Cell Sarcoma																				
Granulosa Cell Tumor	P											3	3							
Amyloid							4					X							A	4
UTERUS																				
Glandular Dilatation		4	3	2	3	3	4	2	4	4	3		3				3	3	2	4
Glandular Hyperplasia					2		2										2			
Polyp																				
Thrombosis																				
Acute Endometritis																				
Angioma	P									4										3
Angiosarcoma																				
Endometriosis										4								P		
Leiomyosarcoma																				3
Carcinoma / Scirrhus																				
Angiectasis		2																		
Arteritis										4								3		
Lymphosarcoma																				
Hemorrhage																				
Leiomyoma										4										
Reticulum Cell Sarcoma							P					4						3		



DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 231 -

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(7) Sacrificed	(27) Deaths	
Group II - Females				
VAGINA				
Acute Vaginitis	01272	X		01272
Carcinoma	01275	X		01275
Hemorrhage	01284	2		01284
	01285	X		01285
	01286	X		01286
	01288	X		01288
	01295	X		01295
	01265		2	01265
	01267	2	2	01267
	01269		2	01269
	01294	X		01294
	01300	X		01300
	01266			01266
	01268			01268
	01271			01271
	01273			01273
	01274			01274
	01276			01276
	01277			01277
SALIVARY GLAND				
Mononuclear Infiltration				3
Amyloid				
Lymphosarcoma				
Adenitis				
URINARY BLADDER				
Mononuclear Infiltration				A
Acute Cystitis	01272	2		01272
Lymphosarcoma				
Nonsuppurative Cystitis				
Mucosal Separation				
Hemorrhage				
Arteritis				
Epithelial Hyperplasia	01272	2		01272
NERVE				
Reticulum Cell Sarcoma				

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(27) Deaths	
Group II - Females	01279		
	01281		
	01283		
	01282		
	01287		
	01289		
	01290		
	01291		
	01292		
	01293		
	01296		
	01297		
	01298		
	01299		
	01280		
VAGINA			
Acute Vaginitis			
Carcinoma			
Hemorrhage			
SALIVARY GLAND			
Mononuclear Infiltration			
Amyloid			
Lymphosarcoma			
Adenitis			
URINARY BLADDER			
Mononuclear Infiltration			
Acute Cystitis			
Lymphosarcoma			
Nonsuppurative Cystitis			
Mucosal Separation			
Hemorrhage			
Arteritis			
Epithelial Hyperplasia			
NERVE			
Reticulum Cell Sarcoma			

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Animal No.	(7) Sacrificed	(27) Deaths
01272		
01275		
01284		
01285		
01286		
01288		
01295		
01265		
01267		
01269		
01294		
01300		
01266		
01268		
01271		
01273		
01274		
01276		
01277		

Group II - Females

MUSCLE

Myositis  
Lymphosarcoma  
Reticulum Cell Sarcoma  
Sarcoma  
Parasite

EYE

Dacryoadenitis  
Ophthalmitis  
Retinal Degeneration  
Keratitis  
Lymphosarcoma  
Lens Vacuolation  
Lacrimal Gland Hyperplasia

BONE

Fibroplasia

BONE MARROW

Hematogenic Activity  
Lymphosarcoma  
Angiectasis  
Osteomyelitis

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Animal No.	Deaths (27)	
01279		
01281		
01283		
01282		
01287		
01289		P
01290		
01291		
01292		
01293		
01296		
01297		
01298		
01299		
01280		

Group II - Females

MUSCLE	
Myositis	
Lymphosarcoma	
Reticulum Cell Sarcoma	
Sarcoma	
Parasite	
EYE	
Dacryoadenitis	
Ophthalmitis	
Retinal Degeneration	
Keratitis	
Lymphosarcoma	
Lens Vacuolation	
Lacrimal Gland Hyperplasia	
BONE	
Fibroplasia	
BONE MARROW	
Hematogenic Activity	
Lymphosarcoma	
Angiectasis	
Osteomyelitis	

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Animal No.	(7) Sacrificed	(27) Deaths
01272		
01275		
01284		
01285		
01286		
01288		
01295		
01265		
01267		
01269		
01294		
01300		
01268		
01271		
01273		
01274		
01276		
01277		

Group II - Females

MAMMARY GLAND

Acinar Tissue  
Ductal Tissue  
Mastitis

SPINAL CORD

Lymphosarcoma

SKIN

Parasite  
Acute Dermatitis  
Lymphangiectasis  
Edema

TISSUE MASS

Lymphosarcoma  
Undiff. Sarcoma

MESENTERY

Peritonitis  
Arteritis  
Lymphosarcoma  
Sarcoma

4

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Animal No.	(27) Deaths	
01279		
01281		
01283		
01282		
01287		
01289		
01290		
01291		
01292		
01293		
01296		
01297		
01298		
01299		
01280		

Group II - Females

MAMMARY GLAND

Acinar Tissue  
Ductal Tissue  
Mastitis

SPINAL CORD

Lymphosarcoma

SKIN

Parasite  
Acute Dermatitis  
Lymphangiectasis  
Edema

TISSUE MASS

Lymphosarcoma  
Undiff. Sarcoma

MESENTERY

Peritonitis  
Arteritis  
Lymphosarcoma  
Sarcoma







Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Female	Animal No.	(6) Sacrifice	(29) Deaths	
HEART	01341	X		
Nonsuppurative Myocarditis	01349	2		
Amyloid	01347	2		
Arteritis	01350	X		
Angioma	01354	2		
Epicarditis	01361	X		
Mesothelioma	01339	X		
Thrombosis	01342	X		
Lymphosarcoma	01344	X		
Reticulum Cell Sarcoma	01362	X		
	01360		3	
	01364		2	
	01345		2	
	01351		2	
	01353		2	
	01356			P
	01363		3	
	01365			P
	01367			X
PANCREAS				
Lymphosarcoma				
Cystic Ducts				
Nonsuppurative Pancreatitis				
Reticulum Cell Sarcoma				
Mononuclear Infiltration				
Atrophy				
Amyloid				
Arteritis				
Islet Cell Hyperplasia				
Islet Cell Tumor				

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Females	Animal No.	Deaths
HEART		
Nonsuppurative Myocarditis		
Amyloid		
Arteritis		
Angioma		
Epicarditis		
Mesothelioma		
Thrombosis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
PANCREAS		
Lymphosarcoma		
Cystic Ducts		
Nonsuppurative Pancreatitis		
Reticulum Cell Sarcoma		
Mononuclear Infiltration		
Atrophy		
Amyloid		
Arteritis		
Islet Cell Hyperplasia		
Islet Cell Tumor		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Female	Animal No.	(6) Sacrifice	(29) Deaths	
LUNG	01341	X		A
Interstitial Pneumonitis	01347	X		
Peribronchial Lymphoid Hyperplasia	01349	X		
Perivascular Lymphoid Hyperplasia	01350		2	
Adenoma	01354	X		
Epithelial Hyperplasia	01361		2	
Amyloid	01367			
Alveolar Macrophages	01368			
Adenocarcinoma	01369	X		
Pneumonia	01370	X		
Thrombosis	01371	X		
Mesothelioma	01372	X		
Metastatic Tumor	01373	X		
Pigment	01374	X		
Lymphosarcoma	01375	X		
Reticulum Cell Sarcoma	01376	X		
Lymph Node	01377			
Amyloid	01378			
Lymphoid Hyperplasia	01379			
Lymphosarcoma	01380			
Reticulum Cell Sarcoma	01381			
Hemorrhage	01382			
Adenitis	01383			
Angioma	01384			
R.E. Hyperplasia	01385			
Arteritis	01386			
Angiosarcoma	01387			

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Females	Animal No.	Deaths	(29)
LUNG			
Interstitial Pneumonitis			
Peribronchial Lymphoid Hyperplasia	1		
Perivascular Lymphoid Hyperplasia		2	
Adenoma			P
Epithelial Hyperplasia			
Amyloid			
Alveolar Macrophages			
Adenocarcinoma			
Pneumonia			
Thrombosis			
Mesothelioma			
Metastatic Tumor			
Pigment			
Lymphosarcoma			
Reticulum Cell Sarcoma			
LYMPH NODE			
Amyloid			
Lymphoid Hyperplasia			
Lymphosarcoma			
Reticulum Cell Sarcoma			
Hemorrhage			
Adenitis			
Angioma			
R.E. Hyperplasia			
Arteritis			
Angiosarcoma			

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 244 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Females	Animal No.	(29) Deaths	
LIVER			
Amyloid			
Necrosis/Caudate Lobe			
Pericholangitis	2		
Vacuolation			
Necrosis			
Acute Hepatitis			
Nodular Hyperplasia			
Nonsuppurative Hepatitis	2		
Mononuclear Infiltration			
Hepatoma			
Sinusoidal Infiltrate			
Angiosarcoma			
Thrombosis			
Lymphosarcoma			
Reticulum Cell Sarcoma			P
Cyst			
Cytomegaly			
Bile Duct Carcinoma			
Metastatic Sarcoma			
Angioma			
Angiectasis			
	01369		X
	01370		X
	01372		A
	01346		
	01337		
	01338		X
	01340		
	01348		
	01355		
	01357		
	01358		
	01359		
	01366		
	01368		
	01371		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Female	Animal No.	(6)						(29)					
		Sacrifice						Deaths					
GALL BLADDER													
Lymphosarcoma													
Acute Cholecystitis							2						
KIDNEY													
Interstitial Nephritis	2	3		1									A
Regenerative Epithelium	2	3											
Dilated Pelvis													
Perivascular Mononuclear Infiltration	2	3	3	2	3	3							
Tubular Dilatation													
Glomerular Amyloid	4	4			2								
Interstitial Amyloid													
Mineral Deposition													
Lymphosarcoma													
Pyelonephritis													
Arteritis													
Pigment/Tubular													
Reticulum Cell Sarcoma													
Adenocarcinoma													
STOMACH													
Gastritis	X	X	X	X	X	X							
Ulceration													
Lymphosarcoma													
Metastatic Tumor													
Amyloid													
Carcinoma													
Mucosal Hyperplasia													
Adenoma													



Table No. 8 - Continued  
PROJECT NO. 700-260

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Group III - Females	(29)	
		Animal No.	Deaths
GALL BLADDER		A	A
Lymphosarcoma			
Acute Cholecystitis			
KIDNEY			X
Interstitial Nephritis		4	
Regenerative Epithelium		3	
Dilated Pelvis			
Perivascular Mononuclear Infiltration	1		
Tubular Dilatation			
Glomerular Amyloid	4	4	
Interstitial Amyloid			
Mineral Deposition			
Lymphosarcoma			
Pyelonephritis			
Arteritis			
Pigment/Tubular			
Reticulum Cell Sarcoma			
Adenocarcinoma			
STOMACH		X	X
Gastritis		X	X
Ulceration			
Lymphosarcoma			
Metastatic Tumor			
Amyloid			
Carcinoma			
Mucosal Hyperplasia			
Adenoma			

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 248 -

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Females	Animal No.	(29) Deaths	01369	01370	01372	01346	01337	01338	01340	01348	01355	01357	01358	01359	01366	01368	01371
SMALL INTESTINE																	
Amyloid				A	2	A			2								
Mucosal Erosion																	
Enteritis																	
Hemorrhage																	
LARGE INTESTINE																	
Nematodiasis																	
Lymphosarcoma																	
Amyloid																	
Hemorrhage																	
SPLEEN																	
Extramedullary Hematopoiesis																	
Angiosarcoma																	
Angioma																	
Reticulum Cell Sarcoma																	
Amyloid																	
Lymphoid Depletion																	
Lymphosarcoma																	
R.E. Hyperplasia																	
Congestion																	
Thrombosis																	
Lymphoid Hyperplasia																	
Macrophages																	

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(6) (29)  
Deaths

Animal No.	Sacrifice	Deaths
Group III - Female		
OVARY		
Cystic Follicles		
Hemorrhagic Cyst		
Mineralization		
Arteritis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Granulosa Cell Tumor		
Amyloid		
UTERUS		
Glandular Dilatation		
Glandular Hyperplasia		
Polyp		
Thrombosis		
Acute Endometritis		
Angioma		
Angiosarcoma		
Endometriosis		
Leiomyosarcoma		
Carcinoma / Scirrhus		
Angiectasis		
Arteritis		
Lymphosarcoma		
Hemorrhage		
Leiomyoma		
Reticulum Cell Sarcoma		

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Females	Animal No.	Deaths
OVARY		
Cystic Follicles		
Hemorrhagic Cyst		
Mineralization		
Arteritis		
Lymphosarcoma		
Reticulum Cell Sarcoma		
Granulosa Cell Tumor		
Amyloid		
UTERUS		
Glandular Dilatation		
Glandular Hyperplasia		
Polyp		
Thrombosis		
Acute Endometritis		
Angioma		
Angiosarcoma		
Endometriosis		
Leiomyosarcoma		
Carcinoma / Scirrhous		
Angiectasis		
Arteritis		
Lymphosarcoma		
Hemorrhage		
Leiomyoma		
Reticulum Cell Sarcoma		

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Female	Animal No.	(6) Sacrifice	(29) Deaths	
VAGINA	01341	X		01341
Acute Vaginitis	01347	X		01347
Carcinoma	01349	N		01349
Hemorrhage	01350	X		01350
	01354	X		01354
	01361	X		01361
SALIVARY GLAND	01339	X		01339
Mononuclear Infiltration	01342	X		01342
Amyloid	01344	X		01344
Lymphosarcoma	01352	X		01352
Adenitis	01362	X		01362
	01364	X		01364
	01345	X		01345
	01351		4	01351
	01353			01353
	01356			01356
	01363			01363
	01365			01365
	01367			01367
URINARY BLADDER				
Mononuclear Infiltration	2			2
Acute Cystitis				
Lymphosarcoma				
Nonsuppurative Cystitis				
Mucosal Separation				
Hemorrhage				
Arteritis				
Epithelial Hyperplasia				
NERVE				
Reticulum Cell Sarcoma				

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Females	Animal No.	(29)	Deaths	
VAGINA	01369	X		
Acute Vaginitis	01372	X		
Carcinoma	01346	X	X	
Hemorrhage	01337		X	
SALIVARY GLAND	01338			
Mononuclear Infiltration	01340			
Amyloid	01348			
Lymphosarcoma	01355			
Adenitis	01357			
URINARY BLADDER	01358			
Mononuclear Infiltration	01366			
Acute Cystitis	01368			
Lymphosarcoma	01371			
Nonsuppurative Cystitis				
Mucosal Separation				
Hemorrhage				
Arteritis				
Epithelial Hyperplasia				
NERVE				
Reticulum Cell Sarcoma				

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Female	Animal No.	Sacrifice (6)	Deaths (29)	
	01341			
	01347			
	01349			
	01350			
	01354			
	01361			
	01339			
	01342			
	01344			
	01352			
	01362			
	01360			
	01364			
	01345			
	01351			
	01353			
	01356			
	01363			
	01365			
	01367			
MUSCLE				
Myositis				
Lymphosarcoma				
Reticulum Cell Sarcoma				
Sarcoma				
Parasite				
EYE				
Dacryoadenitis				
Ophthalmitis				
Retinal Degeneration				
Keratitis				
Lymphosarcoma				
Lens Vacuolation				
Lacrimal Gland Hyperplasia				
BONE				
Fibroplasia				
BONE MARROW				
Hematogenic Activity				
Lymphosarcoma				
Angiectasis				
Osteomyelitis				





Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group III - Female	Animal No.	(6) Sacrifice	(29) Deaths
	01341		
	01347		
	01349		
	01350		
	01354		
	01361		
	01339		
	01342		
	01344		
	01352		
	01362		
	01360		
	01364		
	01345		
	01351		
	01353		
	01356		
	01363		
	01365		
	01367		
MAMMARY GLAND			
Acinar Tissue			
Ductal Tissue			
Mastitis			
SPINAL CORD			
Lymphosarcoma			
SKIN			
Parasite			
Acute Dermatitis			
Lymphangiectasis			
Edema			
TISSUE MASS			
Lymphosarcoma			
Undiff. Sarcoma			
MESENTERY			
Peritonitis			
Arteritis			
Lymphosarcoma			
Sarcoma			

Table No. 8 - Continued  
PROJECT NO. 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Animal No.	(29) Deaths	
01369		
01370		
01372		
01346		
01337		
01338		
01340		
01348		
01355		
01357		
01358		
01359		
01366		
01368		
01371		
Group III - Females		
MAMMARY GLAND		
Acinar Tissue		
Ductal Tissue		
Mastitis		
SPINAL CORD		
Lymphosarcoma		
SKIN		
Parasite		
Acute Dermatitis		
Lymphangiectasis		
Edema		
TISSUE MASS		
Lymphosarcoma		
Undiff. Sarcoma		
MESENTERY		
Peritonitis		
Arteritis		
Lymphosarcoma		
Sarcoma		

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

a = total number survivors  
b = total number of nonsurvivors for which one or more tissues were available for histologic preparation

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)  
Deaths

Group IV - Females	Animal No.	01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444
BRAIN																
Mineral Deposition																
Meningioma																
Hemorrhage																
Reticulum Cell Sarcoma																
Perivascular Cuffing																
Lymphosarcoma	P															
PITUITARY																
THYROID																
Amyloid																
Nonsuppurative Thyroiditis																
Adenomatous Hyperplasia																
ADRENAL																
Cortical Hyperplasia																
Amyloid																
Cortical Hypertrophy																
Cortical Atrophy																
Cortical Adenoma																
Lymphosarcoma																

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Females	Animal No.	(9) Sacrificed									(26) Deaths										
		01410	01411	01413	01416	01424	01426	01427	01429	01443	01391	01380	01412	01414	01415	01417	01418	01419	01420	01421	01422
HEART																					
Nonsuppurative Myocarditis	1		X	X	X		X		X						X	X	X			X	
Amyloid								1										2			
Arteritis																					
Angioma						2															
Epicarditis																					
Mesothelioma																					
Thrombosis																					
Lymphosarcoma										2	P		4	4					P		P
Reticulum Cell Sarcoma																					
PANCREAS																					
Lymphosarcoma		X	X	X	X		X	X	X	X	P		X	X			X		A	X	P
Cystic Ducts																					
Nonsuppurative Pancreatitis						2										3					
Reticulum Cell Sarcoma																					
Mononuclear Infiltration																		2			
Atrophy																					
Amyloid						4															
Arteritis																					
Islet Cell Hyperplasia																					
Islet Cell Tumor																					

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Females	Animal No.	(26) Deaths																									
		01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444											
HEART		X	A		A	2		X	X	X	X	X	X		X												
Nonsuppurative Myocarditis				2		2										2											
Amyloid																											
Arteritis																											
Angioma																											
Epicarditis																											
Mesothelioma																											
Thrombosis																											
Lymphosarcoma																											
Reticulum Cell Sarcoma													P														
PANCREAS																											
Lymphosarcoma																											
Cystic Ducts																											
Nonsuppurative Pancreatitis																											
Reticulum Cell Sarcoma																											
Mononuclear Infiltration																											
Atrophy																											
Amyloid																											
Arteritis																											
Islet Cell Hyperplasia																											
Islet Cell Tumor																											

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Females	Animal No.	Sacrificed (9)	Deaths (26)	
LUNG	01410			
Interstitial Pneumonitis	01411	X		
Peribronchial Lymphoid Hyperplasia	01413	1		
Perivascular Lymphoid Hyperplasia	01416	3		
Adenoma	01424	2		
Epithelial Hyperplasia	01426	2		
Amyloid	01427	2		
Alveolar Macrophages	01429	2		
Adenocarcinoma	01443	X		
Pneumonia	01391	X		
Thrombosis	01380			
Mesothelioma	01412	X		
Metastatic Tumor	01414	A		
Pigment	01415			
Lymphosarcoma	01417	X		
Reticulum Cell Sarcoma	01418	X		
	01419		2	
	01420			
	01421			
	01422			
Lymph Node				
Amyloid				
Lymphoid Hyperplasia				
Lymphosarcoma				
Reticulum Cell Sarcoma				
Hemorrhage				
Adenitis				
Angioma				
R.E. Hyperplasia				
Arteritis				
Angiosarcoma				



DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 263 -

### DETAILED HISTOPATHOLOGY INCIDENCE TABLE

- 264 -

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE  
(26)

Group IV - Females	Animal No.	Deaths
LIVER	01423	
Amyloid	01425	A
Necrosis/Caudate Lobe	01428	
Pericholangitis	01431	A
Vacuolation	01432	3
Necrosis	01433	A 3
Acute Hepatitis	01434	X
Nodular Hyperplasia	01435	X
Nonsuppurative Hepatitis	01436	X
Mononuclear Infiltration	01437	
Hepatoma	01438	2
Sinusoidal Infiltrate	01439	1
Angiosarcoma	01440	
Thrombosis	01442	A 2
Lymphosarcoma	01444	3
Reticulum Cell Sarcoma		
Cyst		
Cytomegaly		
Bile Duct Carcinoma		
Metastatic Sarcoma		
Angioma		
Angiectasis		

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)  
Deaths

(9)  
Sacrificed

Group IV - Females

Animal No.	01410	01411	01413	01416	01424	01426	01427	01429	01443	01391	01380	01412	01414	01415	01417	01418	01419	01420	01421	01422
GALL BLADDER	X								X	A	A	X	A	A	A	A			A	A
Lymphosarcoma																				
Acute Cholecystitis		3	3																	
KIDNEY																				
Interstitial Nephritis	1	1	1	2	2	2	1	2	2				X	A	X	X				
Regenerative Epithelium		2				1						2								
Dilated Pelvis																				
Perivascular Mononuclear Infiltration	2	2	2	2	2	2	2	2	2					2			2	2	2	1
Tubular Dilatation																				
Glomerular Amyloid																				
Interstitial Amyloid			3	4	4	2		4	2	2		4		3						1
Mineral Deposition																				1
Lymphosarcoma											P							P		P
Pyelonephritis																				
Arteritis																				
Pigment/Tubular																				
Reticulum Cell Sarcoma																				
Adenocarcinoma																				
STOMACH																				
Gastritis																				
Ulceration																				
Lymphosarcoma																				
Metastatic Tumor																				
Amyloid																				
Carcinoma																				
Mucosal Hyperplasia																				
Adenoma																				

P

P

P

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Group IV - Females	Animal No.	(26)														Deaths	
			01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444	
GALL BLADDER			A	A	A	A	A	A	A	A	A	N	X	X	A	A		
Lymphosarcoma																		
Acute Cholecystitis																		
KIDNEY				A		A	2	A	X	X	X	A	A	2		A	A	
Interstitial Nephritis							2						2	2				
Regenerative Epithelium													2					
Dilated Pelvis																		
Perivascular Mononuclear Infiltration							2	2						3			2	
Tubular Dilatation																		
Glomerular Amyloid				4			4	4					3			4	4	
Interstitial Amyloid								4										
Mineral Deposition																		
Lymphosarcoma			P		P													
Pyelonephritis																		
Arteritis																		
Pigment/Tubular																		
Reticulum Cell Sarcoma															P			
Adenocarcinoma																		
STOMACH				A	A	A	X	X	X	X	X	X	X	X	X	X	X	
Gastritis																		
Ulceration																		
Lymphosarcoma			2															
Metastatic Tumor			P															
Amyloid																		
Carcinoma																		
Mucosal Hyperplasia																		
Adenoma																		

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Females	Animal No.	(9) Sacrificed										(26) Deaths									
		01410	01411	01413	01416	01424	01426	01427	01429	01443	01391	01380	01412	01414	01415	01417	01418	01419	01420	01421	01422
SMALL INTESTINE																					
Amyloid	X		2	2	4	X	X	X	X	X	A	A	3	A	A	X	X	A	A	X	
Mucosal Erosion																					
Enteritis																					
Hemorrhage																					
LARGE INTESTINE																					
Nematodiasis	P	X	X	X	X	X	X	P	X	X	A	P	P	X	X	X	X	A	X	P	
Lymphosarcoma																					
Amyloid																					
Hemorrhage																					
SPLEEN																					
Extramedullary Hematopoiesis	2	X	X			X	X	X	X	X	X			X				X	A		
Angiosarcoma																					
Angioma																					
Reticulum Cell Sarcoma																					
Amyloid					2								2			3					
Lymphoid Depletion																					
Lymphosarcoma																					
R.E. Hyperplasia	3											P						P		P	
Congestion															4						
Thrombosis															4						
Lymphoid Hyperplasia																					
Macrophages																				3	

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

		(26)		Deaths		Animal No.	
Group IV - Females							
SMALL INTESTINE	Amyloid	A	A	A	A	01423	
	Mucosal Erosion					01425	
	Enteritis	A	A	A	A	01428	
	Hemorrhage					01431	
LARGE INTESTINE	Nematodiasis	A	A	A	A	01432	
	Lymphosarcoma					01433	3
	Amyloid					01434	
	Hemorrhage	X	A	A	A	01438	
SPLEEN	Extramedullary Hematopoiesis					01439	
	Angiosarcoma					01440	
	Angioma					01442	
	Reticulum Cell Sarcoma					01444	
	Amyloid						
	Lymphoid Depletion						
	Lymphosarcoma						
	R.E. Hyperplasia						
	Congestion						
	Thrombosis						
	Lymphoid Hyperplasia						
	Macrophages						

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(9) Sacrificed									(26) Deaths								
		P	N	P	P	P	P	P	P	P	N	P	X	X	X	X	X	X	X
Group IV - Females																			
OVARY																			
Cystic Follicles																			
Hemorrhagic Cyst																			
Mineralization																			
Arteritis																			
Lymphosarcoma																			
Reticulum Cell Sarcoma																			
Granulosa Cell Tumor																			
Amyloid																			
UTERUS																			
Glandular Dilatation																			
Glandular Hyperplasia																			
Polyp																			
Thrombosis																			
Acute Endometritis																			
Angioma																			
Angiosarcoma																			
Endometriosis																			
Leiomyosarcoma																			
Carcinoma / Scirrhus																			
Angiectasis																			
Arteritis																			
Lymphosarcoma																			
Hemorrhage																			
Leiomyoma																			
Reticulum Cell Sarcoma																			



Table No. 3 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)

Group IV - Females	Animal No.	Deaths	01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444
OVARY																	
Cystic Follicles																	
Hemorrhagic Cyst																	
Mineralization																	
Arteritis																	
Lymphosarcoma																	
Reticulum Cell Sarcoma																	
Granulosa Cell Tumor																	
Amyloid																	
UTERUS																	
Glandular Dilatation																	
Glandular Hyperplasia																	
Polyp																	
Thrombosis																	
Acute Endometritis																	
Angioma																	
Angiosarcoma																	
Endometriosis																	
Leiomyosarcoma																	
Carcinoma / Scirrhous																	
Angiectasis																	
Arteritis																	
Lymphosarcoma																	
Hemorrhage																	
Leiomyoma																	
Reticulum Cell Sarcoma																	

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Females	Animal No.	(9) Sacrificed									(26) Deaths										
		01410	01411	01413	01416	01424	01426	01427	01429	01443	01391	01380	01412	01414	01415	01417	01418	01419	01420	01421	01422
VAGINA		X	X	X	X	X	X	X	X	2	X	X			X	X	A	A	A	X	X
Acute Vaginitis																					
Carcinoma																					
Hemorrhage																					
SALIVARY GLAND																					
Mononuclear Infiltration	X									X						X		X	X	X	
Amyloid			2	2	3	2	1	2	2				1		2		2				
Lymphosarcoma												1					4				
Adenitis											P										P
URINARY BLADDER																					
Mononuclear Infiltration	X								X	X						X	A	A	A	1	A
Acute Cystitis			1		3	1	1	1				1	2	2			2				
Lymphosarcoma																					
Nonsuppurative Cystitis											P								P		P
Mucosal Separation				3		2		3													
Hemorrhage																					
Arteritis																					
Epithelial Hyperplasia																					
NERVE																					
Reticulum Cell Sarcoma	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

Table No. 3 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)  
Deaths

Group IV - Females	Animal No.	01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444
VAGINA		X	A	A	N	X	X	X	N	X	X	X	X	X	X	
Acute Vaginitis																2
Carcinoma																
Hemorrhage																
SALIVARY GLAND																
Mononuclear Infiltration		A			A			X	X	X	X	X		X		
Amyloid				3	2	2	2						2		3	2
Lymphosarcoma																
Adenitis																
URINARY BLADDER																
Mononuclear Infiltration			A	A	A	1	1	A	A	X	A	X	X	A	N	2
Acute Cystitis									2					1		
Lymphosarcoma	P															
Nonsuppurative Cystitis																
Mucosal Separation																
Hemorrhage																
Arteritis																
Epithelial Hyperplasia																
NERVE		X	A	X	A	X	X	X	X	X	N	X	X	X	X	X
Reticulum Cell Sarcoma																

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(9) Sacrificed									(26) Deaths										
		01410	01411	01413	01416	01424	01426	01427	01429	01443	01391	01380	01412	01414	01415	01417	01418	01419	01420	01421	01422
Group IV - Females																					
MUSCLE																					
Myositis		X	X	X	X	X	X	X	X	X		X	X	X	X	X	X	X		X	
Lymphosarcoma											P								P		P
Reticulum Cell Sarcoma																					
Sarcoma																					
Parasite																					
EYE																					
Dacryoadenitis		X	X	X		X	X	X	X	A	A		X	A	A	A	A	A	A		A
Ophthalmitis																				2	
Retinal Degeneration												3									
Keratitis					3											3					
Lymphosarcoma																					
Lens Vacuolation																					
Lacrimal Gland Hyperplasia																					
BONE																					
Fibroplasia		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
BONE MARROW																					
Hematogenic Activity		5	5	4	4	4	4	4	4	4	4	4	4		4	4	4	4	P	4	P
Lymphosarcoma																					
Angiectasis																					
Osteomyelitis														3							

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

(26)

Deaths

Animal No.

Group IV - Females

MUSCLE	01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444
Myositis	X	X	X	A	X	X	X	X	X	N	X	X	X		X
Lymphosarcoma														P	
Reticulum Cell Sarcoma															
Sarcoma															
Parasite															
EYE		A	A	A	A	A	A	A	A	A	A	X	A	A	A
Dacryoadenitis															
Ophthalmitis															
Retinal Degeneration															
Keratitis															
Lymphosarcoma	P														
Lens Vacuolation															
Lacrimal Gland Hyperplasia															
BONE	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Fibroplasia															
BONE MARROW		A													
Hematogenic Activity	5	4	4	4	4	4	3	4	3	4	4	4	4	4	4
Lymphosarcoma															
Angiectasis															
Osteomyelitis															

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

Group IV - Females	Animal No.	(9)									(26)								
		Sacrificed									Deaths								
	01410																		
	01411	2	2	3	3	1	2												
	01413	3	2	3	3														
	01416																		
	01424																		
	01426																		
	01427																		
	01429																		
	01443																		
	01391																		
	01380																		
	01412																		
	01414																		
	01415																		
	01417																		
	01418																		
	01419																		
	01420																		
	01421																		
	01422																		
MAMMARY GLAND																			
Acinar Tissue *																			
Ductal Tissue *																			
Mastitis																			
SPINAL CORD																			
Lymphosarcoma																			
SKIN																			
Parasite																			
Acute Dermatitis																			
Lymphangiectasis																			
Edema																			
TISSUE MASS																			
Lymphosarcoma																			
Undiff. Sarcoma																			
MESENTERY																			
Peritonitis																			
Arteritis																			
Lymphosarcoma																			
Sarcoma																			

\* N in this instance indicates acinar/ductal tissue not present in section examined.

Table No. 8 - Continued  
PROJECT 700-260

DETAILED HISTOPATHOLOGY INCIDENCE TABLE

	Animal No.	(26) Deaths															
		01423	01425	01428	01431	01432	01433	01434	01435	01436	01437	01438	01439	01440	01442	01444	
Group IV - Females																	
MAMMARY GLAND																	
Acinar Tissue	N	N	N	N	N	2		N	N	N	N	2					
Ductal Tissue	N	N	N	N	N	2	2	N	N	N	N	3	1	3	2	2	
Mastitis																	
SPINAL CORD																	
Lymphosarcoma	X	X	X	X	X	X	X	X	N	N	X	X	X	X	X	X	
SKIN																	
Parasite																	
Acute Dermatitis																	
Lymphangiectasis																	
Edema																	
TISSUE MASS																	
Lymphosarcoma																	
Undiff. Sarcoma																	
MESENTERY																	
Peritonitis																	
Arteritis																	
Lymphosarcoma																	
Sarcoma																	

\* N in this instance indicates acinar/ductal tissue not present in section examined.